Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ~~(Check one):~~

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

The aggregate market value of common stock held by non-affiliates of the registrant ~~(182,622,092~~(246,062,968 shares) based on the closing price of the registrant’s common stock as reported on the Nasdaq Global Select Market on June 30, ~~2018,~~2020, which was the last business day of the registrant’s most recently completed second fiscal quarter, was ~~$1,139,561,854.~~$307,578,710.

As of ~~February 18, 2019,~~March 1, 2021, there were outstanding ~~241,161,845~~387,825,545 shares of the registrant’s common stock, par value $0.001 per share.

Portions of the registrant’s definitive Proxy Statement for its ~~2019~~2021 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form ~~10- K~~10-K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant’s fiscal year ended December 31, ~~2018.~~
2020.

Throughout this Annual Report, the terms “we,” “us,” “our,” “TherapeuticsMD,” or “our company” refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.

TherapeuticsMD owns or has rights to trademarks, service marks, or trade names that are used in connection with the operation of its business including TherapeuticsMD^®, vitaMedMD^®, BocaGreenMD^®, ANNOVERA^®, BIJUVA^®, and ~~IMVEXXY®~~IMVEXXY^®. This Annual Report also contains trademarks and trade names of other companies.

This Annual Report includes our trademarks, trade names and service marks, such as vitaMedMD^®, BocaGreenMD^®, IMVEXXY^®, BIJUVA^® and ANNOVERA^® which are protected under applicable intellectual property laws and are the property of, or licensed to, our company. This Annual Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Annual Report may appear without the ^®, ™ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties’ trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.

In addition, this Annual Report includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government-agency sources, filings of public companies in our industry, and internal-company surveys. Industry publications and surveys generally state that their information has been obtained from sources believed to be reliable. Although we believe that the industry and market data below is reliable as of the date of this Annual Report, this information could prove to be inaccurate as a result of a variety of matters.

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales are all forward-looking statements. These statements may be found in the items of this Annual Report entitled “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as in this Annual Report generally. These statements are generally accompanied by words such as “intend,” “anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect,” or the negative of such terms or other comparable terminology.

We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date of this Annual Report, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, research and product-development uncertainties, regulatory policies and approval requirements, competition from other businesses, market and general economic factors, and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto included in this Annual Report.

We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this Annual Report in the section entitled “Risk Factors” that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.

~~We are~~TherapeuticsMD is a women’s healthcare company ~~focused on~~with a mission of creating and commercializing innovative products to support the lifespan of women ~~and championing awareness of women’s healthcare issues, specifically, for~~from pregnancy prevention ~~pregnancy, childbirth, nursing, pre-menopause, and~~through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a novel patient-controlled, procedure free, long-lasting contraceptive to advanced U.S. Food and Drug Administration, or FDA, approved bio-identical hormone therapy pharmaceutical products ~~to patient-controlled, long-acting contraceptive.~~for the treatment of vasomotor symptoms and dyspareunia We also ~~manufacture and distribute~~have a portfolio of branded and generic prescription prenatal vitamins under the ~~vitaMedMD®~~vitaMedMD and ~~BocaGreenMD® brands.~~BocaGreenMD brands that furthers our women’s healthcare focus.

~~With our SYMBODA™ technology, we are developing and commercializing advanced hormone therapy pharmaceutical~~Our portfolio of products ~~to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization~~focused on women’s health allows us to efficiently leverage our sales and ~~grow our~~ marketing ~~and sales organization~~plans to ~~commercialize~~grow our recently approved products.

During 2018, the ~~U.S. Food and Drug Administration, or~~ FDA approval of our ~~drugs~~pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our ~~drugs. In July 2018, we launched our recently FDA approved~~pharmaceutical products.

We have also entered into license agreements with strategic partners to commercialize IMVEXXY and BIJUVA outside of the U.S.

Our business has been, and we anticipate that it will continue to be, impacted by the coronavirus (COVID-19) pandemic. Despite the ongoing COVID-19 pandemic, we remain committed to the execution of our corporate goals, demonstrated in part by the increase in product revenue throughout 2020. We resumed the full launch of ANNOVERA in July 2020 and launched the new consumer marketing campaign for IMVEXXY in August 2020.

At this time, the length and extent of the impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and marketing infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients and prescribers. This contingency plan was designed to monitor the COVID-19 pandemic and adapt to the length of time that COVID-19 may impact our business, which is intended to allow us to conserve our financial resources during the COVID-19 pandemic.

COVID-19 has accelerated telehealth, online pharmacies, and retail pharmacies utilizing home delivery options. These are areas where we have been developing relationships with industry leaders and emerging technology companies and we believe we are well positioned to capitalize on these trends. For example, contraception is an important category within telehealth and since 2019 we have been working with leading online telehealth platforms that focus on directly prescribing and filling birth control to patients.

We reduced our operating expenses at the beginning of COVID-19 pandemic, and we continue to identify areas in which we can further reduce operating expenses in the future. These cost cuts and reductions included permanent cost savings, as well as the interim cessation of certain spending that may be restarted in future quarters. These cost cuts included:

We continue to monitor the COVID-19 pandemic and adapt to the impacts it has on our business. As interactions with HCPs continue to be challenged during the fourth quarter of 2020, we continue to utilize digital engagement tools and tactics and virtual detailing to remain engaged with prescribers and distribution channels to supplement live interactions.

As of the date of this Annual Report on Form 10-K, we are providing continued access to our products for patients.

As of the date of this Annual Report on Form 10-K, we do not anticipate a shortage of our products due to ~~menopause.~~ the COVID-19 pandemic.

While we currently believe that our COVID-19 contingency plan has the ability to mitigate the effect of the COVID-19 pandemic on our business, the severity of the impact of the COVID-19 pandemic on our business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, the effectiveness of, and ability to widely distribute, the COVID-19 vaccine, the duration of “stay at home,” quarantine or “social distancing” orders, the ability of our sales force to access HCPs to promote our products, increases in unemployment, which could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, and the impact of the pandemic on our global supply chain, all of which are ~~also focused on commercialization activities necessary for launch~~uncertain and cannot be predicted. Our future results of ~~BIJUVA™~~operations and ~~ANNOVERA™. BIJUVA™ is our hormone therapy combination~~liquidity could be materially adversely affected by delays in payments of ~~bio-identical 17ß-estradiol~~outstanding receivable amounts beyond normal payment terms, supply chain disruptions, uncertain demand, and ~~bio-identical progesterone in a single, oral softgel capsule, for~~ the ~~treatment~~impact of ~~moderate-to-severe vasomotor symptoms,~~any initiatives or ~~VMS, due~~programs that we may undertake to ~~menopause in women with a uterus, which was approved by the FDA on October 28, 2018. ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), is the first~~address financial and ~~only patient-controlled, procedure-free, reversible prescription contraceptive~~operations challenges that ~~can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018,~~ we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA™ in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY® and BIJUVA™ in Canada and Israel.may face.

Our business may also be affected by negative impacts of the COVID-19 pandemic on capital markets and economies worldwide, and it is possible that the pandemic could cause a local and/or global economic recession. While policymakers globally have responded with fiscal policy actions to support the healthcare industry and economy as a whole, the magnitude and overall effectiveness of these actions remains uncertain.

At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable a new standard of care. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands. Ourour purposeful and continuous partnership with ~~healthcare professionals~~HCPs and women is at the heart of our strategies for delivering innovative solutions for ~~women at every stage of her life.~~women. From pregnancy to ~~after menopause,~~post-menopause, we believe the only way to truly connect with and understand women and their healthcare professionals is to ask questions.

Healthcare has become increasingly consumer driven. Therefore, patients are seeking more information, control, and convenience, which places additional time and financial pressures on ~~physicians,~~HCPs and as a result ~~physicians~~HCPs are looking for improved ways to provide better service to their patients. A ~~recent~~ study by IMS Health Inc. concluded that ~~physicians~~HCPs desire fewer but more encompassing relationships with companies that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients. Our goal is to meet this challenge by focusing on the opportunities in women’s health, specifically the OB/GYN market, to provide a better customer experience for ~~physician, payer, pharmacist,~~healthcare providers, payers, pharmacists, and ~~patient~~patients through the following means:

At the forefront of our sales approach is the philosophy that the ~~physician~~healthcare providers should recommend or prescribe products based only on what is best for the patient. In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having a portfolio of high-quality product options that can be recommended or prescribed by ~~both the physician~~HCPs, and ~~payer~~reimbursed by either government or private third-party payers, is the foundation of providing valuable options to the patient. We are dedicated to enabling healthcare professionals to advance the health of ~~woman~~women by offering new treatment options and giving voice to women’s needs and health concerns. We are committed to partnering with women’s health advocacy organizations as we create and commercialize solutions to help women transform how they experience reproductive health.

Our sales model focuses on the “4Ps”: patient, provider, pharmacist, and payer. We market and sell our products primarily through a dedicated national sales force that calls on HCPs primarily in the OB/GYN market space. In addition, our products allow HCPs to offer an alternative to patients at a co-payment ~~and~~ that provides patients a cost that is competitive in the marketplace. We also believe that our combination of branded and authorized generic lines of prenatal vitamins offers ~~physicians,~~HCPs, women, and payers cost-effective alternatives for top-quality care. We supply our prescription products to consumers through ~~retail~~ pharmacies nationwide. Our fully staffed customer care center uses current customer relationship management software to respond to HCPs, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and ~~live-chat.~~live chat.

We believe our sales force has developed strong relationships in the OB/GYN market to sell our current products. We have ~~also~~ established relationships with some of the largest OB/GYN practices in their respective markets. By delivering ~~additional products through the same sales channel,~~our portfolio to similar customer bases of women and OB/GYNs, we believe we can leverage our already deployed assets to increase sales of our ~~sales~~products and achieve profitability. ~~As a result, we will~~We leverage our existing infrastructure, including our sales force, to efficiently commercialize our FDA-approved pharmaceutical products: ANNOVERA, IMVEXXY, and BIJUVA and our VitaMedMD and BocaGreenMD line of prenatal ~~vitamins and our recently approved products: IMVEXXY®, BIJUVA™, and ANNOVERA™.~~vitamins. In addition to our focus on direct selling from our sales organization, which currently targets approximately 128 territories, we ~~have executed a branded multichannel awareness campaign for HCPs leveraging digital,~~utilize other commercial levers such as non-personal promotion to HCPs and ~~journal advertising~~direct-to-consumer marketing as appropriate to drive awareness and have already reached virtually all the active writing HCPs within the VVA category with IMVEXXY® branded messages. Our sales organization is planned for approximately 200 territories that will cover the most important HCPs foreducation of our product portfolio. ~~In addition,~~Finally, we ~~may~~ partner with ~~additional licensors or other~~ strategic partners and licensees to commercialize our ~~drugs outside~~pharmaceutical products in specialty segments of the ~~OB/GYN market or~~birth control markets and in non-U.S. markets.

As of December 31, ~~2018,~~2020, we marketed and sold ~~IMVEXXY®, our first FDA approved product~~ANNOVERA, IMVEXXY, and BIJUVA under the TherapeuticsMD brand, our prescription prenatal vitamins under our vitaMedMD brand name, and authorized generic formulations of our prescription prenatal vitamin products under our BocaGreenMD ~~Prena1~~ brand name. We believe that our vitaMedMD brand name has become a recognized name for high quality women’s healthcare, while our BocaGreenMD products provide physicians, women, and payers with a lower wholesale acquisition cost alternative for prenatal vitamins. We intend to leverage our existing relationships and distribution system to introduce our next two products, BIJUVA™ and ANNOVERA™, which will enable us to provide a comprehensive line of women’s healthcare products.

We believe that the relationships our national sales force has developed with OB/~~GYN’s,~~GYNs, through our ~~current~~ prescription prenatal vitamin products and ~~newly-approved~~our FDA-approved pharmaceutical products, ~~such as IMVEXXY®,~~ will continue to grow as these products ~~along with ANNOVERA™ and BIJUVA™~~ offer HCPs new opportunities to serve the needs of their ~~patients at each stage of their life.~~patients. By delivering our entire portfolio through the same sales channel and demonstrating how these products can help women as different needs emerge throughout their lifetime, we believe we can create efficiencies and synergies to further our growth.

Exclusive Focus on Women’s Health Issues. We have steadily developed relationships with many of the largest OB/GYN practices in the country through the sales of our prenatal vitamins and ~~IMVEXXY®.~~our FDA-approved pharmaceutical products. We believe that our singular focus on women’s health issues ~~will enable~~enables us to continue to build long-term relationships with women as they move through their life cycles of family planning to ~~after menopause.~~post-menopause.

Focus on Hormone Therapy Products. We ~~plan to~~ continue our focus on the ~~development, clinical trials, and~~ commercialization of FDA-approved bio-identical hormone therapy products designed to (1) alleviate the symptoms of, and reduce the health effects resulting from, menopause-related hormone deficiencies, including VMS and VVA, and (2) ~~demonstrate equivalent clinical efficacy at lower doses. We believe there is a~~fill the large unmet need in this segment of the market.

Deepening focus on other parts of a women’s reproductive lifecycle. With the acquisition and ~~forthcoming~~ launch of ~~ANNOVERA™,~~ANNOVERA, we are demonstrating our intent to provide effective and innovative products for women at all lifecycle stages.

Penetrate Compounding Market with ~~FDA-approved~~FDA-Approved Products. ~~We believe BIJUVA™~~BIJUVA is currently the only ~~current~~ FDA-approved hormone therapy combination product that is bio-identical to the estradiol and progesterone produced by the ovaries, and will provide a proven alternative to non-FDA approved compounded bio-identical hormone therapy products, and potentially at a lower price to patients since most insurance companies do not provide coverage for ~~non-FDA approved~~ compounded ~~products.~~products, which are not FDA-approved and supported by professional societies. We continue to work with independent and community-based pharmacies that currently compound bio-identical hormone therapy products to help introduce patients and prescribers to our FDA-approved ~~hormone therapy~~ products. ~~We launched~~Our BIO-IGNITE program is focused on supporting the ~~BIO-IGNITE™ program, an outreach program to quantify the number of compounded bio-identical estradiol and progesterone prescriptions currently dispensed by the 3,000-3,500 high-volume compounding~~synergistic relationships between community pharmacies and qualify their interests in potentially dispensing our FDA-approved products. As part of the BIO-IGNITE™ program, qualified pharmacies may be eligible to participate in certain purchasing groups and wholesaler programsHCPs so that offering ~~BIJUVA™~~BIJUVA, IMVEXXY and ~~IMVEXXY®~~ANNOVERA as appropriate treatment alternatives is economically practical for ~~the pharmacy.~~independent and community-based pharmacies. A dedicated team of Key Account Management, or KAM, is focusing their efforts on growing BIJUVA through our higher writing BIJUVA prescribers and our BIO-IGNITE partners. As of December 31, 2020, there were approximately 260 BIO-IGNITE compounding pharmacies that were dispensing BIJUVA, IMVEXXY, and ANNOVERA.

Multi-Channel Marketing Emphasis. We ~~plan to~~ continue our emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that are receptive to the data and savings we provide. In addition, we ~~may partner~~work with ~~additional licensors or other~~ strategic partners and licensees to commercialize and/or market our ~~drugs outside of the OB/GYN market or~~pharmaceutical products in non-U.S. markets. In ~~addition, the~~our U.S. markets, we have broadened our channels that allow for wide patient access. The proliferation of digital technology has dramatically increased the amount of information available to patients and providers. We believe this makes patient/provider engagement and experience a more important factor for life sciences companies and that providing patients and providers with important information on a real-time basis is a critical piece of serving this market. As an example of the impact of technology on women’s health, products such as ANNOVERA can be prescribed to patients via online platforms, and other direct-to-consumer telehealth platforms. Subject to state telehealth and prescribing laws, prescribers affiliated with direct-to-consumer telehealth platforms can prescribe or offer products to patients through a convenient virtual platform.

Multiple Distribution Partners. We ~~plan to continue to pursue~~have multiple distribution partners, including large chain pharmacies, independent community pharmacies, mail order, and compounding and specialty pharmacies. We believe that providing a higher level of customer care through unique programs targeted at each of these distribution partners can produce better outcomes and value for the patient, provider, and payer.

Geographical Expansion. We ~~currently plan~~continue to ~~expand~~adjust our ~~geographic~~ marketing footprint in the United States and sales team, towhich currently targets approximately ~~200 professionals~~128 territories, as we continue to commercialize ~~IMVEXXY®, BIJUVA™~~ANNOVERA, IMVEXXY, and ~~ANNOVERA™.~~BIJUVA.

We plan to commercialize the products in our portfolio through a common model focused on the belief that providing good experiences for both HCPs and patients will drive profitability for TherapeuticsMD. Given that our portfolio focus is exclusively in women’s health, each new product launch will allow us to further leverage our existing infrastructure and build out our reputation as the premier women’s health organization in the United Sates. Below is more detail on our commercialization model:

We accomplish educating HCPs primarily with our field sales organization. We have defined a sales force targeting approximately 200 territories, covering approximately 26,000 HCPs which covers approximately 63% of the addressable market. We are deploying a hybrid sales model that combines an internal sales leadership team with a fully dedicated contract sales force to call on our target HCPs. Additionally, we have an inside sales team that covers areas of the U.S. where key HCPs are located but where we do not have defined territories. In addition to the traditional sales organization, we have launched our key account management organization, or KAMs, to engage with our BIO-IGNITE™ partners.

In addition to our sales organization, we leverage non-personal promotion (multi-channel advertising) to targets and non-targets that drive awareness, education, and action. These efforts allow for pull through of the sales organization efforts and identification of new targets that have interest in writing prescriptions for one or more of our products. We believe this will drive increased prescribing for our products and lift the overall writing universe by keep the menopause categories and our products top of mind in the HCP community.

The pharmaceutical industry is subject to intense competition and is characterized by extensive research efforts and rapid technological change. Competition in our industry occurs in a variety of areas, including developing and bringing new products to market before others, developing new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower cost, and developing new products to provide benefits superior to those of existing products. Most major pharmaceutical companies, as well as numerous specialty pharmaceutical companies, sell products in the women’s health sector of the pharmaceutical industry, which is comprised of products designed for post-pubescent females and is generally considered very fragmented. There are many companies focused on the women’s health sector of the pharmaceutical industry that have significantly greater financial and other resources than we do, including generic manufacturers, drug compounding pharmacies, and large pharmaceutical companies. In addition, academic and other research institutions could be engaged in research and development efforts for the indications targeted by our products.

According to the BBC Research report “Pharmaceuticals for Women’s Health: Global markets to 2023,” post-menopausal osteoporosis, pregnancy disorders and management, menopause, endometriosis, and polycystic ovary syndrome (PCOS) are the largest segments within the global market for women’s health therapeutics. The global market for women’s health therapeutics reached nearly $30.5 billion in 2018 and should reach nearly $37.3 billion by 2023, at a compound annual growth rate, or CAGR, of 4.2% for the period of 2018-2023. In addition, the menopause market for women’s health therapeutics reached $5.4 billion in 2018 and should reach $6.7 billion by 2023 at a CAGR of 4.5% through 2023. According to the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report “Women’s Health Therapeutic Market through 2018,” the women’s health therapeutics market is one of the most attractive markets in the global pharmaceutical industry.

According to the BBC Research report “Pharmaceuticals for Women’s Health: Global markets” post-menopausal osteoporosis, pregnancy disorders and management, menopause, endometriosis, and polycystic ovary syndrome (PCOS) are the largest segments within the global market for women’s health therapeutics. Women’s health therapeutics established a very strong presence in the global pharmaceutical market over the last few decades. The market is expected to grow moderately, mainly due to patent expirations of blockbuster drugs such as Evista, the Premarin family, Forteo, Mirena, Boniva, Actonel, Gonal-F and several other. However, the launch of new drugs in the market, and novel drugs under research and development in the late-stage pipeline, has the strong potential to drive the market during the forecast period. The global market for women’s health therapeutics is projected to grow from $31.5 billion in 2019 to $41.2 billion by 2025, at a compound annual growth rate (CAGR) of 4.7% for the period of 2019-2025. The menopause market is projected to grow from $5.7 billion in 2019 to $7.7 billion by 2025 at a CAGR of 5.4% through 2025.

Menopause is the spontaneous and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. In the U.S., there are approximately 42 million women in this age group with an additional 6,000 women reaching menopause age every day, or over 2 million additional women per year. Classic symptoms of menopause are VMS (including hot flashes and night sweats), vulvovaginal symptoms (including dyspareunia and vaginal dryness) and sleep disturbances. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. Common treatments for menopausal VMS and vulvovaginal symptoms of menopause range from prescription medications, including hormone therapy and non-hormonal options, to over-the-counter supplements and lubrication options.

Hormone therapy is the most effective treatment in the United States and Canada for relief of menopausal symptoms according to the North American Menopause Society, or NAMS. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. The symptoms include hot flashes, night sweats, sleep disturbances, and vaginal dryness. According to Symphony Health Solutions,Approved FDA prescriptions for FDA-approved hormone therapy products for the treatment of menopause symptoms or prevention of osteoporosis generated total U.S. sales of over $5.0 billion on over 30 million prescriptions for the 12 months ended December 31, 2018, of which prescriptions for oral hormone therapy accounted for approximately $2.1 billion in U.S. sales on 20 million prescriptions over the same period.

~~Prescriptions~~ for menopausal hormone therapy in the United States dropped significantly following the Women’s Health Initiative, or WHI, study results published in 2002, which found that subjects using conjugated equine estrogens plus the synthetic progestin medroxyprogesterone acetate had, among other things, a greater incidence of coronary heart disease, breast cancer, stroke, and pulmonary embolism. ~~Several additional studies regarding the benefits and risks of~~This study caused a significant change in hormone therapy prescribing habits. Since 2002, many women and HCPs have ~~been conducted over~~chosen compounded hormone therapy, a bio-identical solution for treating VMS, and the ~~last decade since the WHI results were first published.~~use of local vaginal therapy increased during this time. The FDA recommends that women with moderate-to-severe menopausal symptoms who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.

There were approximately 41.7 million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly by 2.8% to 42.9 million in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures.

Estrogen (with or without a progestin) is the most effective treatment of VMS and VVA due to menopause according to NAMS. According to Symphony Health Solutions, total U.S. sales of FDA-approved oral, transdermal, and suppository estrogen (with and without a progestin) hormone therapy products were approximately $4.1 billion for the 12 months ended December 31, 2018. The three primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, emulsion, or vaginal suppositories and creams.

Estrogen therapies are used to treat VMS due to menopause that are a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause. Estrogen therapy has been used to manage these symptoms for more than 50 years. Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen. Based upon the age demographic for all women receiving prescriptions for estrogen therapy and the average age range during which women experience VMS, we believe that estrogen is primarily used for the treatment of VMS, but also is prescribed for the prevention of osteoporosis.

Estrogen-only therapy, or ET, is used primarily in women who have had a hysterectomy and/or have undergone surgical menopause, as those women do not require a progestin to protect the uterine endometrium. Approximately 433,000 women undergo a hysterectomy each year in the United States according to the United States Centers for Disease Control and Prevention. ET is also used for the treatment of VVA, which has a variety of indications, including dyspareunia (painful intercourse), vaginal dryness, vaginal itching and irritation, painful urination, and other symptoms.

ET is also approved for the prevention of osteoporosis. Multiple studies conducted on various estrogen compositions, including studies published in the Journal of the American Medical Association in 2002, Osteoporosis International in 2000, The Lancet in 2002, Maturitas in 2008, and Climacteric in 2005, suggested efficacy based on increases in bone mineral density. Epidemiological and some fracture prevention studies, such as the study published in the New England Journal of Medicine in 1980, also have suggested a decrease in bone fractures as a result of ET.

According to Symphony Health Solutions, total FDA-approved ET only U.S. sales amounted to $4.1 billion, of which $1.9 billion was specifically used for the treatment of VVA, for the 12 months ended December 31, 2018.

Progestins include the naturally occurring hormone progesterone and several synthetic progestin compounds that have progestational activity. These agents are used for a variety of indications and conditions, but most often, progestins are used either alone or in combination with an estrogen for hormonal contraception and to prevent endometrial hyperplasia from unopposed estrogen in hormone therapy. Progestins alone are also used to treat women with secondary amenorrhea to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis. Progesterone has also been used to prevent threatened or recurrent pregnancy loss and for the prevention of preterm birth. Progestins have also been used in fertility treatments. Progestins have also been used as a palliative measure for metastatic endometrial carcinoma and in the treatment of renal and breast carcinoma.

Progestins are used in combination with estrogen in menopausal women with uteruses to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer. Studies have shown that, after one year, the incidence of endometrial hyperplasia is less than 1% in women taking estrogen/progestin combinations, in contrast to up to 20% in women taking estrogen alone. In accordance with FDA recommendations, doctors typically recommend that a menopausal or post-menopausal woman who has a uterus take estrogen plus a progestin, either as a combination drug or as two separate drugs. Symphony Health Solutions estimates that sales of FDA-approved combinations of estrogen and progestins were approximately $580 million and the sales of estrogens and progesterone on a stand-alone basis were approximately $1.6 million and approximately $746 million, respectively, in the United States for the 12 months ended December 31, 2018. ~~According to national surveys of compounding pharmacists, it is estimated that compounding pharmacies fill $1.3 billion annually in menopausal hormone therapy.~~

According to the EvaluatePharma® World Preview 2018, Outlook to 2024 report, despite the global pharmaceutical industry facing pricing and market access concerns, worldwide prescription drug sales are expected to reach approximately $1.2 trillion by 2024, which would represent a compound annual growth rate of approximately 6.4% between 2018 and 2024. New drug approvals in 2017 increased to 55 (consisting of new molecular entities and biologics), up 104% as compared to the low of 27 approvals in 2016. Following the drop in 2016 approvals, 2017 suggests a return to form in industry research and development productivity. A record of 55 new molecular entities were approved in 2017 with total US sales five years post launch for products approved in 2017 reaching $33.2 billion. There were 56 new drugs (consisting of new molecular entities and biologics) approved by FDA in 2015 and 51 new drugs approved by FDA in 2014. The value of these drugs continues to be high, and with U.S. five years post-launch sales of the new drugs approved in 2017, 2016 and 2015 forecast to be over $33 billion, $13 billion, $28 billion, respectively.

On May 30, 2018, we announced that the FDA had approved the 4 μg and 10 μg doses of IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-μg formulation of IMVEXXY® represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY® 10-μg became available for commercial distribution in late July 2018 and both doses were commercially available by September 2018.

As part of the FDA’s approval of IMVEXXY®, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to also participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product’s specifications, which we submitted to FDA.

On July 9, 2018, we launched IMVEXXY® 10-μg with our early experience program to a targeted sample of HCPs throughout the U.S. The national launch of the 10-μg dose of IMVEXXY® began in August 2018, and the 4-μg dose of IMVEXXY® launched on September 13, 2018.

Since FDA approval of our NDA for IMVEXXY®, we have been focused on executing our launch plan. The key objectives of our launch plan include: (i) providing broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of IMVEXXY® amongst HCPs, (iii) designing and deploying our customer facing model, and (iv) developing our internal capabilities (for example, in the areas of finance, human resources, medical affairs, information technology, data analytics, pharmacovigilance capacity and compliance) to support our commercial-stage company. We have made progress in each of these key strategic areas:

According to Symphony Health Solutions, the FDA-approved U.S. market for treatment of VVA in menopausal women was approximately $2.0 billion for the 12 months ended December 31, 2018. Approximately $1.7 billion of such sales were by three products currently on the market: PREMARIN® cream (Pfizer), ESTRACE® cream, both brand and generic (Allergan and Mylan) and Vagifem® which is now mostly generic (Yuvafem by Amneal Pharmaceuticals). The two recent launches were Osphena® (Duchesnay USA, Inc) ~~and Intrarosa® (Amag Pharmaceuticals), which still have relatively small market share.~~

On October 28, 2018, the FDA approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms, or VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA™ have the same chemical and molecular structure as the hormones that are naturally produced in a woman’s body. With the approval of BIJUVA™, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA™ is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to FDA as required in our approval.

We believe the substitutable menopausal hormone therapy market for BIJUVA™ consists of three distinct product categories, two of which are FDA-approved products that are easily measured and monitored, and the third of which is typically referred to as “bio-identicals,” which are not FDA-approved, not easily measured, and sold through compounding pharmacies. The first category, representing approximately 2.5 million annual prescriptions as of December 31, 2018, is for FDA-approved synthetic hormone combinations, which have been linked to the risks identified in the WHI, and do not represent our target market. The other two categories consist of bio-identical hormone markets that represent our target market. The second category includes approximately ~~3.9 million~~ prescriptions of FDA-approved separate bio-identical hormone products, like Estrace® and Prometrium®, as of December 31, 2018. This bio-identical hormone regimen has not been studied or FDA-approved to be used together. Instead, these products are often used off-label to provide patients with an FDA-approved bio-identical hormone regimen but require two separate copays as well as issues related to compliance with separate products. We believe that there is no reason healthcare providers and patients would continue to use this combination of two separate products once BIJUVA™ is available. The third and largest category represents at least 10 million prescriptions annually of the unapproved, compounded bio-identical hormones that have not been proven safe and effective, are not covered by insurance, and are substitutable with BIJUVA™.

The approval of BIJUVA™, based on the phase 3 clinical trials established for the first time, a combination of bio-identical estradiol and bio-identical progesterone used in a continuous combined daily fashion with safety and efficacy data to support FDA-approval. Our hormone therapy drugs are characterized by safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bio-identical market. We believe that our drugs offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.

BIJUVA™ is planned to launch early in the second quarter of 2019 with a similar model to IMVEXXY®. The key objectives of our launch plan include: (i) broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of BIJUVA™ amongst HCPs, (iii) expanding and leveraging our existing customer facing model, and (iv) leverage our internal capabilities (for example, in the areas of finance, human resources, information technology, data analytics and compliance) to support launch of BIJUVA™.

Our focus will first be on key OB/GYN targets, particularly those that have already adopted IMVEXXY®, to deliver the core clinical messages as well as provide information on our patient affordability and adherence programs. In support of BIJUVA™, our field force is expanding to approximately 200 territories. In addition, we will continue to expand our BIO-IGNITE program throughout 2019 with a fuller expansion towards the end of 2019 when the six-month payer block for BIJUVA™ is expected to lift.

We believe that the successful launch of IMVEXXY® will allow us to leverage existing contracts with our third-party logistics partner and our distribution partners. With regards to payer coverage, we anticipate similar timing as experienced with IMVEXXY® as many commercial payers employ “new-to-market blocks” for newly launched brands until they have the opportunity to make a coverage decision based upon their internal review. However, our ability to leverage existing payer contracts by amending to include BIJUVA™ along with our recent experience with the payers may simplify the process.

Symphony Health Solutions estimates that sales of FDA-approved combinations of estrogen and progestins were approximately $580 million and the sales of estrogens and progesterone on a stand-alone basis were approximately $1.6 million and approximately $746 million, respectively, in the United States for the 12 months ended December 31, 2018. ~~According to national surveys of compounding pharmacists, it is estimated that compounding pharmacies fill $1.3 billion annually in menopausal hormone therapy.~~

~~The largest competitors for BIJUVA™ in the FDA-approved market are Pfizer (PREMPRO~~®~~) and Premarin, Teva and Mylan (generic estradiol, generic version of Estrace~~® ~~oral), and Noven (CombiPatch~~®~~), with sales of PREMPRO~~® constituting the largest branded product. None of the current FDA-approved drugs for the treatment of moderate-to-severe VMS due to menopause are bio-identical to both the estradiol and progesterone produced by the ovaries. Based on various reports, including data recently presented at the NAMS Annual Meeting, “Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It’s Not What You Think,” by JoAnn V. Pinkerton, et al., we estimate that U.S. sales of non-FDA-approved compounded combination addressable estradiol and progesterone products approximate $1.5 billion per year. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that BIJUVA™ represents the first time a combination product of estradiol and progesterone that is bio-identical to the estradiol and progesterone produced by the ovaries in a single combined product.

On July 30, 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up a full year, which was approved by the FDA on August 10, 2018. ANNOVERA™ was classified by the FDA as a “new chemical entity,” or NCE, and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act.

ANNOVERA™ is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA™, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone®, or NES, and ethinyl estradiol, or EE. EE is an approved active ingredient in many marketed hormonal products. Segesterone acetate, a new chemical entity, is a potent progestin that is not active orally but is active when administered via non-oral routes such as vaginal rings, implants, and transdermal systems. NES has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.

ANNOVERA™ can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or OCs, ANNOVERA™ does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA™ for 7 days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (1 year).

ANNOVERA™ releases daily vaginal doses of both active ingredients (NES and EE). The claimed release rate of 150 μg/day NES and 13/day μg EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA™ used for 13 cycles and is also supported by data from 13 cycles of in vitro release.

We currently estimate that ANNOVERA™ will be commercially available as early as the third quarter of 2019 with a planned full commercial launch by the first quarter of 2020. We intend to leverage our existing infrastructure, including our sales force, to commercialize ANNOVERA™, together with our recently approved IMVEXXY® and BIJUVA™. ANNOVERA™ will also follow the same commercialization model as IMVEXXY® and BIJUVA™.

Contraception can be defined as the deliberate prevention of pregnancy by interfering with normal process of ovulation, fertilization and implantation through the use of barriers, drugs, medical devices, or surgical techniques. ~~Contraceptive~~The contraceptive market includes non-hormonal ~~barrier~~ methods, such as the non-hormonal intrauterine device, or IUD, contraceptive sponge, diaphragm, cervical cap or shield and condoms, and hormonal methods such as oral contraceptives, injections, implants, hormonal IUDs and vaginal ring and transdermal contraceptive products. ~~Contraceptive drugs include pills, topical, and injectables.~~ Hormonal contraceptives can be composed of synthetic estrogens and progestins. Contraceptives containing both estrogen and a progestin are referred to as combination hormonal contraceptives, or CHCs, and contraceptives containing only progestin are referred to as progestin-only, or P-only. ~~There are three~~

The most common synthetic ~~estrogens~~estrogen approved in the ~~United States~~U.S. for use in contraceptive ~~products: EE, mestranol, or ME, and~~products is ethinyl estradiol ~~valerate, or EV. EE has been available for over 40 years and is the estrogen component in nearly all CHCs today.~~(EE). There are 10 different progestins that have been used in contraceptives sold in the ~~United States.~~U.S. The progestin component provides most of the contraceptive effect, while the estrogen component primarily provides cycle control, for example, minimizing bleeding or spotting between cycles. The progestin exerts its contraceptive effect by inhibiting ovulation, or release of an egg from the ovary, and by thickening cervical mucus. Thickening cervical mucus helps to prevent sperm entry into the upper genital tract. The estrogen component, in addition to providing cycle control, makes a small contribution to contraception by decreasing the maturation of the egg in the ovary. The latest data from ~~2015~~2017 to ~~2017~~2019 from the Centers for Disease Control and Prevention, or CDC, indicate that approximately ~~65%~~65.3% of women aged 15 to 49 were using some type of contraceptive ~~method.~~method with approximately half of these women in this age group using reversable prescription contraception. Most women who were not using contraception had reasons for not doing so, such as seeking pregnancy, being pregnant or postpartum, or not being sexually active.

According to Grand View Research: “Contraceptives Market Analysis By Drug (Oral Contraceptive Pills, Injectables, Topical), By Device (Male, Female Condoms, Copper, Hormonal IUD, Vaginal Rings, Subdermal Implants) And Segment Forecasts To 2022,” male and female condoms, vaginal implants, subdermal implants, diaphragms, sponges, and intrauterine devices, or IUDs, are key devices and accounted for the largest share of the contraceptives market in terms of revenue. The IUD segment held one of the largest shares of the contraceptive devices in 2014, owing to the rising demand in the regions of Europe and Asia Pacific. A rising number of gynecologists opting for these contraception devices is expected to drive this segment over the forecast period. Contraceptive pills dominated the overall drugs market in 2014 in terms of revenue, owing to a significantly large consumer base, very high usage and government programs and initiatives to address the unmet needs of the women of the reproductive age. TherapeuticsMD now has presence in both the early and late reproductive years with our portfolio.

The U.S. contraceptive market size is expected to reach at $11.6 billion by 2025, expanding at a CAGR of 5.3% over the forecast period, according to Grand View Research, Inc. Increasing awareness about ~~LARC~~long-acting reversible contraceptives, or LARCs, is expected to augment the product demand, thereby driving the market over the next few years. According to the National Center for Health and Statistics, the use of LARCs in the ~~U.S.~~United States has increased nearly five-fold in the last decade among women aged 15 to 44 and we believe that this segment of the contraceptive market is attractive given its current growth trajectory. We believe that the increasing awareness about ~~long-acting~~long-lasting reversible contraceptive options will grow incremental product demand, thereby driving market growth over the coming years. This is currently led by IUDs. The market leader in the IUD market is Bayer with the following products: ~~Mirena®~~Mirena^®, ~~Kyleena®, Jaydess®~~Kyleena^® and ~~Skyla®~~Skyla^®. The remainder of the market is dominated by oral contraceptives, which is represented by one major brand, Lo ~~Loestrin®~~Loestrin^® Fe by ~~Allergan,~~AbbVie and a variety of generics led by generic manufacturers such as Teva Pharmaceuticals, Mylan and Lupin Pharma.

According to the CDC, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 73% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most HCPs encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.

The ~~industry~~prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either nonprescription products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2020, approximately 4.9 million prescriptions for ~~contraceptive products is characterized by intense competition~~prenatal vitamins were issued in the U.S. resulting in total sales of approximately $290 million.

In July 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA (segesterone acetate and strong promotion of proprietary products. While we believe that ANNOVERA™ provides us with a competitive advantage, we may face potential competition from many different sources, including large pharmaceutical companies, specialty pharmaceutical and generic drug companies, and medical device companies. We expect that primary competition for ANNOVERA™ will come from oral contraceptives, a vaginal ring contraceptive and LARCs. The vaginal ring contraceptive is represented by NuvaRing, (etonogestrel/ethinyl estradiol vaginal ~~ring)~~system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a ~~monthly~~total of 13 cycles (one year), which was approved by the FDA in August 2018. In October 2019, we began a “test and learn” market introduction phase of launch for ANNOVERA. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed this initiative in July 2020.

The segesterone acetate component of ANNOVERA was classified by the FDA as a “new chemical entity,” or NCE, and thus ANNOVERA has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year (13 cycles) ring-shaped contraceptive ~~ring~~vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone^®, or SA, and ethinyl estradiol, or EE. EE is an approved active ingredient in many marketed ~~by Merck. LARC methods include two types of contraceptives: IUDs~~hormonal contraceptive products. Segesterone acetate, an NCE, is a potent progestin that, based on pharmacological studies in animals and ~~subcutaneous hormone-releasing implants. It~~in vitro, does not bind to the androgen or estrogen receptors and has no glucocorticoid activity at contraceptive doses. SA has been ~~reported that newer LARC products have recently gained~~evaluated in ~~popularity, potentially due to their lower rates~~51 clinical studies across these delivery systems with more than 26,794 cycles of ~~side effects, greater effectiveness, and broader acceptability among different populations of women.~~exposure.

ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active ingredients (SA and EE). The claimed release rate of 150 μg/day SA and 13 μg/day EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.

As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. In accordance with the post-marketing requirements, the full protocol for the study was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.

We believe that ANNOVERA will compete across all the contraception options for women with focus on those women seeking a long-lasting option without a procedure.

For patients, ~~we believe that ANNOVERA™~~ANNOVERA provides a single, ~~long-acting~~long-lasting, reversible birth control product that ~~would~~does not require a procedure at the doctor’s office for insertion ~~at a doctor’s office,~~or removal, empowering women to be in complete control of their fertility and menstruation with a 21/7 ~~regime.~~regimen. We ~~anticipate~~believe that ~~ANNOVERA™~~ANNOVERA is ~~acceptable~~a unique alternative for women who have previously chosen other forms of birth control. These include nulliparous women or(or women who have never given ~~birth. Further, ANNOVERA™ is softer~~birth), women who are considering an IUD but would rather not have a procedure, women who are between pregnancies but desire protection without a long-term commitment, and ~~more pliable than NuvaRing and, unlike NuvaRing, does~~women who are not require refrigeration before being prescribed. NuvaRing generated approximately $564 million, $576 million and $515 million in net sales in 2017, 2016 and 2015, respectively, based on approximately 4.3 million, 4.5 million and 4.4 million prescriptions, respectively. We believe that ANNOVERA™ will have significant competitive advantagessatisfied with oral options due to ~~NuvaRing and anticipated generic versions of NuvaRing, including~~ the ~~ability to fill a one-year prescription in one pharmacy visit and the lack of a requirement to refrigerate the ring.~~

~~ANNOVERA™ Commercialization Strategy~~daily usage or potential side effects.

We believe that the strong initial commercial net revenue per unit of ANNOVERA and commercial insurance adoption provide us with an opportunity to deploy additional financial resources to maximize ANNOVERA’s consumer-focused commercialization strategy and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when necessary. As part of this strategy, we are pursuing distribution opportunities for ANNOVERA to provide women with additional access to ANNOVERA, particularly during the COVID-19 pandemic, with multiple direct-to-consumer telehealth platforms that extend the reach of ANNOVERA.

In May 2018, the FDA approved the 4-μg and 10-μg doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-μg formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available. IMVEXXY 10-μg became available for commercial distribution in July 2018 and both doses were commercially available in September 2018.

IMVEXXY is a small, digitally inserted, softgel vaginal insert that dissolves when inserted into the vagina. It is administered mess-free, without the need for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that is comfortable for patients, with no patient education required for dose application or applicators. Additionally, the dose packaging for IMVEXXY is designed to optimize compliance and convenience for users. IMVEXXY demonstrated efficacy as early as two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known).

As part of the FDA’s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material on an annual basis.

Based on prescription data from Symphony Health Solutions, the FDA-approved prescription market in the U.S. for the treatment of VVA symptoms includes seven products (including branded products and their generic equivalents), which generated an aggregate of approximately $1.8 billion in gross sales on approximately 6.0 million prescriptions for the 12 months ended December 31, 2020. Approximately $436 million in gross sales were generated by PREMARIN^® cream (Pfizer), the leading brand in the market. ESTRACE^®cream and Vagifem^® are now mostly generics which generated approximately $ 1.1 billion in gross sales for the 12 months ended December 31, 2020. These three products are localized estrogen therapy which is the most commonly used method for the treatment of VVA.

In October 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have the same molecular structure as the hormones that are naturally produced in a woman’s body. We launched BIJUVA in April 2019.

BIJUVA offers the convenience of a single-capsule combination of two hormones (estradiol and progesterone), which may improve a user’s compliance. The estradiol and progesterone in BIJUVA are plant-based, not animal-sourced, and does not contain peanut oil unlike other FDA-approved progesterone products. BIJUVA provides a sustained steady state of estradiol which reduced the frequency and severity of hot flashes in clinical studies with no demonstrated impact on a patient’s weight or blood pressure. Additionally, through clinical trials, BIJUVA has demonstrated endometrial safety and greater than 90% amenorrhea rates, while providing no clinically meaningful changes in mammograms, or in coagulation or lipid parameters, and while providing clinically meaningful improvements in quality of life and sleep disturbance.

In January 2020, we submitted a New Drug Application, or NDA, efficacy supplement for the 0.5 mg/100 mg dose of BIJUVA to the FDA for review and potential approval. The NDA efficacy supplement used existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses. On November 5, 2020, we withdrew the NDA efficacy supplement. We currently intend to file a Formal Dispute Resolution Request, or FDRR, with the FDA that disputes the FDA’s requirement that the efficacy supplement meet approval standards that have not been required of other approved drugs in BIJUVA’s therapeutic class. There can be no assurance that we will prevail with respect to the FDRR, if filed, or that the 0.5 mg/100 mg dose of BIJUVA will be approved.

Estrogen (with or without a progestin) is most commonly used to treat VMS due to menopause that is a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause. Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen. According to NAMS, the most effective treatment for VMS due to menopause is estrogen therapy.

Progestins are used in combination with estrogen in menopausal women with a uterus to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer. Progestins include the naturally occurring hormone progesterone and several synthetic progestin compounds that have pregestational activity. These agents are used for a variety of indications and conditions. Progestins alone are also used to treat women with secondary amenorrhea to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis.

According to Symphony Health Solutions, the total FDA-approved prescription market in the U.S. for all estrogen and progestin drug products for the treatment of VMS generated an aggregate of approximately $2.2 billion of gross revenue on approximately 23.4 million prescriptions for the 12 months ended December 31, 2020. The three primary hormone therapy products are estrogen, progestin, and a combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, and emulsions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA-approved branded and generic products for estrogen-only amounted to an aggregate of approximately $1.4 billion on approximately 13.7 million prescriptions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA-approved branded and generic products for progestins-only amounted to an aggregate of approximately $389.2 million on approximately 7.8 million prescriptions. For the 12 months ended December 31, 2020, gross sales in the U.S. of FDA approved branded and generic products for estrogens/progestins combined amounted to an aggregate of approximately $431.7 million on approximately 1.9 million prescriptions.

Based on the Symphony Health Solutions data and the uses of these products, we estimate that sales of FDA-approved combinations of estrogen and progestins (the addressable market for BIJUVA) were approximately $1.3 billion in the United States for the 12 months ended December 31, 2020. Based on various reports, including data recently presented at the NAMS Annual Meeting, “Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It’s Not What You Think,” by JoAnn V. Pinkerton, et al., we estimate, that U.S. sales of non-FDA-approved compounded combination addressable estradiol and progesterone products approximate $1.5 billion per year.

With the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to the FDA as required in our approval.

Our hormone therapy pharmaceutical products are characterized by safety and efficacy profiles that can be consistently manufactured to target specifications. This provides an alternative to the non-FDA approved compounded bio-identical market. We believe that our FDA-approved pharmaceutical products offer advantages in terms of demonstrated safety and efficacy, consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.

The largest competitors for BIJUVA in the FDA-approved market are Pfizer (PREMPRO^®) and Premarin, with sales of PREMPROand Premarin constituting the largest branded products. The remainder of the market is represented almost exclusively by generic products (estradiol, the generic version of Estraceoral, and generic micronized progesterone). The leading generic manufacturers of these products are Teva, Mylan, Sandoz Inc, and Amneal Pharmaceuticals. None of the competing FDA-approved drugs for the treatment of moderate-to-severe VMS due to menopause are a combination of both bio-identical estradiol and progesterone produced by the ovaries. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that BIJUVA represents the first time a combination product of estradiol and progesterone that is bio-identical to the estradiol and progesterone produced by the ovaries in a single combined product has been approved in the U.S.

We continue to manufacture and distribute our prescription prenatal vitamin product lines under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prena1 name. We will continue to support the vitaMedMD and BocaGreenMD products as they are important products to our core customers and help provide us with continued access to sell our women’s health portfolio. Our current prenatal vitamin product line features a unique, proprietary combination of FOLMAX™, FePlus™, and pur-DHA™ and includes the following products:

For the years ended December 31, 2020, 2019, and 2018, approximately 16%, 20%, and 93%, respectively, of our consolidated product revenue was generated by our prenatal vitamin products.

We are commercializing the products in our portfolio through a common model focused on the belief that providing good experiences for both HCPs and patients will drive profitability for TherapeuticsMD. Given that our portfolio focus is exclusively on women’s health, we believe that each new product launch will allow us to further leverage our existing infrastructure and build out our reputation as the premier women’s health organization in the U.S. Below is more detail on our commercialization model:

HCP Education - Initially, we focus on the high writing and high potential HCPs in each territory to gain a full understanding of their prescribing behavior and practices. Our focus is on driving initial prescriptions of these writers for each new product launch and utilizing the time to also pull through on our portfolio of existing products. Once regular writing is established with the initial group of HCPs, we expand our reach to a larger set of HCPs writing in the category. We educate HCPs on our products primarily with our field sales organization supplemented by non-personal promotion. Our sales force currently has approximately 128 territories ~~cover a~~targeting approximately 20,000 physicians, which includes the most significant part of the addressable markets across our product portfolio. As of December 31, 2020, more than 5,200 HCPs had written at least one prescription for ANNOVERA, more than 21,500 HCPs had written at least one prescription for IMVEXXY and more than 7,100 HCPs had written at least one prescription for BIJUVA, the majority of whom are also IMVEXXY writers, thereby demonstrating the ~~area where the leading monthly contraceptive ring prescribers~~value of portfolio and focus. In addition to our sales organization, we leverage non-personal promotion (multi-channel advertising) to HCPs designed to drive awareness, education, and action. These efforts are ~~located. Our existing HCP targets represent approximately 87%~~designed to allow for pull through of the ~~current prescription volume~~sales organization’s efforts and identification of ~~the leading monthly contraceptive ring.~~new targets that have interest in writing prescriptions for one or more of our products. We believe this will ~~allow us~~drive increased prescribing for our products and lift the overall writing universe and our products to top of mind in the HCP community.

BIO-IGNITE - In addition to our sales organization calling on HCPs, we have ~~strong coverage of target HCPs while using~~a KAM team to support our existing ~~sales force~~BIO-IGNITE pharmacy partners and additional pharmacies that wish to ~~commercialize ANNOVERA™.~~enroll in the BIO-IGNITE program. Additionally, KAMs are focusing on supporting current prescribers of BIJUVA. As of December 31, 2020, there were approximately 260 BIO-IGNITE compounding pharmacies that were dispensing our products.

Payer Access - With the ever-changing payer environment, we believe it is critical to maximize breadth of coverage as quickly as possible to not inhibit patient access to product. We ~~intend~~do this while working to ~~add~~negotiate the best possible contracts for us. Many commercial payers employ “new-to-market blocks” for newly launched products until the payers have the opportunity to make a ~~dedicated marketing team exclusively focused~~coverage decision based upon their internal review of the product. When a product is not covered, the patient is responsible to pay the full price for the medication, which can significantly limit utilization of the product. As we seek to increase the number of lives covered by commercial payers, it is our objective to continue to seek unrestricted coverage. As of December 31, 2020, we have obtained coverage for the majority of commercial payers by commercial payer lives for IMVEXXY and BIJUVA and continue to seek unrestricted coverage from the remaining commercial insurance plans that we have not yet contracted with to provide affordable access for patients. For IMVEXXY, we achieved unrestricted coverage with the top ten commercial payers of VVA products by commercial payer lives and we continue to sign new agreements with other payers to cover IMVEXXY. In addition, as of December 31, 2020, four of the top eight Medicare Part D payers of VVA products, based on ~~ANNOVERA™~~covered lives, were adjudicating IMVEXXY. For BIJUVA, through December 31, 2020, we have achieved unrestricted coverage with nine of the top ten commercial payers of VMS products by commercial payer lives and we continue to sign new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the VMS market, as of December 31, 2020, two of the top six Medicare Part D payers of VMS products, based on covered lives, were adjudicating BIJUVA.

For ANNOVERA, we believe that ~~much of the marketing plan will focus in the digital space given the target patient demographics.~~

~~We believe that the~~its unique characteristics ~~of ANNOVERA™~~ will assist us in pursuing favorable commercial payer coverage, including only one pharmacy fill fee per year and no office visit or procedure fees. ~~However, obtaining~~We have made substantial progress in achieving unrestricted access to ANNOVERA through commercial payers, including having achieved adjudication with six of the top ten commercial payers by commercial payer lives as of December 31, 2020, and ~~maintaining favorable reimbursement can be a time-consuming and expensive process, and there is no guarantee that~~ we ~~will be able to negotiate or~~ continue to ~~negotiate reimbursement or pricing terms for our products, including ANNOVERA™,~~pursue discussions with ~~payers at profitable levels.~~several of the country’s largest commercial insurers to further expand coverage. As of December 31, 2020, approximately 62% of the commercial payer market covered ANNOVERA with unrestricted access under pharmacy benefits and approximately 74% covered ANNOVERA with step access.

In addition, the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act of 2010, or the ACA, mandates that private health plans provide coverage for women’s preventative services, without imposing patient cost-sharing requirements, as recommended by the Health Resources and Services Administration, or HRSA. HRSA ~~Guidelines~~guidelines require private health plans to cover, without cost-sharing, at least one form of contraception, or product, in each of the methods, or classes, identified by the FDA for women in its Birth Control Guide, which currently includes 1817 separate classes. For classes with more than one type of treatment, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. We believe that given no other vaginal contraceptive product offers contraceptive benefits for an entire year that it is possible that FDA could determine that ~~ANNOVERA™~~ANNOVERA constitutes a new class of contraceptive, which could allow for coverage of ~~ANNOVERA™~~ANNOVERA by private health plans with no out-of-pocket cost for patients. However, there is no assurance that FDA will make such a determination and it is possible that other FDA-approved products could also be included in such a new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. To the extent ~~ANNOVERA™~~ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover ~~ANNOVERA™~~ANNOVERA or may require patient cost-sharing obligations. Recently, some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. As of January 2021, 29 states require insurers that cover prescription drugs to provide coverage of FDA-approved prescription contraceptive drugs and devices. However, the Trump administration implemented new policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA. Originally, the religious exemption applied only to churches, but the Department of Health and Human Services extended that privilege in 2017 to family-owned, non-publicly traded corporations whose owners state that paying for birth control would violate their religious beliefs. Exempted entities no longer need to certify their objection or otherwise notify the federal government of their decision to stop providing coverage. Health plans sponsored by certain exempt religious employers and non-profit religious organizations that have religious objections do not need to offer contraception coverage through their health benefit plans. In July 2020, the U.S. Supreme Court issued a ruling in the case styled Little Sisters of the Poor Saints Peter and Paul Home v. Pennsylvania et al., upholding the legality of the Trump Administration’s religious exemption to the contraceptive mandate. As of January 2021, 21 states allow certain employers and insurers to refuse to comply with the ACA’s contraceptive coverage mandate. Prior to his election, President Biden stated that he would undo the religious exemption expansion if he were elected. To date, the Biden Administration has not issued any Executive Order, regulation, or other policy change to reverse the Trump Administration religious exemption policy, but such action may be forthcoming. We anticipate that any impact on contraception coverage due to religious exemption will be low; however, healthcare reform continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have a material adverse effect on patient usage of ANNOVERA.

In February 2020, we entered into an agreement with Afaxys Pharma, LLC, a pharmaceutical company focused on serving women in the public health system, to market ANNOVERA in the U.S. public health sector. As part of the Population Council License Agreement, we have agreed to provide significantly reduced pricing to federally designated Title X family planning clinics serving underrepresented women. We also have agreements to market ANNOVERA to the U.S. Department of Defense, the U.S. Department of Veteran’s Affairs, and in Puerto Rico.

~~The Population Council has previously entered into~~Obtaining and maintaining favorable reimbursement can be a ~~supply agreement~~time-consuming and expensive process, and there is no guarantee that we will be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with ~~Crystal Pharma SAU~~payers at profitable levels.

Supply - We take active steps to ensure our products are available in all classes of trade and delivery systems. We offer our products through traditional chain wholesalers (Cardinal, McKesson and AmerisourceBergen) and independent retail pharmacies, community compounding pharmacies with our BIO-IGNITE program, and online pharmacies. We continue to develop unique opportunities to sell direct to pharmacies to streamline distribution and better control costs.

Patient Affordability Programs - We have affordability and adherence programs in place for patients so that we can support appropriate use of our products by patients. Our co-pay assistance programs allow all patients to access our products at a reasonable cost.

Patient Adherence - Establishing compliance and adherence programs that make getting on a prescription medication and obtaining prescribed refills easy and convenient for the ~~supply~~patient and HCPs is a critical lever in our commercial model. Our focus is on minimizing complications in patients filling their first prescription and engaging with them throughout the life of ~~Nestorone®, one of the active pharmaceutical ingredients for ANNOVERA™,~~their treatment to ensure patients stay on and ~~a letter agreement with QPharma AB~~use therapy for the ~~optimization~~appropriate length of time. We have delivered effective patient engagement programs for all of our products.

Consumer Communication - Another critical level in the commercial ~~manufacturing process for ANNOVERA™. We intend~~model is consumer outreach. Our initial focus is on those patients who are already predisposed to ~~enter into agreements Crystal Pharma SAU for~~seek treatment, such as those patients new to therapy, and those patients dissatisfied with their current therapy. Next, we are focused on expanding the ~~supply~~market by energizing patients who are experiencing bothersome symptoms but who have not been motivated to seek treatment. Methods of ~~Nestorone®~~communication include online and ~~the Population Council has agreed~~offline media and span branded and unbranded communication to ~~use commercially reasonable efforts~~ensure we drive action from awareness of symptoms to ~~assist us in doing so. However, Crystal Pharma could decline~~desire to ~~enter into similar agreements with us on the terms we anticipate, or at all. We entered into~~speak to an HCP to acquire a ~~manufacturing agreement with QPharma for the manufacturing of ANNOVERA™, with an effective date of September 28, 2018.~~prescription.

Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of ~~$20 million~~$20,000,000 within 30 days following approval by the FDA of the NDA for ~~ANNOVERA™ and will be required to pay the Population Council an additional $20 million within 30 days following the release of the~~ANNOVERA. The first commercial batch of ~~ANNOVERA™.~~ANNOVERA was released during the third quarter of 2019 and we paid the Population Council a second milestone payment of $20,000,000 as a result of the commercial batch release. The Population Council is ~~also~~ eligible to receive additional milestone payments and royalties from commercial sales of ~~ANNOVERA™,~~ANNOVERA, as detailed below.

We assumed responsibility for marketing expenses related to the commercialization of ~~ANNOVERA™.~~ANNOVERA.

We are required to pay the Population Council additional milestone payments of $40 million upon cumulative net sales of ~~ANNOVERA™~~ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $200.0 million, $400.0 million and $1.0 billion.

In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ~~ANNOVERA™~~ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:

The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ~~ANNOVERA™~~ANNOVERA that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.

~~As part of~~The Population Council has agreed to perform and pay the ~~approval of ANNOVERA™,~~costs and expenses associated with two post-approval studies required by the FDA ~~has required a post-approval observational study be performed to measure the risk of venous thromboembolism. A protocol submission~~ for ~~the study is due to the FDA in August 2019. We~~ANNOVERA and we have agreed to perform and pay the costs and expenses associated with ~~this~~a post-approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. ~~Given~~We and the ~~observational nature~~Population Council formed a joint product committee responsible for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the ~~study, we do not believe that~~one-year vaginal contraceptive system, subject to oversight and decisions made by the ~~costs of the study will be material on an annual basis.~~joint product committee.

Unless earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council’s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ~~ANNOVERA™~~ANNOVERA in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 ~~days~~days’ prior notice to the Population Council.

As part of the Population Council License Agreement, we have the exclusive right to negotiate co-development and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council: a three-month contraceptive ring using Nestorone® plus bio-identical estradiol, which is currently in phase 2 clinical trials, and a new one-year contraceptive ring using Nestorone® plus EE, which is designed as a life cycle management product for the CVS that we have licensed.Council.

OnIn July ~~30,~~ 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™~~BIJUVA in Canada and Israel.

~~Under~~ Pursuant to the terms of the Knight License Agreement, Knight ~~will pay~~paid us $2 million in milestone fees ~~when it receives~~upon the first regulatory approval in Canada ~~for: (i) IMVEXXY®;~~for IMVEXXY and ~~(ii) BIJUVA™. Additional~~BIJUVA in the third quarter of 2020, and is also required to pay us sales milestone fees ~~and royalties are~~ based upon certain aggregate annual sales in Canada and Israel ~~for both IMVEXXY®~~of each of IMVEXXY and ~~BIJUVA™.~~BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™.~~

BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™~~BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.

~~As we commercialize our recently approved hormone therapy drugs, we continue to manufacture and distribute our prescription prenatal vitamins product lines under our vitaMedMD~~^®~~brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD~~^®~~Prena1 name. We believe that our vitaMedMD brand name has become a recognized name for high quality women’s health care, while our BocaGreenMD products provide physicians, women, and payers~~License Agreement with a lower wholesale acquisition cost alternative for prenatal vitamins. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our over-the-counter, or OTC, product lines, except for Iron 21/7 which we ceased manufacturing and distributing in October 2017. The sales of discontinued products have declined steadily over time resulting in immaterial sales.Theramex

In ~~March 2012,~~June 2019, we ~~launched~~entered into a licensing and supply agreement, or the Theramex License Agreement, with Theramex pursuant to which we granted Theramex an exclusive, perpetual license to commercialize BIJUVA and IMVEXXY for human use outside of the U.S., except for Canada and Israel, or the Theramex Territory. Pursuant to the terms of the Theramex License Agreement, Theramex paid us an upfront fee of EUR 14 million in cash. We are also eligible to receive up to an additional EUR 29.5 million in cash milestone payments, comprised of (i) an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets and (ii) an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments based on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex has agreed to submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY in certain specified markets within certain specified time periods and we may terminate the Theramex License Agreement if Theramex does not submit certain of such regulatory applications, submissions and/or registrations. We may also terminate the Theramex License Agreement if Theramex challenges our ~~first prescription prenatal vitamin, vitaMedMD Plus Rx, with subsequent launches~~patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. Pursuant to the terms of ~~our second prescription prenatal vitamin, vitaMedMD One Rx, in April 2012~~the Theramex License Agreement, we agreed to supply, or cause to be supplied, BIJUVA and ~~our third prescription prenatal vitamin, vitaMedMD RediChew™ Rx, in May 2012. In~~IMVEXXY to Theramex. We and Theramex have agreed to form a joint product committee responsible for advising and overseeing activities under the fourth quarter of 2012, we launched our BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were authorized generic formulations of our vitaMedMD-branded prescription prenatal vitamins. In the first quarter of 2014, we introduced a new prescription prenatal vitamin product under our branded vitaMedMD name as vitaPearl and under our authorized generic Prena1 name as Prena1 Pearl, which features a unique, proprietary combination of FOLMAX™, FePlus™, and pur-DHA™. In January 2016, we launched vitaTrue. Our current vitamin product line is as follows:

~~For the years ended December 31, 2018, 2017, and 2016, approximately 93%, 99.9%, and 99.8%, respectively, of our consolidated revenue was generated by our prenatal vitamin products.~~

According to the Centers for Disease Control and Prevention, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 73% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most doctors encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.

The prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either OTC products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2018, approximately 5.4 million prescriptions for prenatal vitamins were issued in the United States resulting in total sales of approximately $338 million.

TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bio-identical to – or having the same chemical and molecular structure as - the hormones that naturally occur in a woman’s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board, or IRB, approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we suspended enrollment and in October 2014 we stopped the SPRY Trial to update the phase 3 protocol based on discussions with the FDA. Our IND related to TX-002HR is currently inactive. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it. We have suspended further development of this drug candidate to prioritize our leading drugs.

TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is bio-identical to the hormones that naturally occur in a woman’s body. We currently do not have plans to further develop this hormone therapy drug candidate. Our IND related to TX-003HR is currently inactive. We have suspended further development of this drug candidate to prioritize our leading drugs.

We currently have placed on hold our four preclinical ~~projects that include development of~~projects: a progesterone-alone ~~and~~transdermal cream (TX-005HR), a combination estradiol and progesterone ~~products~~ transdermal cream (TX-006HR), and a pair of transdermal patch product candidates (TX-007HR and TX-008HR). In vivo and in ~~a topical cream form, which we refer~~vitro proof-of-concept preclinical studies were conducted to asassess TX-005HR and TX-006HR ~~respectively,~~with respect to penetration of the estradiol and ~~transdermal patch form, which we refer to as TX-00THR~~progesterone, and TX-0008HR, respectively. We completed a proof-of-concept preclinical study of TX-005HR in 32 rats. The study used four groups of eight female ovariectomized rats, each of whom were treated with subcutaneous injections of estradiol for eight days. On day four of treatment, they were dosed with a placebo, subcutaneous injections of progesterone, or a dose of TX-005HR topical progesterone cream. The results, presented at NAMS meeting in October 2015, showed that the progesterone in TX-005HR penetrated the skin and opposed the effectsuccessful opposition of subcutaneous estradiol on the endometrium. In ~~the fourth quarter of 2016,~~addition to menopausal treatments, we ~~submitted an IND application for TX-006HR. In 2018, we investigated the capability of the estradiol~~are also evaluating various other indications targeted to women’s health and ~~progesterone in TX-006HR to penetrate human skin. This experiment used donated skin from a postmenopausal woman and showed significant penetration of both active ingredients.~~wellness. We may, in the future, engage with a financing partner to advance ~~our topical cream and transdermal patch projects.~~one or more of these product candidates. We have also ~~developed~~placed on hold our oral progesterone and ~~patented novel, oral formulations of progesterone that have shown~~estradiol formulation (TX-009HR). Previously, TX-009HR showed improved bioavailability in animals. In ~~the fourth quarter~~2019, TX-009HR was tested in a Phase 1 study of ~~2018, we submitted an IND for TX-009HR, an estradiol~~healthy postmenopausal women and ~~progesterone containing oral formulation. In addition to menopausal treatments, we are also evaluating various other indications for our hormone technology, including contraception.~~was well-tolerated in that study.

We sell our prescription ~~prenatal vitamin~~pharmaceutical products and ~~hormone therapy drug~~prenatal vitamin products to wholesale distributors and retail pharmacy distributors. See Note 1213 to the consolidated financial statements included in this Annual Report for a discussion of the concentration of sales of our products.

The pharmaceutical markets in which we compete are not subject to seasonal sales fluctuation. However, our net revenues for the first quarter of each year can be negatively affected by the annual reset of high-deductible commercial insurance plans.

We have sourced and qualified third-party contract manufacturing organizations, or CMOs, for the commercial supply of our products. The regulations for manufacturing of approved drug products are significantly more stringent than the standards for manufacturing supplements or drug product for clinical trials. Our CMOs are responsible for the manufacture of our products in accordance with our specifications and applicable regulatory requirements. We have entered into long-term supply agreements with Catalent Pharma Solutions, LLC, or Catalent, for the commercial supply of our ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™,~~BIJUVA, and QPharma for the supply of ~~ANNOVERA™.~~ANNOVERA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each product. We may terminate the agreement for a particular drug for certain specified reasons. If we are unable to obtain sufficient quantities of drugs or receive raw materials in a timely manner, we could be required to delay our manufacturing and seek alternative manufacturers, which would be costly and time-consuming.

We have a multi-faceted risk management approach to ensure continuous supply from our qualified CMOs for the commercial supply of our products. This approach includes oversight of the manufacturing processes, regular Good Manufacturing Practice, or GMP, audits, a review of their business continuity plans, management of finished product inventory and safety stock, and second sourcing as appropriate.

We have also sourced and qualified manufacturers of the active pharmaceutical ingredient, or APIs, to be used in our drugs and drug candidates. We follow a risk management approach for our API manufacturer similar to that followed for the commercial supply of the finished drug product.

We use third-party manufacturers to manufacture and package our vitamin and supplement products, as well as meet applicable contract and regulatory requirements. We currently obtain all of our vitaMedMD and BocaGreen products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for the manufacture of our vitamin and supplement products. In addition to manufacturing, Lang also provides a variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review, and packaging production. We believe that Lang maintains multiple supply and purchasing relationships throughout the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.

We have experienced no difficulties in obtaining the vitamin and supplement products we need in the amounts we require and do not anticipate those issues in the future. We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang as our third-party manufacturer for most of our vitamins and supplements. Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services in the event our relationship with Lang terminates. Accordingly, we do not believe that such termination would have a material adverse effect on our business.

Our products for the U.S. market are required to be manufactured in accordance with the FDA’s current Good Manufacturing Practice, or cGMPs. Our third-party suppliers and manufacturers are also responsible for continued compliance with cGMP requirements. We have executed ~~Quality Agreements~~quality agreements that delineate the responsibilities of each company in the quality assurance process. To comply with these drug commercialization standards, we have personnel with pharmaceutical development, manufacturing, and quality assurance experience who are responsible for the relationships with our suppliers. We have contracted with Catalent, an established manufacturer of softgel drug products, to manufacture the commercial supply for both ~~IMVEXXY®~~IMVEXXY and BIJUVA™. In 2018, the Catalent facility that manufactures IMVEXXY® and BIJUVA™ received FDA Form 483 observations from an FDA inspection. For our vitaTrue product, a subcontractor to Lang received FDA Form 483 observations from an FDA inspection during 2018. Neither of these investigations were specific to our products.BIJUVA. We have also contracted with QPharma to manufacture the commercial supply for ~~ANNOVERA™.~~ANNOVERA. For the prenatal vitamins, our quality assurance team collaborates with Lang to monitor the cGMP compliance of Lang’s contracted manufacturers and packagers. Although each of Catalent, QPharma ~~has~~and Lang have received Form FDA ~~Form~~ 483 observations from FDA inspections in the past, we are not aware of any open FDA investigations into ~~its~~the manufacturing and/or packaging processes at the facilities that ~~would be~~are used ~~to manufacture~~for our products.

Our quality assurance team establishes controls that are designed to document the manufacturing process and ensure that our contract manufacturers meet product specifications and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations. ~~Our~~Depending on their roles and activities, certain of our contractors are subject to applicable requirements to test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards, ~~(when applicable),~~ including quantitative and qualitative assay and microbial and heavy metal contamination (as appropriate).

We distribute our products within the U.S. through our third-party logistics partner, Cardinal Logistics, who ~~ship~~ships to national ~~wholesaler~~wholesale distributors such as Cardinal, McKesson, and AmerisourceBergen, regional wholesalers such as Smith Drug, Anda, Value Drug and RDC, and alternate distribution partners. Wholesaler product inventory is monitored daily and sales out isare monitored weekly. We are subject to compliance responsibilities under the Drug Supply Chain Security Act, or the DSCSA, and the Prescription Drug Marketing Act, or PDMA, in relation to distribution of drug products in the commercial supply and dispensing chain and drug samples to HCPs, respectively, and are further subject to state laws on these topics. National and regional retail pharmacies along with online pharmacies are also an area of focus to make sure our products are purchased and dispensed properly.

Our goal is 100% customer satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal, we maintain a ~~fully-staffed~~fully staffed customer care center that uses current customer relationship management software to respond to HCPs, pharmacies, and consumers. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships and facilitate repeat visits and purchases.

Our representatives receive regular training so that they can effectively and efficiently field questions from current and prospective customers and are also trained not to answer questions that should be directed to a customer’s physician. Having a quality customer care center allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead generation, and customer retention.

We sell our prescription products through third-party logistics providers, wholesale distributors, and retail pharmacy distributors. We accept returns of unsalable prescription products sold through wholesale distributors ~~all~~within a return period of ~~whom may return a product within~~ six months ~~before~~prior to and ~~twelve~~up to 12 months ~~after~~following product expiration. Our vitamin and supplement products and IMVEXXY currently have a shelf life of 24 months from the ~~expiration~~ date of ~~the product. Once customers buy~~manufacture and BIJUVA and ANNOVERA currently have a ~~prescription product~~shelf life of 18 months from the ~~pharmacy, the~~date of manufacture. We do not allow product ~~may not be returned.~~returns for prescription products that have been dispensed to a patient.

We proudly stand behind the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under our quality guarantee, we:

We value frequent communication with and feedback from our customers to continue to improve our offerings and services.

~~Our~~Historically, our product development programs ~~are~~have been concentrated in advanced hormone therapy pharmaceutical products. We have engaged, and may continue to engage, in programs to provide alternatives to the FDA and non-FDA-approved compounded bio-identical market for hormone therapy. Our programs ~~seek~~have sought to bring new products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing hormone therapy alternatives.

~~Our research and development expenses were approximately $27.3 million in 2018, $33.9 million in 2017, and $53.9 million in 2016.~~

Our success depends, in part, on our ability to obtain patents, maintain trade-secret protection, and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one way we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products and to maintain our competitive position. We are diligently seeking ways to protect our intellectual property through various legal mechanisms in relevant jurisdictions. Where permitted, patents for our hormone therapy drug products have been submitted to the Orange Book.

As of December 31, ~~2018,~~2020, we had 2138 issued domestic ~~or U.S.~~ patents and 2439 issued foreign patents, including:

As of December 31, ~~2018,~~2020, we have a license to three Orange Book listed patents relating to ANNOVERA. These patents will expire in 2039 and establish an important intellectual property foundation. In addition, we have a license to six U.S. pending applications relating to ANNOVERA.

The sponsor of an approved 505(b) drug product, which approval is the first permitted commercial marketing of a drug with that drug’s active ingredient, may apply for a patent term extension (PTE) under 35 U.S.C. § 156. The length of a PTE is calculated based on the “regulatory review period,” which consists of one-half of the time between the initial effective date of the Investigational New Drug, or IND, for the clinical study(ies) supporting FDA approval of the drug and the date of the NDA submission, plus the time between the submission of the NDA and the date of FDA approval. Any period of time during the regulatory review period in which the applicant is deemed to have not acted with due diligence will be deducted from regulatory review period calculation. A PTE may not exceed five years, and the remaining term of a patent as extended by a PTE will be limited as necessary such that the remaining term does not exceed 14 years from the date of the NDA approval. Only one patent may be extended based on a regulatory review period, and a patent may not receive more than one PTE. The rights provided during the term of a PTE generally are limited to the approved use(s) of the product.

As of December 31, 2020, we had filed over ~~107~~138 patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our technology or our hormone-therapy drugs and drug candidates, and over ~~162~~193 international patent applications with respect to our technology or our hormone-therapy drugs and drug candidates, including Patent Cooperation Treaty (PCT) and national-stage filings.

We hold multiple U.S. trademark registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all the areas in which it is used. Federally registered trademarks have a perpetual life so long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.

We intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by expiration or otherwise, of any one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to account for patent rights of third parties.

~~OPERA® is~~ See “– Pharmaceutical Regulation – Regulatory Exclusivity” below for information regarding our ~~patented information technology platform used in our business. We believe the deployment of OPERA®~~intellectual property and ~~the further development and deployment of related technology creates a sustainable competitive advantage in clinical development and product improvement.~~challenges thereto.

As we continue to develop proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that will enable us to gain patent protection for these products.

While we seek broad coverage under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition, patents expire, and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially issued patents will adequately protect our intellectual property.

In the United States, the FDA regulates pharmaceuticals, biologics, medical devices, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including federal and state consumer protection laws, laws regarding pricing transparency, laws requiring the implementation of compliance programs, laws requiring the reporting of payments or other transfers of value to HCPs or other healthcare professionals, laws governing the financial relationships between manufacturers and HCPs or other referral sources and industry stakeholders, laws protecting the privacy of health-related information, laws restricting items and services of value provided to patients, and laws prohibiting unfair and deceptive acts and trade practices. See also Item 1A. Risk Factors – Risks Related to Our Business for a discussion, among other things, of the extensive and costly governmental regulation we are subject to.

The process required by the FDA before a new drug product may be marketed in the United States generally involves the following:

An IND application is a request for authorization from the FDA to administer an investigational drug product to humans. We have submitted six INDs for our hormone therapy drug ~~candidates, including an IND for TX-009HR in 2018.~~candidates. The INDs for TX-002HR and TX-003HR ~~are currently on~~were withdrawn in December 2019, the IND for TX006-HR was made inactive ~~status.~~in October 2020 and the INDs for TX-009HR was made inactive in December 2020. The INDs for TX-004HR, TX-001HR, ~~TX-006HR,~~remain active. The IND for ANNOVERA was transferred from the Population Council to us in May 2019 and ~~TX-009HR remain~~is also active.

Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in the clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from a central or each clinical trial site’s institutional review board, or IRB, before the trials may be initiated, and the IRB must monitor the study until completed and re-assess and approve the study at least annually. There are also requirements governing the reporting of ~~ongoing~~certain clinical trials and clinical trial results to public ~~registries.~~registry and results databases.

Clinical trials are usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety, characterize pharmacokinetics, and assist in finding the potential dosing range. ~~After phase 1,~~During Phase 2, the drug is administered to small populations of patients ~~(phase 2)~~ to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess dosing and safety. Phase 3 clinical trials are usually multi-center, double-blind, controlled trials in hundreds or even thousands of subjects ~~at various sites~~ to assess the safety and effectiveness of the drug.

During a clinical trial, we are required to inform the FDA and the IRB about adverse events associated with our drug candidate. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews unblinded data from clinical trials and ~~provides authorization~~assesses interim data to make recommendations regarding the feasibility and appropriateness for ~~whether or not~~ a trial ~~may~~to move forward ~~at designated check points based on access~~or continue to ~~certain data from the study.~~completion. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climates.

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including, among other things, negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed ~~labeling, among other things.~~labeling.

Once the NDA submission has been accepted for filing, the FDA’s goal is to review standard applications within 10 months of the 60-day filing date for new molecular entity NDA and original BLA submissions, or 12within 10 months of receipt for ~~a new molecular entity. However,~~non-NME and original BLA submissions. For Original Efficacy Supplements, the FDA’s goal is to review the application within 10 months of the receipt date. The review process ~~is often significantly~~can be extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.

Since regulatory approval of some of our drug products has been obtained, we are required to comply with several post-approval requirements. As a holder of an approved NDA, we are required to report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, to adhere to product sampling and distribution requirements, fulfill post-marketing study commitments, and to comply with requirements concerning advertising and promotional labeling for any of our ~~products.~~ drug products, which include, among other things, standards for direct-to-consumer advertising, restrictions that prohibit promoting products for certain uses or in patient populations that are not described in the product’s approved indications or that are not otherwise consistent with the approved, FDA-required label (known as “off-label use”), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available products for off-label use if they deem such use to be appropriate in their professional medical judgment, manufacturers may not market or promote such off-label uses.

Also, quality control and manufacturing procedures must continue to conform to ~~cGMP~~cGMPs to ensure and preserve the long-term stability of the drug product. ~~The FDA periodically inspects manufacturing facilities to assess compliance with~~ cGMP which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that we have contracted with for the commercial supply of our BIJUVA™ and IMVEXXY® hormone therapy drug products, was issued a Form FDA-483 in 2018 with respect to its softgel manufacturing plant. The observations and associated corrective actions identified in Catalent’s response to the Form FDA 483 do not relate specifically to our products. The current status of that Form FDA 483 is No Action Indicated. No Action Indicated status indicates that the FDA is satisfied with Catalent’s responses and proposed corrective measures to the observations and that no further regulatory action is needed following Catalent’s responses.

~~After regulatory approval of a drug product is obtained, we would be required to comply with several post-approval requirements. As a holder of an approved NDA, we would be required to report,~~regulations require among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of our products. Also, quality control and ~~manufacturing procedures must continue~~quality assurance as well as the corresponding maintenance of records and documentation and the obligation to ~~conform~~investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are, depending on the nature and scope of their activities, subject to ~~cGMP after approval~~FDA and certain state agency requirements relating to ~~ensure~~establishing and preserve the long-term stability of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements.

~~In addition, changes~~maintaining product quality. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.

The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. For example, Catalent, the CMO that we have contracted with for the commercial supply of our BIJUVA and IMVEXXY hormone therapy drug products, was issued a Form FDA 483 in 2019 with respect to its softgel manufacturing plant. The observations and associated corrective actions identified in Catalent’s response to the Form FDA 483 related to our BIJUVA product. The current inspection classification status of that Form FDA 483 is that the response was adequate and Voluntary Action Indicated. Voluntary Action Indicated status indicates that objectionable conditions or practices were found but the FDA is not prepared to take or recommend any administrative or regulatory action.

We rely, and expect to continue to rely, on third parties to produce clinical and commercial quantities of our drugs and drug candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution or require substantial resources to correct. In addition, discovery of previously unknown problems (for example, through adverse events observed in the post-marketing context, or in Phase 4 / post-marketing studies) with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition of new warnings and contraindications, and may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of our products under development.

Our hormone therapy ~~drugs~~pharmaceutical products and ~~drug~~product candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient. The medications created by the compounding pharmacy are ~~theoretically “new drugs” that would otherwise be subject~~not approved by the FDA and are therefore not reviewed to ~~the new drug approval requirements of the FDCA.~~evaluate their safety, effectiveness, or quality.

~~However, for~~For approximately 50 years, the FDA left regulation of compounding pharmacies to the states. In 1992, in response to various safety concerns, the FDA issued a Compliance Policy Guide, which announced that the “FDA may, in the exercise of its enforcement discretion, initiate federal enforcement ~~actions...when~~actions... when the scope and nature of a pharmacy’s activities raises the kinds of concerns normally associated with a manufacturer ~~and...results~~and.. results in significant violations of the new drug, adulteration, or misbranding provisions of the Act.” Thereafter, Congress enacted the Food and Drug Administration Modernization Act of 1997, or FDAMA, which sought to clarify FDA’s regulatory authority over compounding pharmacies. FDAMA exempted “compounded drugs” from the FDA’s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular compounded drugs. In 2002, though, the Supreme Court declared this provision of FDAMA to be unconstitutional under the First Amendment, effectively ~~re-instating~~reinstating the pre-FDAMA regime. Shortly thereafter, the FDA issued its 2002 Compliance Policy Guide 460.200, which states that the FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding pharmacies act more akin to traditional drug manufacturers.

To further clarify the FDA’s jurisdiction and following a prior history in which states were primarily responsible for the regulation of compounding pharmacies, in light of industry changes to large-scale compounding operations and concerns regarding product quality and patient safety, Congress enacted and ~~the~~ President Obama signed into law the Drug Quality and Security Act of 2013 which, among other things, formalized the relationship between the FDA and large-scale compounding pharmacies ~~by exempting~~allowing for certain compounding pharmacy products ~~from the~~to be offered without FDA approval requirements (e.g., an NDA or ANDA) and the requirement to label products with adequate directions for use, but ~~not~~requiring that the ~~exemption from~~facilities and products meet FDA cGMP requirements. To qualify for this exemption, a compounding pharmacy must register with the FDA as an “outsourcing facility,” subject to FDA inspection and other requirements. The FDA does not exercise the same authority to regulate compounding pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.

We received marketing approval for three NDAs in 2018, two for our hormone therapy drug products, IMVEXXY® and BIJUVA™, and one for our in-licensed contraceptive drug ANNOVERA™. Where permitted, patents for our hormone therapy drug products have been submitted to the Orange Book.

A Section 505(b) NDA applicant may be eligible for its own regulatory exclusivity period, such as a five-year or three-year exclusivity. The first approved Section 505(b) NDA applicant for a drug containing ~~a new~~an active ingredient that has not previously been approved in any other 505(b) NDA (a “new chemical entity,” or ~~NCE,~~NCE), is ~~entitled to~~eligible for a five-year ~~Hatch-Waxman~~NCE exclusivity ~~period.~~period starting on the date of the NDA approval. During this period, an Abbreviated New Drug Application, or ANDA, or 505(b)(2) application for a drug containing the protected active ingredient of the NCE product generally cannot be submitted to FDA until the end of the five-year exclusivity period, ~~(or~~except that such applications can be submitted at year four if the product is covered by an Orange Book listed ~~patent).~~patent and the ANDA or 505(b)(2) NDA includes a Paragraph IV Certification challenging such patent. Additional exclusivities may also apply.

The first approved Section 505(b) NDA applicant for a particular condition, or a supplemental NDA approval for a change to a marketed product, such as a new ~~extended release~~extended-release formulation for a previously approved product, may be ~~granted~~eligible for a three-year Hatch-Waxman exclusivity if one or more new clinical studies, other than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from ~~making effective~~granting final approval to any ANDA or 505(b)(2) application for the same condition of use or ~~for a~~ change to the ~~marketing~~marketed product that was granted exclusivity until after that three-year exclusivity period has run. ~~Additional exclusivities may also apply.~~

Additionally, any ANDA or 505(b)(2) NDA that references the 505(b) product must include one of several types of patent certifications. If the Section 505(b) NDA ~~applicant may have relevant~~drug has one or more unexpired patents listed in the Orange Book, an ANDA or 505(b)(2) NDA must include either a “Paragraph III Certification” or a “Paragraph IV Certification.” A Paragraph III Certification identifies the expiration date of the listed patent and ~~if it does, it can initiate~~requires FDA to withhold final approval until that patent has expired. A “Paragraph IV Certification” states that, in the applicant’s opinion, the relevant patent is invalid, unenforceable, or would not be infringed by the commercial marketing of the proposed ANDA or 505(b)(2) NDA product. The sponsor of a Paragraph IV ANDA or 505(b)(2) NDA must also provide the holder of the marketed product NDA, and the owner of the challenged patent, with notification of the Paragraph IV filing along with a detailed statement of the reasons the applicant believes the patent is invalid, unenforceable, or would not be infringed. If the patent owner brings an infringement ~~litigation~~action against ~~those applicants that challenge such patents,~~the Paragraph IV applicant within 45 days of the notification, a statutory stay is imposed which ~~could result in a~~prevents FDA from granting final approval of the Paragraph IV application for 30 months from the date of the Paragraph IV Notification. Generally, no more than one 30-month stay ~~delaying~~may be applied against any specific Paragraph IV ANDA or 505(b)(2) NDA. A 30-month stay can be terminated early, and the Paragraph IV application can be immediately approved, if the district court rules in favor of the Paragraph IV applicant that the patent is invalid, unenforceable, or would not be infringed.

On February 20, 2020, we received a Paragraph IV certification notice letter, or the IMVEXXY Notice Letter, regarding an ANDA submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint against Teva in the U.S. District Court for the District of New Jersey asserting infringement of the IMVEXXY patents, arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA ~~applications further.~~would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Teva’s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed. We intend to vigorously enforce our above-described intellectual property rights relating to IMVEXXY.

On March 17, 2020, we received a Paragraph IV certification notice letter, or the BIJUVA Notice Letter, regarding an ANDA submitted to the FDA by Amneal Pharmaceuticals, or Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 1 mg estradiol /100 mg progesterone dose of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of BIJUVA, or the BIJUVA Patents, are invalid, unenforceable, and/or will not be infringed by Amneal’s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified in the Notice Letter expire in 2032. On April 29, 2020, we filed a complaint against Amneal in the U.S. District Court for the District of New Jersey asserting infringement of the BIJUVA Patents, arising from Amneal’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal’s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Amneal’s ANDA until the earlier of 30 months or entry of a district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed (“the 30-month”). On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed. We intend to vigorously enforce our above-described intellectual property rights relating to BIJUVA.

Our currently marketed prenatal vitamins are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.

Generally, our nutritional product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that ~~appear~~are intended to have a beneficial impact in prenatal women based upon scientific literature and input from ~~physicians;~~HCPs; however, we are generally prohibited from making disease treatment and prevention claims in the promotion of our products that use these formulations.

The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United States before October 15, 1994 may be used in dietary supplements without notifying the FDA. “New” dietary ingredients (i.e., dietary ingredients that were “not marketed in the United States before October 15, 1994”) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been “present in the food supply as an article used for food” without being “chemically altered.” A new dietary ingredient notification must provide the FDA evidence of a “history of use or other evidence of safety” establishing that use of the dietary ingredient “will reasonably be expected to be safe.” A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification of new dietary ingredients. FDA guidance is not mandatory, and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA’s “current thinking” on the topic discussed in the guidance, including its position on enforcement. The draft guidance on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such action would have material adverse impact on our business and growth prospects.

The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based in part on such reports, the FDA has issued public warnings to consumers to stop using certain third-party dietary supplement products.

The FDCA permits “statements of nutritional support” to be included in labeling for dietary supplements without premarket approval. Such statements must be submitted to the FDA within 30 days of marketing. Such statements may describe how a particular dietary ingredient affects the structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of nutritional support is an unacceptable drug claim, conventional food claim, or an unauthorized version of a “health claim,” or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading, we would be prevented from using the claim.

In addition, DSHEA provides that so-called “third-party literature,” such as a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used “in connection with the sale of a dietary supplement to consumers” without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not “promote” a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug.

In June 2007, pursuant to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA is conducting inspections of dietary supplement manufacturers pursuant to these requirements. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility “adulterated,” and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the manufacturing of dietary ingredients contained in dietary supplements are subject to similar or even more burdensome manufacturing requirements, which has the potential to increase the costs of dietary ingredients and subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA also requires importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.

The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA’s ability to order mandatory recalls, administratively detain domestic products, require certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.

The FTC exercises jurisdiction over the advertising of dietary ~~supplements and cosmetics.~~supplements. In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and “free” offers.

We are also subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against non-compliant parties and can result in substantial costs and fines.

Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients’ rights, among other topics, are and will be applicable to our business. We are ~~also~~ subject to ~~additional healthcare~~ regulation ~~and enforcement~~ by both the federal government and the states in which we or our partners conduct our business. ~~Applicable federal and state~~The healthcare laws and regulations ~~include the following:~~that may affect our ability to operate include:

Pharmaceutical company interactions with HCPs, patient advocacy groups, and patients, including with respect to product and patient assistance programs and other education and support initiatives, have been and continue to be, the subject of regulatory scrutiny for compliance with fraud and abuse laws.

Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations could be costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party payer programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the ~~physicians,~~HCPs, providers, or entities with whom we do business are found to not be ~~not~~ in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded healthcare programs.

In addition to the fraud and abuse laws, we continue to monitor the potential impact of proposals to lower prescription drug costs at the federal and state level. For example, on May 11, 2018, President Trump laid out his administration’s “Blueprint” to lower drug prices and reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Following on this initiative, the Department of Health and Human Services announced a drug payment model through the Center for Medicare and Medicaid Innovation at CMS to lower Medicare Part B payments for certain drugs to the lowest price for similar countries. Beginning January 1, 2021, the model, known as the Most Favored Nation (MFN) Model, will test a new model of drug payments whereby Medicare will pay no more for high cost, physician-administered Medicare Part B drugs than the lowest price charged in other similar countries. The MFN Model may be subject to industry challenges but we expect that drug pricing will remain a priority under the Biden Administration. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare.

In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, U.S. Department of Health and Human Services, or HHS, or by other federal, state, local, or foreign regulatory authorities, toor the repeal of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.

The growth and demand for eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers. These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business. There is currently great uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities in several states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.

In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the U.S., the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.

We believe the growth of our employees drives the growth of our company. Therefore, to ensure the continued growth of our employees, our human capital strategy is measured around four key pillars; attracting talent, engaging the workforce, developing leaders, and promoting our culture. To attract key talent, we offer a competitive benefit package, 401(k) match, paid time off, referral bonus, and an employee stock purchase program (ESPP). To engage our workforce, in 2020 we refined our compensation approach to match our company’s size and stage of growth. We introduced a new framework as a foundation to our talent and reward programs, to clarify career paths, to promote pay equity and pay for performance, and to ensure pay is competitive to attract and retain talent. To develop leaders, we provide self-directed learning and company leadership training. Such leadership and self-development progress is measured through our learning management system, and we evaluate our leaders according to their achievement against goals and company values. To promote our culture, we actively seek feedback from our employees to create a culture where they feel engaged, appreciated, and fulfilled. The feedback from our employees has earned us recognition as a “Top Workplace” according to the Sun Sentinel.

As of December 31, ~~2018,~~2020, we had ~~241~~400 employees, six of whom are executive officers. Our sales force currently consists mainly of employees with a limited number of contract sales agents who call on 340B entities, the Department of Defense, and Puerto Rico, with the sales management being employees. Additionally, from time to time, we hire temporary contract employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.

On October 3, 2011, we changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD pursuant to which (1) all outstanding membership units of VitaMedMD were exchanged for shares of our common stock, (2) all outstanding VitaMedMD options and warrants were exchanged and converted into options and warrants to purchase shares of our common stock, and (3) VitaMedMD became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMedMD would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the following paragraph were discontinued.

We were incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff’s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a “shell company” under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America’s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America’s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America’s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011, we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum Health Network for commissions.

We are a Nevada corporation. We maintain our principal executive offices at ~~6800 Broken Sound Parkway NW, Third Floor,~~951 Yamato Road, Suite 220, Boca Raton, Florida ~~33487.~~33431. Our telephone number is (561) 961-1900. We maintain a corporate website at www.therapeuticsmd.com as well as various product websites. The information contained on our websites or that can be accessed through our websites is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC.

We file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, other filings required by the SEC, and all amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. These reports may also be obtained directly from the SEC’s website at www.sec.gov.

Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with all of the information included in this Annual Report and our other filings with the SEC, before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

Our business is subject to a number of risks and uncertainties. The following is a summary of the principal risk factors described in this section:

Our financial condition and results of operations for fiscal year 2020 were, and our financial condition and results of operations for fiscal year 2021 and beyond may be, adversely affected by the ongoing COVID-19 (coronavirus) pandemic.

Our business has been, and we anticipate that it will continue to be, impacted by the COVID-19 pandemic. During the fourth quarter of 2020, all of our products remained affected by the COVID-19 pandemic, primarily due to our sales force having limited access to healthcare professionals and our patients deferring visits to healthcare professionals in certain areas. While we have developed a comprehensive COVID-19 contingency plan designed to preserve the value of our investments in our sales and marketing infrastructure, protect our balance sheet during this period of market disruption, and meet the needs of our patients and prescribers, the severity of the impact of the COVID-19 pandemic on our business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted.

Stay at home, quarantine and social distancing orders and closures and restrictions on travel have negatively affected the ability of our sales force to access healthcare providers to promote our products and the ability of patients to visit their healthcare professionals for non-emergent matters. Our sales force is continuing to use a hybrid model of office visits when necessary and digital engagement tools and tactics and virtual detailing, which may be less effective than our ordinary course sales and marketing programs. Increases in unemployment could reduce access to commercial health insurance for our patients, thus limiting payer coverage for our products, which could lead to increased use of our co-pay assistance programs and negatively affect our results of operations.

Our future results of operations and liquidity could be adversely affected by, and we may require an increased level of working capital as a result of, extended billing and collection cycles as a result of displaced employees at our company, payers, revenue cycle management contractors, or otherwise; delays in payments of outstanding receivable amounts beyond normal payment terms; supply chain disruptions; uncertain demand; and the impact of any initiatives or programs that we may undertake to address financial and operations challenges that we may face.

Additionally, although we currently continue to have uninterrupted wholesale and retail distribution of our products and we do not anticipate a shortage of our products due to COVID-19 at this time, disruptions may occur for our customers or suppliers that may affect our ability to obtain supplies or other components for our products, manufacture additional products or deliver inventory in a timely manner. This would result in lost sales, additional costs, or penalties, or damage to our reputation.

We may also experience other unknown impacts from COVID-19 that cannot be predicted. Accordingly, disruptions to our business as a result of COVID-19 could continue to result in an adverse effect on our business, results of operations, financial condition and prospects in the near-term and beyond 2021.

We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.

We have incurred recurring net losses, including net losses of approximately ~~$133~~$184 million, ~~$77~~$176 million, and ~~$90~~$133 million for the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016,~~2018, respectively. As of December 31, ~~2018,~~2020, we had an accumulated deficit of approximately ~~$519~~$879 million. We have generated limited revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We may incur substantial additional losses over the next few years because of our commercialization, research, development, and clinical trial ~~and commercialization~~ activities. As a result, we may never achieve or maintain profitability, even if we successfully commercialize all of our ~~hormone therapy drugs.~~pharmaceutical products. If we continue to incur substantial losses and are unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, refinance then-existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.

~~We currently derive all~~Our level of indebtedness and the terms of the Financing Agreement could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with certain net revenue covenants and other restrictions in the Financing Agreement, the repayment of our ~~revenue from sales~~existing indebtedness could be accelerated.

Under the Financing Agreement, we have incurred a substantial amount of debt, which could adversely affect our business. In April 2019, we drew down the first tranche of $200.0 million under the Financing Agreement and in February 2020 we drew down the second tranche of $50.0 million under the Financing Agreement. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment No. 8, pursuant to which we, among other things, repaid $15.0 million in principal under the Financing Agreement on such date and agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, in each case plus a 5.0% prepayment fee. Our high level of indebtedness could affect our business in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our ~~women’s health care products,~~cash flow from operations to pay interest and principal, which would reduce funds available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management’s discretion in operating our business; and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy.

The Financing Agreement requires us to make certain payments of principal and interest over time and contains certain minimum quarterly net product revenue requirements and several other restrictive covenants. We are required to achieve total minimum net revenue for ANNOVERA, IMVEXXY, and BIJUVA equal to at least (i) $17.0 million, $20.0 million, $23.0 million, and $26.5 million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million, $60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023, and (iv) $70.0 million for the first quarter of 2024. Among other requirements of the Financing Agreement, we and our ~~failure~~subsidiaries party to the Financing Agreement must maintain a minimum unrestricted cash balance of $60.0 million, less the amount of certain payables. The Financing Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the Financing Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain permitted indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. In order to maintain compliance with the minimum unrestricted cash balance requirement of the Financing Agreement, we anticipate that we may need to raise additional capital. We cannot guarantee that future financing sufficient to maintain or ~~increase sales~~exceed the minimum unrestricted cash balance will be available in sufficient amounts, in a timely fashion, or on terms acceptable to us, if at all. If we are unable to maintain the minimum unrestricted cash balance, achieve any of ~~these products could~~the total minimum net revenue requirements or otherwise comply with any other covenant of the Financing Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which would have ~~a material~~an adverse effect on our business, ~~financial condition,~~ results of operations and ~~growth prospects.~~financial condition.

~~In 2018,~~Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies, especially in light of the COVID-19 pandemic. If we derived most of our revenue from sales of women’s health care products, including hormone therapy drugs, prenatal and women’s multi-vitamins and iron supplements. Sales of products varied from 2010 through 2018. We cannot assure you that we will be ableare unable to ~~sustain~~generate such sales or that such sales will grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to several risks and uncertainties, including the following:

~~If revenue from sales of our products does not increase,~~cash flow, we may be required to ~~reduce~~adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our ~~operating expenses or to seek to raise additional funds, which could have a material adverse effect~~indebtedness will depend on the capital markets and our ~~business,~~ financial condition ~~results of operations, and growth prospects, or we~~at such time. We may not be able to ~~commercialize~~engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our ~~hormone therapy drugs or commence or continue clinical trials to seek approval for any other products we may choose to develop in the future.~~debt obligations, including under our current debt obligations.

We may not be able to complete the ~~development and~~ commercialization of our ~~hormone therapy drug~~pharmaceutical products and development of future product candidates if we fail to obtain additional financing.

We need substantial amounts of cash to complete the commercialization of ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™~~ANNOVERA and the clinical development and commercialization of future ~~hormone therapy drug~~pharmaceutical product candidates. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs. We may attempt to raise additional capital from the issuance of equity securities, collaborations with third parties, licensing of rights to our products, the issuance of debt securities and the incurrence of debt, in each case to the extent permitted under the Credit Agreement, dated May 1, 2018, as amended, by and among us and our subsidiaries party thereto from time to time, each as a borrower, MidCap Financial Trust, as an agent and as lender, and the additional lenders party thereto from time to time, or the CreditFinancing Agreement, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of management’s attention away from our day-to-day activities, which may adversely affect our ability to conduct our day-to-day operations.

We cannot guarantee that future debt or equity financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to ~~take one or more of the following actions:~~

significantly delay, scale back, or discontinue our commercialization and product development ~~efforts;~~

~~seek collaborators for our hormone therapy drug products and candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be the case; or~~

~~license, potentially on unfavorable terms, our rights to our hormone therapy drug products and candidates that we otherwise would seek to develop or commercialize ourselves.~~efforts.

The ~~Credit~~Financing Agreement does, and any agreements governing future debt financing, if available, may, include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms that may not be favorable to us.

If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing ~~discovery,~~commercialization and development ~~and commercialization~~ efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.

We may not recognize any anticipated benefits of the proposed disposition of vitaCare Prescription Services or any other divestitures we may pursue in the future.

We have commenced a process for the divestiture of vitaCare Prescription Services. Additionally, we may evaluate other potential divestiture opportunities with respect to portions of our business from time to time, and may determine to proceed with a divestiture opportunity if and when we believe such opportunity is consistent with our business strategy and we would be able to realize value for our stockholders in so doing. There can be no assurance that we will be able to sell vitaCare Prescription Services. Any divestiture or disposition, including the potential disposition of vitaCare Prescription Services, could expose us to significant risks, including, without limitation, fees for legal and transaction-related services, diversion of management resources, transaction execution risks (including risks resulting from buyer financing and due diligence contingencies and other closing conditions), loss of key personnel and reduction in revenue. Further, we may be required to retain or indemnify a buyer against certain liabilities and obligations in connection with any such divestiture, and we may also become subject to third-party claims arising out of such divestiture. In addition, we may not achieve the expected price in a divestiture transaction, including the potential sale of vitaCare Prescription Services. A divesture of vitaCare Prescription Services may be subject to various third-party consents. There can be no assurances that we will obtain any necessary consents of governmental authorities or other third parties that might be required in order for us to sell vitaCare Prescription Services or effectuate any other divesture. If we are unable to consummate the divestiture of vitaCare Prescription Services or do not realize the expected strategic, economic, or other benefits of that or any other divestiture transaction, it could adversely affect our business and financial position.

We currently derive all of our revenue from sales or licenses of our women’s healthcare products, and our failure to maintain or increase sales of these products could have an adverse effect on our business, financial condition, results of operations, and growth prospects.

In 2020, we derived all of our revenue from sales or licenses of our women’s healthcare products, including patient-controlled, long-acting contraceptive, hormone therapy pharmaceutical products, prenatal and women’s multi-vitamins, and iron supplements. We cannot assure you that we will be able to sustain such sales or that such sales will grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to several risks and uncertainties, including the following:

If revenue from sales of our products does not increase, we may be required to reduce our operating expenses or to seek to raise additional funds, which could have an adverse effect on our business, financial condition, results of operations, and growth prospects, or we may not be able to commercialize all of our pharmaceutical products or commence or continue clinical trials to seek approval for any other products we may choose to develop in the future.

The commercial success of our existing products and other pharmaceutical products that we may develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payers.

Physicians may not prescribe our products, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our hormone therapy pharmaceutical products and patient-controlled, long-acting contraceptive, by physicians, patients, and payers, will depend on a number of factors, many of which are beyond our control, including the following:

Even if the medical community accepts that our products are safe and effective for their approved indications, physicians may not immediately be receptive to their use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. Labeling approved by the FDA may not permit us to promote our products as being superior to competing products, because the FDA applies a heightened level of scrutiny to comparative claims when applying its statutory standards for advertising and promotion, including with regard to its requirements for supporting data and that promotional labeling be truthful and not misleading, and there is potential for differing interpretations of whether certain communications are consistent with a product’s FDA-required labeling. If our products do not achieve an adequate level of acceptance by physicians and payers, we may not generate sufficient or any revenue from these products and we may not become profitable. In addition, our efforts to educate the medical community and third-party payers on the benefits of our products may require significant resources and may never be successful.

The products we are currently ~~market,~~commercializing, including ~~IMVEXXY®~~IMVEXXY, BIJUVA, and ANNOVERA and our prenatal vitamins, ~~the products that we are currently commercializing, including BIJUVA™ and ANNOVERA™,~~ and the pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare & Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions. If any ~~drug~~pharmaceutical products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.

We are also subject to additional ~~health care~~healthcare regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state ~~health care~~healthcare laws and regulations include the following:

Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Many state laws differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws and to prosecute companies and individuals who are believed to be violating them. In particular, the ACA includes a number of provisions aimed at strengthening the government’s ability to pursue AKS and FCA cases against pharmaceutical manufacturers and other health care entities, including substantially increased funding for health care fraud enforcement activities, enhanced investigative powers, and amendments to the FCA that make it easier for the government and whistleblowers to pursue cases for alleged kickback and false claim violations. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of government investigations and enforcement actions. For example, federal enforcement agencies recently have shown interest in pharmaceutical companies’ product and patient assistance programs, including manufacturer reimbursement support services and relationships with specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements.

Efforts to ensure that our operations, including our business arrangements with third parties, comply with applicable ~~health care~~healthcare laws and regulations could be costly. In connection with the commercial ~~launch~~launches of ~~IMVEXXY®,~~IMVEXXY, BIJUVA, and ANNOVERA, we have grown our compliance program and are in the process of developing a program based on industry best practices and tailored to evolving risks as we launch additional products, identify new distribution channels and target new ~~customer~~patient types. ~~As this program has not yet been tested and the requirements in this area are constantly evolving, our program may not eliminate all areas of potential exposure.~~ Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement actions, and prosecution for violations of these laws, the risks cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. ~~Although we believe~~We cannot guarantee that a government agency will agree with our ~~business practices are structured to be compliant with applicable laws,~~interpretations and it is possible that ~~governmental authorities will conclude~~an enforcement authority may find that one or more of our business practices may not ~~comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other health care laws and regulations.~~comply. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government ~~health care~~healthcare programs, and the curtailment or restructuring of our operations. If any of the physicians, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government health care programs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, and could result in related ~~shareholder~~stockholder suits, any of which could also have an adverse effect on our business, financial condition and results of operations.

In addition, from time to time in the future, we may become subject to additional laws or regulations ~~administered~~issued by federal or state agencies. Federal and state elections in 2020 have changed which persons and parties occupy the ~~FDA,~~presidency of the ~~FTC, or by other federal, state, local, or foreign regulatory authorities,~~United States and control both chambers of Congress and many states’ governors and legislatures. These changes will likely result in new agency priorities, rulemakings, and legislation. We anticipate that the new Biden administration will issue a number of Executive Orders, which may alter the policies of the previous administration. Additionally, certain agency rules and policy statements of the prior administration may be rescinded. Further, the Biden administration may propose substantial changes to the repeal of laws or regulations that we generally consider favorable, such as the Dietary Supplement Health and Education Act of 1994, or to more stringent interpretations of current laws or regulations.U.S. healthcare system, including expanding government-funded health insurance options. We are ~~not able to predict~~uncertain of the ~~nature~~impact or outcome of ~~such future laws, regulations, repeals,~~these potential Executive Orders, rescission of rules and policy statements, or ~~interpretations,~~new legislation, especially any relative impact on the healthcare regulatory and ~~we cannot predict what effect additional governmental regulation, if it occurs, would~~policy landscape, or the impact they may have on our ~~business in the future.~~business. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have ~~a material~~an adverse effect on our business.

Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability.

Market acceptance and sales of our products, including ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™,~~ANNOVERA, and our ~~hormone therapy drug candidates or~~ prescription vitamins, will depend on coverage and reimbursement policies and may be affected by ~~health care~~healthcare reform measures. Government ~~health care~~healthcare programs and third-party payers decide which prescription ~~drug~~pharmaceutical products they will pay for and establish reimbursement levels. Payers generally do not cover OTC products, and coverage for prescription vitamins and dietary supplements varies. Many private third-party payers, such as managed care plans, manage access to ~~drug~~pharmaceutical products’ coverage partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Factors considered by these payers include product efficacy, cost effectiveness, and safety, as well as the availability of other treatments including generic prescription drugs. Our ability to commercialize ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™~~ANNOVERA successfully depends on coverage and reimbursement levels set by government ~~health care~~healthcare programs and third-party private payers. Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and we may not be able to negotiate or continue to negotiate reimbursement or pricing terms for our products with payers at levels that are profitable to us, or at all.

In both the ~~United States~~U.S. and some foreign jurisdictions, there have been several legislative and regulatory proposals to change the ~~health care~~healthcare system in ways that could affect our ability to sell our products profitably. Payment or reimbursement of prescription drugs by Medicaid or Medicare requires manufacturers of the drugs to submit pricing information to CMS. The Medicaid Drug Rebate statute requires manufacturers to calculate and report price points, which are used to determine Medicaid rebate payments shared between the states and the federal government and Medicaid payment rates for the drug. For drugs paid under Medicare Part B, manufacturers must also calculate and report their Average Sales Price, or ASP, which is used to determine the Medicare Part B payment rate for the drug. The federal government sets general guidelines for Medicaid and requires rebates on outpatient drugs. Each state creates specific regulations that govern its individual program, including supplemental rebate programs that prioritize coverage for drugs on the state Preferred Drug List. In the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government provides reimbursement through the Medicare ~~Prescription Drug, Improvement,~~or Medicaid programs for such products and ~~Modernization Act~~services. In addition, government programs like Medicaid include substantial penalties for increasing commercial prices over the rate of ~~2003, also called~~inflation which can affect realization and return on investment. The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest and states have begun to take action to increase transparency in drug pricing through mandatory reporting requirements. We expect that the ~~Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for~~ pharmaceutical ~~products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D~~industry will experience pricing pressures due to the ~~Medicare program. However, unlike Medicare Part A~~trend toward managed healthcare, the increasing influence of managed care organizations, and ~~Part B—through which Medicare provides coverage for certain drugs in certain circumstances—coverage under Part D is provided~~additional legislative proposals. Our results of operations could be adversely affected by ~~private insurers operating under contract with CMS. In addition, this legislation provided authority for limiting the number of certain outpatient drugs that~~current and future healthcare reforms. While we cannot predict whether any proposed cost-containment measures will be ~~covered~~adopted or otherwise implemented in the future, any ~~therapeutic class. Because of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These and future~~such cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™,~~ANNOVERA, and could significantly harm our business. It was historically unclear whether products approved to treat moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, such as ~~IMVEXXY®,~~IMVEXXY, were excluded under Medicare Part D, which resulted in limited Medicare coverage for such products. ~~Recent~~A clarification issued by CMS in May 2018 indicated that drugs, such as ~~IMVEXXY®,~~IMVEXXY, that are approved for the treatment of moderate-to-severe dyspareunia (as well as drugs approved for the treatment of moderate-to-severe symptoms of vulvar and vaginal atrophy associated with menopause) are not excluded from Medicare Part D coverage. CMS’s clarification, however, is no guarantee that such coverage will be obtained for ~~IMVEXXY®,~~IMVEXXY and obtaining Medicare or other government ~~health care~~healthcare program reimbursement for any new ~~drug~~pharmaceutical products may take up to several years following FDA approval. While the MMA applies only to drug benefits for Medicare beneficiaries, third-party payers often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from third-party payers.

Our ability to commercialize ~~ANNOVERA™~~ANNOVERA depends on coverage and reimbursement levels set by government ~~health care~~healthcare programs and third-party private payers. The ACA mandates that private health plans provide coverage for women’s preventative services, without imposing patient cost-sharing requirements, as recommended by HRSA. HRSA Guidelines require private health plans to cover, with no patient out-of-pocket costs, at least one form of treatment (e.g., one product) in each of the methods (e.g., classes of contraception) identified by the FDA for women in its Birth Control Guide. To the extent ~~ANNOVERA™~~ANNOVERA is deemed a new class of contraception by the FDA, such a designation could allow for coverage by private health plans with no patient out-of-pocket costs. However, there is no guarantee that such coverage will be obtained, and it is possible that other FDA-approved products could also be included in this new class. For instance, the FDA may find that ANNOVERA fits into the vaginal contraceptive ring class, which it would share with NuvaRing and its generic equivalents, and potentially others. Pursuant to HRSA Guidelines, private payers need only provide no-cost coverage for one product in each class and may use reasonable medical management to determine whether and to what extent to cover other products in the class. Private payers may interpret the statute and its associated rules in ways in which they decline to cover ANNOVERA, even if we believe ANNOVERA should be covered without cost sharing under the ACA framework. To the extent ~~ANNOVERA™~~ANNOVERA is not the only FDA-approved product in a designated class of contraception, private payers may choose not to cover our one-year vaginal contraceptive system or may require patient cost-sharing obligations. Some states have amended and expanded requirements to match the standard set in the ACA mandate, specifically requiring coverage for the full range of contraceptive methods, counseling and services used by women and eliminating out-of-pocket costs and limiting other health plan restrictions. The prior administration implemented policies that permit certain employers to claim a religious or moral objection to the birth control coverage mandate under the ACA. On July 8, 2020, the Supreme Court held in Little Sisters of the Poor Saints Peter and Paul Home v. Pennsylvania, et. al. that health plans sponsored by certain exempt religious employers and non-profit religious organizations that certify they have religious objections do not need to offer contraception coverage through their health benefit plans. This exemption could be overturned by the new Biden administration through an Executive Order or other policy or regulatory action. Further, despite our progress with commercial payers, there is no guarantee that we will be able to retain our agreements or obtain new agreements or that we will be able to negotiate favorable reimbursement or pricing terms for our products in the future. In addition, healthcare reform, including potential repeal of or changes to the ACA, continues to attract significant legislative and administrative interest, legal challenges, regulatory and compliance requirements, new approaches and public attention that create uncertainty and the potential for additional changes. Healthcare reform implementation, additional legislation or regulations, and other changes in government policy or regulation may repeal the contraception coverage mandate, affect our reimbursement or impose additional coverage limitations and/or cost-sharing obligations on patients, any of which could have an adverse effect on coverage and reimbursement of our products, and our business, financial condition, results of operations, and prospects could be harmed.

To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service’s 340B Program, which impose additional ~~requirements.~~reporting requirements and price concessions. Manufacturer compliance with 340B Program requirements can be costly. In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply.

We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed ~~health care,~~healthcare, the increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. As discussed more below, the goal of the ACA, as enacted in 2010, was to reduce the cost of health care and substantially change the way health care is financed by both government health care programs and third-party payers. Among other measures, the ACA increased rebates on manufacturers for certain covered drug products reimbursed by state Medicaid programs. While we cannot predict the full effect that the ACA will have on government health care programs’ reimbursement policies in general or on our business specifically, the ACA may result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, weWe cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted.

The availability of generic products at lower prices than branded products may substantially reduce the likelihood of reimbursement for branded products, such as ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™.~~ANNOVERA.

If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed.

Future legislation or regulations may adversely affect reimbursement from government ~~health care~~healthcare programs and third-party payers.

Legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the legislation’s automatic reduction of several government programs. This includes aggregate reductions to Medicare payments to health care providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of health care providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the ACA. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug reimbursements or coverage and it is also unclear what programs, if any, Congress might enact to replace the repealed portions of the ACA. The Trump administration may also take executive action in the absence of legislative action. For example, in October 2017, the President announced that the administration will withhold the cost-sharing subsidies paid to health insurance exchange plans serving low-income enrollees. With respect to IMVEXXY®, BIJUVA™ and ANNOVERA™, and to the extent we ever obtain regulatory approval and commercialization of our other drug candidates, these new laws and policies (as well as proposed legislation, if enacted) may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.

On December 13, 2016, President Obama signed into law the 21st Century Cures Act, which, among other things, may increase the types of clinical trial designs that would be acceptable to support an NDA. It is unclear, at this time, how these provisions will be implemented or whether they would have any effect on our company. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on our drug products and drug candidates may be.

There have ~~also~~ been efforts by government officials orand legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. ~~Recently, there has been considerable public~~On May 11, 2018, the prior administration issued its “Blueprint” to lower drug prices and ~~government scrutiny~~reduce out of pocket costs of drugs, as well as additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, and incentivize manufacturers to lower the list price of their products. Following on this initiative, HHS announced a drug payment model through the Center for Medicare and Medicaid Innovation at CMS to lower Medicare Part B payments for certain drugs to the lowest price for similar countries. Beginning January 1, 2021, the model, known as the Most Favored Nation (MFN) Model, will test a new model of drug payments whereby Medicare will pay no more for high cost, physician-administered Medicare Part B drugs than the lowest price charged in other similar countries.

While drug pricing was a priority for the prior administration, we expect that it will continue to be a focus of the Biden administration in 2021 and beyond. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and ~~proposals~~marketing cost disclosure and transparency measures, and, in some cases, designed to ~~address~~encourage importation from other countries and bulk purchasing.

We are unable to predict the ~~perceived high~~future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of ~~pharmaceuticals; proposed~~healthcare. The ACA and ~~enacted legislation generally~~any further changes in the law or regulatory framework that reduce our revenue or increase our costs could also have ~~focused on increasing transparency around drug costs or limiting drug prices, including drug rebates. For example, in 2017, California enacted a new law, which went into~~an adverse effect on ~~January 1, 2018, to facilitate greater transparency in brand-name~~our business, financial condition and ~~generic drug pricing through the implementation~~results of specific price reporting requirements for pharmaceutical manufacturers. If adequate reimbursement levels are not maintained by government and third-party payers for our products, our ability to sell our products may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.operations.

Further, if a federal government shutdown were to occur for a prolonged period, federal government payment obligations, including its obligations under Medicaid and Medicare, may be delayed. Similarly, if state government shutdowns were to occur, state payment obligations may be delayed. If the federal or state governments fail to make payments under these programs on a timely basis, our ability to sell our products to government payers may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.

Our dependence upon third parties for the manufacture and supply of our existing women’s ~~health care~~healthcare products and our ~~hormone therapy drug~~pharmaceutical product candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.

We do not currently have, nor do we currently plan to build or acquire, the infrastructure or capability to internally manufacture our existing women’s ~~health care~~healthcare products, ~~IMVEXXY®, BIJUVA™, or ANNOVERA™,~~IMVEXXY, BIJUVA, and ANNOVERA, or our ~~hormone therapy drug~~pharmaceutical product candidates. We have relied, and will continue to rely, on third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory ~~requirements.~~requirements, including cGMPs. We have entered into long-term supply agreements with Catalent for the commercial supply of ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™.~~BIJUVA. Under the terms of the agreements, we are obligated to purchase certain minimum annual amounts of each ~~product once we commence commercial sales of such product following regulatory approval of Catalent as a manufacturer of such~~ product. We have also entered into a long-term supply contract with QPharma AB for ~~ANNOVERA™.~~ANNOVERA. Under the terms of the QPharma agreement, we are obligated to purchase certain minimum annual amounts of ~~ANNOVERA™.~~ANNOVERA. We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply ~~approximately 100% of~~ our vitaMedMD and BocaGreen products. We do not have long-term contracts for the commercial supply of our ~~existing women’s health care~~vitaMedMD and BocaGreen products, however, in certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells. We intend to enter into agreements with Crystal Pharma SAU for the commercial supply of one of the active pharmaceutical ingredients for ANNOVERA™. However, if we experience delays in finalizing this agreement or are unable to execute this agreement on commercially reasonable terms, we may need to find alternative manufacturing facilities, which would result in disruption in our commercialization of ANNOVERA™.

Regulatory requirements could pose barriers to the manufacture of our ~~existing~~ women’s ~~health care~~healthcare products and our ~~hormone therapy drug~~pharmaceutical product ~~and drug~~ candidates. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third-party contract manufacturing organization, or CMO. All of our existing products are manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. The CMO that manufactures ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™~~BIJUVA has previously been inspected by the FDA and received Form 483 observations with respect to its softgel manufacturing plant that is used for the manufacture of the commercial supply of ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™. QPharma, the~~BIJUVA. The CMO that ~~will manufacture ANNOVERA™,~~manufactures ANNOVERA has previously been inspected by the FDA and received Form 483 observations ~~on December 15, 2017,~~ with respect to its facility that ~~will be~~is used for the commercial supply of ~~ANNOVERA™.~~ANNOVERA. We believe that corrective actions to address the compliance issues identified in the referenced Forms 483 have been implemented by the CMOs; however, the FDA has not yet reinspected the CMOs to confirm that the corrective actions were implemented as described to the agency in the respective Form 483 responses.

If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, our regulatory submissions may be delayed or disapproved, and our marketed products may be affected. If these facilities are not in compliance for the manufacture of our ~~vitamin~~ products, ~~our hormone therapy drug product and our drug candidates,~~ we may need to find alternative manufacturing facilities, which would result in substantial disruptions of our sales of existing products and significant delays of up to several years in obtaining approval for our ~~hormone therapy drug~~pharmaceutical product candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. After generally suspending in-person inspections due to COVID-19, the FDA announced it would resume domestic facility inspections, although the agency continues its general suspension of foreign facility inspections (although “mission-critical” inspections may be considered on a case-by-case basis). Because of the global pandemic, decision-making around facility inspections by the FDA (including preapproval inspections) continues to evolve. Failure by any of our manufacturers to comply with applicable cGMP regulations or other applicable requirements could result in sanctions being imposed on us, including fines, injunctions, civil penalties, violation letters, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have ~~a material~~an adverse impact on our business, financial condition, results of operations, and prospects. We do not currently have alternative manufacturers, and we may not be able to enter into a long-term agreement with alternative manufacturers, or do so on commercially reasonable terms, and if we do enter into agreements with alternative manufacturers, those alternative manufacturers may not be approved by the FDA, any of which could have ~~a material~~an adverse impact on our business. ~~Finally, we~~We also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products to the delay or other detriment of our products and proposed products, or otherwise do not satisfactorily perform according to the terms of their agreements with us. Finally, we could experience manufacturing delays or interruptions as a result of the ongoing COVID-19 pandemic.

We also do not have long-term contracts for the supply of the active pharmaceutical ingredient, or API, used in ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™.~~ANNOVERA. If any supplier of the API or other products used in our ~~approved~~ products or ~~hormone therapy drug~~pharmaceutical product candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our ~~approved~~ products or ~~hormone therapy drug~~pharmaceutical product candidates, which could impair our ability to supply our ~~approved~~ products or ~~hormone therapy drug~~pharmaceutical product candidates at the levels required for commercialization and prevent or delay their successful commercialization.

Even after the approval of ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™,~~ANNOVERA, and even if we obtain regulatory approval for ~~our~~ other ~~hormone therapy drug~~pharmaceutical product candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.

With respect to ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™,~~ANNOVERA, the FDA may still impose significant restrictions on a product’s indicated uses or marketing or to the conditions for approval or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™~~ANNOVERA contains restrictions on use and warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the Risk Evaluation and Mitigation Strategy, or REMS, explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™~~ANNOVERA will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance and reporting, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA’s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. As part of the FDA’s approval of ~~IMVEXXY®,~~IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as ~~IMVEXXY®.~~IMVEXXY. As part of the FDA’s approval of ~~ANNOVERA™,~~ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. Foreign regulatory agencies often have similar authority and may impose comparable ~~costs.~~requirement. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our ~~hormone therapy drug candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a~~pharmaceutical product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.

The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of certain clinical trial results on a publicly available database.

In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA’s cGMPs regulations and other regulatory requirements, such as adverse event reporting. If we or a regulatory agency discovers problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws, and are subject to review by FDA. If the FDA raises concerns regarding our promotional materials or messages, we may be required to modify or discontinue using them and may be required to provide corrective information. Should we fail to comply with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions. The distribution of product samples to physicians must comply with the requirements of the Prescription Drug Marketing Act and its implementing regulations.

Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party suppliers fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:

~~Recent government enforcement has targeted pharmaceutical companies for violations of fraud, abuse and other laws.~~

The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, pharmacies, and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exemption or safe harbor. Further, the Trumps administration has taken steps to limit applicability of some of these safe harbors, including those related to discounts and rebates, in regulations proposed in February 2019. Our practices with respect to interactions with health care professionals, including but not limited to consultant relationships, speaker programs, advisory boards, and scientific/educational grant programs, as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants or patient assistance programs. In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit certain marketing-related activities, including the provision of gifts, meals or other items to certain health care providers.

We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate federal or state fraud and abuse laws or other applicable requirements.

Federal enforcement agencies and private whistleblowers recently have shown interest in pharmaceutical companies’ product and patient assistance programs, including reimbursement support, co-pay support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships with specialty pharmacies. Co-pay assistance programs are intended to assist qualified patients with private insurance with any out-of-pocket financial obligations but must exclude any government health care program beneficiaries. Several investigations into patient assistance practices have resulted in significant civil and criminal settlements. We offer co-pay assistance for our vitamin products and IMVEXXY®, including co-pay assistance and free drug sample starter packs for IMVEXXY®, and potentially will do so for BIJUVA™ and ANNOVERA™. If we fail to structure these and other support programs to comply with applicable law, we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. In addition, to the extent we, our subsidiary, VitaCare Prescription Services, or our other contractors or agents receive or obtain individually identifiable health information from patients, health care professionals, pharmacies, or other individuals or entities, although we are not directly subject to HIPAA, we could be subject to criminal penalties if we mishandle individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. In addition, VitaCare Prescription Services' activities could be subject to regulation and enforcement by the federal government and the states in which VitaCare conducts its business, including as a result of potential increased scrutiny of innovation in hub services.

The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.

~~Any failure to adequately expand a direct sales force will impede our growth.~~

We expect to be substantially dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our direct sales force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining direct sales personnel. New and future hires may not become as productive as expected, and we may be unable to hire enough qualified individuals in the future in the markets in which we do business. If we are unable to hire and develop enough productive sales personnel or are required to hire more sales personnel than we expect our business prospects could suffer.

Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality personnel, our ability to commercialize IMVEXXY®, BIJUVA™ and ANNOVERA™ may be limited.

Licensing of intellectual property involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our ability to develop and commercialize other products in the future.

We are currently and may in the future be a party to license agreements of importance to our business and to our current product and product candidates, and we expect to be subject to additional such agreements in the future. Disputes may arise between us and any of these counterparties regarding intellectual property subject to and each parties’ obligations under such agreements, including:

These or other disputes over our obligations or intellectual property that we have licensed may prevent or impair our ability to maintain our current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business.

If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate the respective agreement and upon the effective date of such termination, have the right to re-obtain the related technology as well as, potentially, aspects of any intellectual property controlled by us and developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable product or product candidate after an uncured, material breach of the agreement by us. This may also be the case if we voluntarily terminate the relevant agreement. Any uncured, material breach under a license agreement could result in our loss of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product or product candidates.

In July 2018, we entered into a license agreement with the Population Council to obtain exclusive U.S. rights to commercialize the Population Council’s segesterone acetate/ethinyl estradiol one-year vaginal system for human contraceptive indications, which was approved by the FDA in August 2018 and which we intend to commercialize under the name ANNOVERA™. The agreement requires us to commercialize this product and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the agreement, and indemnify the other party with respect to our development and commercialization activities under the terms of the agreements.

In addition, if we license international rights to our products to third parties that have the right to manufacture such products outside of the U.S., sales of our products in the U.S. and our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if products manufactured outside of the U.S. are reimported and sold in the U.S.

Our level of indebtedness and the terms of the Credit Agreement could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to satisfy certain conditions in our Credit Agreement, we will be unable to draw down the remaining the facility and if we are unable to comply with restrictions in the Credit Agreement, the repayment of our existing indebtedness could be accelerated.

Under the Credit Agreement, we have incurred a substantial amount of debt, which could adversely affect our business. In June 2018, we drew down the first tranche of $75.0 million under the Credit Agreement and we currently intend to draw down up to an additional $125.0 million in the aggregate in two additional tranches under the terms of the Credit Agreement, when and if the conditions precedent to such tranches have been met. Our high level of indebtedness could affect our business in the following ways, among other things: make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital, capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management’s discretion in operating our business; and limit our flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy.

We must satisfy certain conditions to be eligible to draw down the second tranche of $75.0 million and the third tranche of $50.0 million. The second tranche may be drawn by us on or before May 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including (i) the approval by the FDA of the NDA for BIJUVA™ and (ii) that we have consummated our first commercial sale in the United States of BIJUVA™. The third tranche of $50.0 million may be drawn by us on or before December 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including that (i) tranche 2 has been drawn and (ii) we and our subsidiaries party to the Credit Agreement have generated at least $75.0 million of consolidated net revenue attributable to commercial sales of BIJUVA™ and IMVEXXY® during the twelve-month period ending immediately before the funding of tranche 3. If we are unable to satisfy those conditions, we would not be able to draw down the respective tranche of financing and may not be able to obtain alternative financing on commercially reasonable terms or at all.

The Credit Agreement requires us to make certain payments of principal and interest over time and contains several other restrictive covenants. Among other requirements of the Credit Agreement, we and our subsidiaries party to the Credit Agreement must (i) maintain a minimum cash balance of $50.0 million and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our products. The Credit Agreement also contains covenants that limit, among other things, the ability of us and our subsidiaries party to the Credit Agreement to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain permitted indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the Credit Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business.

Our business may not generate cash flow from operations in the future sufficient to service our debt and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations, including under our current debt obligations.

~~If our products do not have the effects intended or cause undesirable side effects, our business may suffer.~~

Although many of the ingredients in our current dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they also contain innovative ingredients or combinations of ingredients. While we believe that all of these products and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions, such as the potential effect of high doses of folic acid masking pernicious anemia. In addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include certain dietary restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.

~~Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results~~.

Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. For example, we suspended enrollment in and subsequently stopped the SPRY trial for our progesterone-alone drug candidate to update the phase 3 protocol based on discussions with the FDA. Failure can occur at any time during the clinical trial process because of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Before approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations, the FDA approves drugs based on a single well-controlled clinical trial. If clinical trials for any of our hormone therapy drug candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve that drug and we would not be able to commercialize it, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Future legislation, or the absence of such legislation, regulations, and policies adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials for our hormone therapy drug candidates.

The FDA has established regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical trials for our hormone therapy drug candidates.

In addition, the FDA’s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability could be adversely affected.

Even after we obtain regulatory approval for our hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.

Even after we obtain regulatory approval for our hormone therapy drug candidates in the United States, the FDA may still impose significant restrictions on a product’s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. For example, as part of the FDA’s approval of IMVEXXY®, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen such as IMVEXXY®. As part of the FDA’s approval of ANNOVERA™, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for our hormone therapy drug candidates includes restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. Our hormone therapy drug candidates will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA’s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.

In addition, manufacturers of ~~drug~~pharmaceutical products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA’s ~~cGMPs regulations.~~cGMP regulations and other regulatory requirements, such as adverse event reporting. If we or a regulatory agency discovers ~~previously unknown~~ problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state ~~laws. The~~laws, and are subject to review by FDA. If the FDA raises concerns regarding our promotional materials or messages, we may be required to modify or discontinue using them and may be required to provide corrective information. Should we fail to comply with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions.

Commercial products must now meet the requirements of the Drug Supply Chain Security Act, or DSCSA, which imposes obligations on manufacturers of prescription pharmaceutical products for commercial distribution, regulating the distribution of ~~product samples to physicians must comply with~~ the products at the federal level, and sets certain standards for federal or state registration and compliance of entities in the supply chain (manufacturers and re-packagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state pedigree laws and the pedigree requirements of the Prescription Drug Marketing ~~Act. Sales, marketing,~~Act, or PDMA, and ~~scientific/educational grant programs~~its implementing regulations. Trading partners within the drug supply chain must ~~comply~~now ensure certain product tracing requirements are met that they are doing business with ~~the anti-fraud~~other authorized trading partners; and ~~abuse provisions~~they are required to exchange transaction information, transaction history, and transaction statements. Product identifier information (an aspect of the ~~Social Security Act,~~product tracing scheme) is also now required. The DSCSA requirements, development of standards, and the ~~False Claims Act,~~system for product tracing have been and ~~similar state laws. We would also~~will continue to be ~~required~~phased in over a period of years, with FDA indicating enforcement discretion on certain aspects due to the COVID-19 pandemic. The distribution of product samples continues to be regulated under the ~~Sunshine provision of the Patient Protection~~PDMA, and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act or ACA, to report annually to the Centers for Medicare & Medicaid Servicessome states also impose regulations on payments that we make to physicians and teaching hospitals and ownerships interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional laws and requirements apply. drug sample distribution.

Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party ~~collaborators~~suppliers fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:

Recent government enforcement has targeted pharmaceutical companies for violations of fraud, abuse and other laws.

The AKS has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, pharmacies, and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices with respect to interactions with healthcare professionals, including but not limited to consultant relationships, speaker programs, advisory boards, and scientific/educational grant programs, as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common practices, such as certain educational and research grants or patient assistance programs. The safe harbors are subject to change through legislative and regulatory action, and we may decide to adjust our business practices or be subject to heightened scrutiny as a result.

In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit or limit certain marketing-related activities, including the provision of gifts, meals or other items to certain healthcare providers.

The FDA also strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. A company can make only those claims relating to safety and efficacy, purity, and potency that are approved by the FDA. Physicians, in their independent professional medical judgment, may prescribe legally available products for unapproved indications that are not described in the product’s labeling and that differ from those tested and approved by the FDA. Pharmaceutical companies, however, are required to promote their pharmaceutical products only for the approved indications and consistent with the FDA-required, approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off label uses may be subject to significant liability, including, but not limited to, criminal and civil penalties under the FDCA and the FCA, exclusion from participation in federal healthcare programs, mandatory compliance programs under corporate integrity agreements, debarment, and refusal of government contracts.

Federal enforcement agencies and private whistleblowers have shown and continue to show interest in pharmaceutical companies’ product and patient assistance programs (PAPs), including reimbursement support, co-pay support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships with specialty pharmacies. Co-pay assistance programs are intended to assist qualified patients with private insurance with any out-of-pocket financial obligations but must exclude any government healthcare program beneficiaries. Several investigations into patient assistance practices have resulted in significant civil and criminal settlements. We offer co-pay assistance for our vitamin products and IMVEXXY and BIJUVA, including co-pay assistance and free drug sample packs for IMVEXXY and BIJUVA, and potentially will enter into similar programs for ANNOVERA. While the OIG has approved certain independent charitable PAPs that help financially needy beneficiaries, advisory opinions on this issue have primarily focused on charities that provide assistance to patients who cannot afford cost-sharing obligations for prescription drugs. A key element for the OIG has been whether the charities are sufficiently independent from drug manufacturer donors. In May 2014, the OIG issued a Supplemental Special Advisory Bulletin regarding Independent Charity Patient Assistance Programs, or the 2014 Special Advisory Bulletin, which updated its 2005 Special Advisory Bulletin relating to PAPs. In the 2014 Special Advisory Bulletin, the OIG stated that although PAPs provide important safety net assistance to financially needy patients, these programs also present a risk of fraud, waste, and abuse with respect to federal health care programs. One of the three factors set forth in the revised guidance was that the PAP could not limit assistance to a single product. In September of 2014, the OIG also released a Special Advisory Bulletin on pharmaceutical manufacturer copayment coupons, specifically stating that manufacturers that did not comply with the law may be subject to sanctions if they fail to take appropriate steps to ensure that such coupons do not induce the purchase of Federal health care program items or services, including, but not limited to, drugs paid for by Medicare Part D. Failure to take such steps may be evidence of intent to induce the purchase of drugs paid for by these programs, in violations of the AKS. PAPs have also been the subject of Congressional review. If we fail to structure our patient assistance and support programs to comply with applicable law, we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from government healthcare programs, and the curtailment or restructuring of our operations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management’s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could also have an adverse effect on our business, financial condition and results of operations.

In addition, to the extent we, our subsidiary, VitaCare Prescription Services, or our other contractors or agents receive or obtain individually identifiable health information from patients, healthcare professionals, pharmacies, or other individuals or entities, we could be subject to criminal penalties if we mishandle individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. In addition, VitaCare Prescription Services’ activities could be subject to regulation and enforcement by the federal government and the states in which VitaCare conducts its business, including state licensing of pharmacies and pharmacists and as a result of potential increased scrutiny of innovation in hub services.

~~The commercial success~~Some of our ~~existing~~ products can be prescribed to patients via a virtual health platform, such as PlushCare, a direct-to-consumer telehealth platform offering primary care medical services, subject to state telehealth and prescribing laws. The federal Ryan Haight Act substantially limits the ability of prescribers to prescribe controlled substances via telehealth. While this federal law applies only to federally controlled substances, the permissibility of prescribing other ~~hormone therapy drugs~~non-controlled substances via a telehealth encounter is addressed at the state level. Constant changes to the telehealth laws and regulations as well as state pharmacy and prescribing laws and emerging enforcement priorities by state legislatures, licensing bodies, and attorney generals’ offices, make it difficult to predict our ability to effectively provide patient access to our products via virtual care offerings. There have been recent waivers of telehealth restrictions, including many of those pertaining to electronic prescribing based on a telehealth encounter, in order to assist in expanding access to care during the COVID-19 pandemic. Many of these waivers are tied to the federal public health emergency declaration but some state laws have different expiration dates. We cannot guarantee that weprescribers will be able, or willing, to prescribe our products to patients via a telehealth encounter and any limitations on such remote prescribing at the state level may impede our ability to expand access to our products.

We are currently and may in the future ~~will depend upon gaining~~be a party to license agreements of importance to our business and ~~retaining significant market acceptance~~to our products and product candidates. Disputes may arise between us and any of these ~~products among physicians~~counterparties regarding intellectual property subject to and ~~payers.~~each parties’ obligations under such agreements, including:

~~Physicians~~If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate the respective agreement and upon the effective date of such termination, have the right to re-obtain the related technology as well as, potentially, aspects of any intellectual property controlled by us and developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable product or product candidate after an uncured, material breach of the agreement by us. This may ~~not prescribe~~also be the case if we voluntarily terminate the relevant agreement. Any uncured, material breach under a license agreement could result in our ~~products which would prevent us from generating revenue or becoming profitable. Market acceptance~~loss of exclusive rights and may lead to a complete termination of our ~~products,~~product development and any commercialization efforts for the applicable product or product candidates.

In July 2018, we entered into a license agreement with the Population Council to obtain exclusive U.S. rights to commercialize ANNOVERA. The agreement requires us to commercialize this product and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the agreement, and indemnify the other party with respect to our development and commercialization activities under the terms of the agreements.

In addition, our current licensing agreement with the Population Council contains limitations and restrictions, including limitations that could limit or adversely affect our ~~hormone therapy drug~~ability to develop and commercialize this or other product candidates ~~by physicians, patients, and payers, will depend on a number of factors, many of which are beyond our control,~~ including the following:

~~Even if~~We have also entered into licensing and supply agreements with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel and with Theramex pursuant to which we granted Theramex an exclusive license to commercialize BIJUVA, and IMVEXXY outside of the ~~medical community accepts that~~U.S., except for Canada and Israel.

Sales of our products ~~are safe~~in the U.S. and ~~efficacious for their approved indications, physicians may not immediately be receptive~~our rights to ~~the use or may be slow~~receive royalties with respect to ~~adopt~~ our products ~~as an accepted treatment~~sold outside the U.S. could be adversely affected if products manufactured outside of the U.S. or for sale outside of the ~~symptoms~~U.S. under the terms of these licensing and supply agreements are reimported and sold in the U.S. In addition, our rights to receive royalties with respect to our products sold outside the U.S. could be adversely affected if our licensees fail to diligently pursue approval of our products, or opt not to sell our products, in certain jurisdictions where they are not required to do so.

If our dietary supplement, hormone therapy pharmaceutical products or patient-controlled, long-acting contraceptive products do not have the effects intended or cause undesirable side effects, our business may suffer.

Although many of the ingredients in our dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they ~~are intended. We cannot assure you that any labeling~~also contain innovative ingredients or combinations of ingredients. Furthermore, our hormone therapy or patient-controlled, long-acting contraceptive pharmaceutical products have been approved by the FDA ~~will permit us to promote our products as being superior to competing~~based on its assessment of the safety and efficacy of these products. ~~If our products do not achieve an adequate level~~While we believe that all of ~~acceptance by physicians and payers, we may not generate sufficient or any revenue from~~ these products and wethe combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions. In addition, these products may not ~~become profitable. In addition, our efforts to educate~~have the ~~medical community and third-party payers~~effect intended if they are not taken in accordance with certain instructions, which include certain dietary or other labeling restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on ~~the benefits~~an unforeseen cohort. If any of our products ~~may require significant resources~~or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and ~~may never~~prospects could be ~~successful.~~harmed significantly.

Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.

Development and awareness of our brand will depend largely upon our success in increasing our ~~customer~~consumer base and maintaining adequate pricing through our exclusivities. The pharmaceutical and dietary supplement ~~and pharmaceutical~~ industries are intensely competitive and subject to rapid and significant technological change. Our products face intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. Many of these companies have greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non-FDA-approved compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful. Finally, loss of exclusivity may provide opportunity for competing products, particularly generics, to erode pricing and siphon off our ~~customers.~~consumers.

On February 20, 2020, we received the IMVEXXY Notice Letter regarding an ANDA submitted to the FDA by Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Teva’s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed. We cannot assure you that the complaint filed on April 1, 2020 or any other patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY for any particular length of time, or at all. If Teva’s ANDA is approved, and a generic version of IMVEXXY is introduced, our sales of IMVEXXY could be adversely affected.

On March 17, 2020, we received the BIJUVA Notice Letter regarding an ANDA submitted to the FDA by Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that the BIJUVA Patents are invalid, unenforceable, and/or will not be infringed by Amneal’s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement against Amneal in the United States District Court for the District of New Jersey arising from Amneal’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal’s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Amneal’s ANDA until the earlier of 30 months or entry of a district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed. On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed. We cannot assure you that the complaint filed on April 29, 2020 or any other patent infringement lawsuit that we may file will prevent the introduction of a generic version of BIJUVA for any particular length of time, or at all. If Amneal’s ANDA is approved, and a generic version of BIJUVA is introduced, our sales of BIJUVA could be adversely affected.

In addition, we cannot predict what additional ANDAs could be filed by Teva, Amneal or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby harm our business and financial condition.

Failure to obtain regulatory approval outside the U.S. will prevent usour licensees from marketing our hormone therapy ~~drugs~~pharmaceutical products in non-U.S. markets.

We ~~are presently attempting, through certain partnering relationships,~~have entered into licensing and supply agreements with Knight and Theramex to ~~market certain of our hormone therapy drugs~~commercialize IMVEXXY and BIJUVA in non-U.S. markets. To market ~~our hormone therapy drugs~~these products in the European Union and many other non-U.S. jurisdictions, weour licensees must obtain separate regulatory approvals. We have had limited interactions with non-U.S. regulatory authorities, the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by other regulatory authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated with obtaining FDA approval or clearance. For these non-U.S. regulatory approvals, weour licensees may not obtain them on a timely basis, if at all. Our licensees’ failure to receive necessary non-U.S. regulatory approvals to commercialize ~~our hormone therapy drugs~~IMVEXXY and BIJUVA in a given market could have ~~a material~~an adverse effect on our business, financial condition, results of operations, and prospects.

In addition, by seeking to obtain approval to market ~~our hormone therapy drugs~~IMVEXXY and BIJUVA in one or more non-U.S. markets, we and/or our licensees will be subject to rules and regulations in those markets relating to our ~~product.~~products. In some countries, particularly countries of the European Union, each of which has developed its own rules and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval in some countries, weour licensees may be required to conduct a clinical trial that compares the cost-effectiveness of our ~~drug candidates~~pharmaceutical product to other available products. If reimbursement of our ~~drug candidates~~pharmaceutical product is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, weour licensees may be unable to generate revenues and achieve or sustain profitability with respect to any given market, which could have ~~a material~~an adverse effect on our business, financial condition, results of operations, and prospects. If weour licensees obtain approval to market ~~our hormone therapy drugs~~IMVEXXY or BIJUVA in one or more non-U.S. markets, we will have additional pharmacovigilance reporting requirements for our products. To the extent that the non-U.S. markets wein which our licensees distribute our products in have different pharmacovigilance reporting requirements than the U.S., there is a risk that the marketing of our drugs in those countries may increase the number of adverse events reported for our products.

We sell our products to wholesale distributors and retail pharmacy distributors. During 2020, three customers each generated more than 10% of our total revenues; revenue generated from these three customers combined accounted for approximately 63% of our total revenue during 2020. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.

We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our pharmaceutical product candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.

We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our pharmaceutical product candidates, as well as for the execution of clinical studies. Although we only have oversight of certain aspects of our CROs’ activities, we are ultimately responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards. Our reliance on the CROs does not relieve us of our regulatory responsibilities as sponsor. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA’s current Good Clinical Practice, or cGCP, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic and pre-approval inspections of trial sponsors, principal investigators, CROs, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our pharmaceutical product candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit enough patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.

In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our pharmaceutical product candidates that we seek to develop. As a result, our financial results and the commercial prospects for our pharmaceutical product candidates that we seek to develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed or end.

We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our pharmaceutical product candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition, results of operations, or prospects.

As of December 31, 2020, we had federal net operating loss carryforwards, or NOLs, of approximately $761.7 million. Subject to applicable limitations, these NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.

Section 382 of the Internal Revenue Code of 1986, as amended, imposes limitations on a corporation’s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. If an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 because of events in the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382.

On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent and imposing new restrictions on the use of NOLs. The Tax Act reduced the corporate tax rate to 21 percent, effective January 1, 2018. Management assessed the valuation allowance analyses with respect to our NOLs as affected by various aspects of the Tax Act and determined that a full valuation allowance continues to be appropriate. Additionally, in order to address the impact of the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was enacted into law on March 27, 2020. The CARES Act includes several significant business tax provisions that, among other things, includes further statutory amendments to the rules governing NOLs, as amended by The Tax Act. The CARES Act limits the NOL carryover deduction in taxable years beginning after December 31, 2020, to the lesser of the NOL carryforward or 80 percent of the taxpayer's taxable income (after considering the deduction for NOLs arising in tax years beginning before January 1, 2018), which may restrict our ability to offset future taxable income with NOLs and increase our future federal income taxes otherwise payable.

Our operations are concentrated in Boca Raton, Florida and interruptions affecting us or our suppliers due to natural disasters, the COVID-19 pandemic, or other unforeseen events could adversely affect our operations.

Our current operations are concentrated in Boca Raton, Florida. A hurricane, the COVID-19 pandemic, or other disaster or unforeseen event resulting in significant damage to our facilities, or causing illness in the personnel operating our facilities, could significantly disrupt or curtail or require us to cease our operations. It would be difficult, costly and time-consuming to transfer resources from one facility to another or to repair or replace our facility if it is significantly damaged, or engage or hire new personnel due to the COVID-19 pandemic. In addition, our insurance may be insufficient to cover all of our losses and may not continue to be available to us on acceptable terms, or at all. In addition, if one of our suppliers, such as Catalent at its manufacturing facility in St. Petersburg, Florida, experiences a similar disaster or is otherwise impacted by the COVID-19 pandemic or unforeseen event, we could face significant delays in obtaining our products. Any significant uninsured loss, prolonged or repeated disruption to operations or inability to operate, experienced by us or by our suppliers, could adversely affect our business, financial condition and results of operations.

We are substantially dependent on a sales force – both those directly employed by us and those engaged through our contract sales organization – to attract new business and to manage existing customer relationships. There is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining direct sales personnel. New and future sales personnel may not become as productive as expected, and we may be unable to hire or engage enough qualified individuals in the future in the markets in which we do business. If we are unable to hire, engage and develop enough productive sales personnel or are required to hire or engage more sales personnel than we expect our business prospects could suffer. In addition to utilizing a contract sales organization for part of our sales force, we also utilize this organization for certain sales support functions, such as fleet and sample management. We currently intend to insource at least some of these functions and personnel in the future. If we are unsuccessful in insourcing these functions or personnel, we may face delays or additional costs in commercializing our pharmaceutical products, which could adversely affect our business, financial condition and results of operations.

We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.

As of December 31, 2020, we had 400 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, sales and marketing, and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional pharmaceutical product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our pharmaceutical products and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.

If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively in our market.

Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy pharmaceutical products and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the U.S., such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S., and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.

While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities’ applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our pharmaceutical products. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.

If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our pharmaceutical products may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.

In addition, mechanisms exist in much of the world permitting some form of challenge by generic drug marketers to our patents before, or immediately following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as “at risk” launches to challenge relevant patent rights. On February 20, 2020, we received the IMVEXXY Notice Letter regarding an ANDA submitted to the FDA by Teva, and on March 17, 2020 we received the BIJUVA Notice Letter regarding an ANDA submitted to the FDA by Amneal. The ANDA submitted by Teva seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY, and the ANDA submitted by Amneal seeks approval from the FDA to commercially manufacture, use, or sell a generic version of BIJUVA.

In the IMVEXXY Notice Letter, Teva alleges that IMVEXXY Patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Teva’s ANDA until the earlier of 30 months or entry of a district court decision finding the IMVEXXY Patents invalid, unenforceable, or not infringed.

In the BIJUVA Notice Letter, Amneal alleges that BIJUVA Patents listed in the FDA’s Orange Book that claim compositions and methods of BIJUVA are invalid, unenforceable, and/or will not be infringed by Amneal’s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement against Amneal in the United States District Court for the District of New Jersey arising from Amneal’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal’s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. The complaint which we filed automatically precludes the FDA from approving Amneal’s ANDA until the earlier of 30 months or entry of a district court decision finding the BIJUVA Patents invalid, unenforceable, or not infringed. On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed.

We cannot assure you that any patent infringement lawsuit that we may file will prevent the introduction of a generic version of IMVEXXY or BIJUVA for any particular length of time, or at all. If Teva’s ANDA or Amneal’s ANDA are approved, and a generic version of IMVEXXY or BIJUVA is introduced, our sales of IMVEXXY or BIJUVA could be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by Teva, Amneal or other potential generic competitors requesting approval to market generic forms of our products, which could require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby harm our business and financial condition.

Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.

We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, including with respect to Teva’s ANDA and BIJUVA Notice Letter, and Amneal’s ANDA and IMVEXXY Notice Letter, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.

In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the U.S. or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of December 31, 2020, our executive officers, directors, holders of 5% or more of our common stock, and their affiliates beneficially owned approximately 25% of our common stock, inclusive of vested options and warrants to acquire shares of our common stock. These stockholders may be able to largely determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to largely control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.

Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting. Due to our current filing status, we are not required to have our independent registered public accounting firm deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by, or voluntarily followed under, Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of the Financing Agreement preclude us from paying dividends, and any future debt agreements may also preclude us from paying dividends. Any return to stockholders will be limited to the capital appreciation, if any, of their stock.

Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our articles of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to remove our current management. These provisions in our articles of incorporation and bylaws include the following:

In addition, we are subject to Nevada’s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits an “interested stockholder” from entering into a “combination” with a company, unless certain conditions are met. An “interested stockholder” is a person who, together with affiliates and associates, beneficially owns (or within the prior two years, did beneficially own) 10% or more of the corporation’s capital stock entitled to vote.

Our business may be affected by unfavorable publicity or lack of consumer acceptance.

We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use, products themselves, or marketing campaigns for our products. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by consumers as less than favorable or that may question earlier favorable research or publicity could have an adverse effect on sales of our products and our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates use of our products or any other similar products with illness or other adverse effects, or that questions the benefits of our products or similar products, or that claims that such products do not have the effect intended, or that question the marketing of our products, could have an adverse effect on our business, reputation, financial condition, or results of operations.

Our success depends on how efficiently we respond to changing consumer preferences and demand.

Our success depends, in part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings depends upon several factors, including our ability to achieve the following:

If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels of our existing products to meet consumers’ demand in a timely manner, our business, results of operations, and financial condition could be adversely affected.

We may initiate product recalls or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.

We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could adversely affect our business, financial condition, and results of operations.

Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.

We face an inherent risk of product liability claims as a result of the ~~marketing~~commercial availability of our current products and the clinical testing of our ~~hormone therapy drug~~pharmaceutical product candidates despite obtaining appropriate informed consents from our clinical trial participants. Additionally, in light of the history of product liability claims related to other hormone ~~replacement~~ therapy products and contraceptives, we will face an even greater risk through commercialization of our ~~hormone therapy drug candidates in the United States or other additional jurisdictions or if we engage in the clinical testing of proposed new products or commercialize any additional~~ products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures to warn of dangers ~~inherent in~~associated with the use of the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted under state consumer fraud and protection ~~acts.~~statutes. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or ~~hormone therapy drugs. Even successful defense would require significant financial and management resources.~~pharmaceutical product candidates. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:

Although we maintain general liability insurance and clinical trial liability insurance for our ~~hormone therapy drugs~~products and ~~drug~~product candidates, this insurance may not fully cover potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial condition, results of operations, and prospects.

~~Our business may be affected by unfavorable publicity or lack of consumer acceptance.~~

We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by our consumers as less than favorable or that may question earlier favorable research or publicity could have a material adverse effect on our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates consumption of our product or any other similar product with illness or other adverse effects, or that questions the benefits of our product or a similar product, or that claims that such products do not have the effect intended could have a material adverse effect on our business, reputation, financial condition, or results of operations.

If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.

Our manufacturing and research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials. In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the ~~United States~~U.S. govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors) comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future. We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, and may adversely affect our business, financial condition, results of operations, and prospects.

If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.

Our ability to compete in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial, scientific, and medical personnel. To induce valuable employees to remain with us, we have, among other things, provided stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams may terminate their employment with us on short notice. ~~We do not~~Although we have employment agreements with several of our key ~~employees. As a result,~~employees, most employees are employed on an at-will basis, which means that any of these employees could leave our employment at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.

We sell our prescription prenatal vitamin products and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. During 2018, four customers each generated more than 10% of our total revenues; revenue generated from these four customers combined accounted for approximately 76% of our total revenue during 2018. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.

A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.

Our ability to maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances, our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials, if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have ~~a material~~an adverse effect on our business, financial condition, results of operations, and cash flows.

Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval ~~and~~or commence or continue product sales.

We may experience delays in future clinical trials for our ~~drug candidates.~~pharmaceutical product candidates or required post-approval clinical trials for our approved products. Clinical trials might not begin on time; may be interrupted, delayed, suspended, or terminated once commenced; might need to be amended or redesigned; might not enroll enough patients; or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:

Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing future clinical trials could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenue from our ~~drug~~pharmaceutical product candidates, or continue to generate revenue from our approved products subject to post-approval clinical trials for our approved products, subject to the trial.

Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.

Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. Failure can occur at any time during the clinical trial process because of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy data and results despite having progressed through earlier clinical trials. Several companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Before approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations, the FDA approves drugs based on a single well-controlled clinical trial. If clinical trials for any of our pharmaceutical product candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve those product candidates and we will not be able to commercialize, which could have an adverse effect on our business, financial condition, results of operations, and prospects.

In addition, the FDA’s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our pharmaceutical product candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability could be adversely affected.

We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our ~~drug~~pharmaceutical product candidates.

Clinical trials may be suspended or terminated at any time for many reasons. A clinical trial may be suspended or terminated by us, our collaborators, the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.

We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our hormone therapy drug candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.

We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our hormone therapy drug candidates, as well as for the execution of clinical studies. Although we control only certain aspects of our CROs’ activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA’s cGCPs, which are regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our hormone therapy drug candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit enough patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.

In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our hormone therapy drug candidates that we seek to develop. As a result, our financial results and the commercial prospects for our hormone therapy drug candidates that we seek to develop could be harmed, our costs could increase, and our ability to generate revenue could be delayed or end.

We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our hormone therapy drug candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operations, or prospects.

~~Our ability to utilize net operating loss carryforwards may be limited.~~

As of December 31, 2018, we had federal net operating loss carryforwards, or NOLs, of approximately $481.4 million. Subject to applicable limitations, these NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce our future federal income taxes otherwise payable.

On December 22, 2017, the U.S. federal government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act, or the Tax Act. The Tax Act makes broad and complex changes to the U.S. federal tax code, including, but not limited to reducing the U.S. federal corporate tax rate from 34 percent to 21 percent and imposing new restrictions on the use of NOLs. The Tax Act reduces the corporate tax rate to 21 percent, effective January 1, 2018. Management assessed the valuation allowance analyses with respect to our NOLs as affected by various aspects of the Tax Act and determined that a full valuation allowance continues to be appropriate. Furthermore, the Tax Act limits the NOL carryover deduction in a taxable year to the lesser of the NOL carryforward or 80 percent of the taxpayer’s taxable income (before considering any deduction on account of such NOLs), which may restrict our ability to offset future taxable income with NOLs and increase our future federal income taxes otherwise payable.

Our business may be impacted by new or changing tax laws or regulations and actions by federal, state, and/or local agencies, or how judicial authorities apply tax laws.

In connection with the products we sell and intend to sell, we calculate, collect, and remit various federal, state, and local taxes, surcharges and regulatory fees, ~~(“tax”~~ or ~~“taxes”)~~taxes, to numerous federal, state and local governmental authorities. In addition, we incur and pay state and local taxes and fees on purchases of goods and services used in our business.

Tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. In many cases, the application of tax laws (including the recently enacted Tax Act) is uncertain and subject to differing interpretations, especially when evaluated against new technologies and services. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse.

If we have incorrectly described, disclosed, calculated, assessed, or remitted amounts that were due to governmental authorities, we could be subject to additional taxes, fines, penalties, or other adverse actions, which could ~~materially~~ impact our business, results of operations, and financial condition.

~~Our success depends on how efficiently we respond to changing consumer preferences and demand.~~

If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels to meet customers’ demand in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.

~~We may initiate product recalls or withdrawals or may be subject to regulatory enforcement actions that could negatively affect our business.~~

We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially and adversely affect our business, financial condition, and results of operations.

~~We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.~~

As of December 31, 2018, we had 241 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, sales and marketing, and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional drug candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our hormone therapy drugs and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.

We may not be able to maintain effective and efficient information systems or properly safeguard our information systems.

Our operations are dependent on uninterrupted performance of our information systems. Failure to maintain reliable information systems, disruptions in our existing information systems or the implementation of new systems could cause disruptions in our business operations, including violations of patient privacy and confidentiality requirements and other regulatory requirements, increased administrative expenses and other adverse consequences.

In addition, information security risks have generally increased in recent years because of new technologies and the increased activities of perpetrators of cyber-attacks resulting in the theft of protected health, business, or financial information. During the COVID-19 pandemic, in particular, cyber-attacks increased as companies shifted to remote work environments, including several high-profile, sophisticated attacks impacting government agencies and security firms alike, the impacts of which are still being uncovered. Despite our layered security controls, experienced computer programmers and hackers may be able to penetrate our information systems and misappropriate or compromise sensitive patient or personnel information or proprietary or confidential information, create system disruptions or cause shutdowns. They also may be able to develop and deploy viruses, worms and other malicious software programs that disable our systems or otherwise exploit any security vulnerabilities. Outside parties may also attempt to fraudulently induce employees to take actions, including the release of confidential or sensitive information or to make fraudulent payments, through illegal electronic spamming, phishing, or other tactics.

A failure in or breach of our information systems because of cyber-attacks or other tactics could disrupt our business, result in the release or misuse of protected health information, or PHI, confidential or proprietary business information or financial loss, damage our reputation, increase our administrative expenses, and expose us to additional risk of liability to federal or state governments or individuals. Although we believe that we have robust information security procedures and other safeguards in place, as cyber threats continue to evolve, we may be required to expend additional resources to continue to enhance our information security measures or to investigate and remediate any information security vulnerabilities. Our remediation efforts may not be successful and could result in interruptions, delays or cessation of service and loss of existing or potential ~~customers~~patients and disruption of our operations. In addition, breaches of our security measures and the unauthorized dissemination of patient healthcare and other sensitive information, proprietary or confidential information about us or other third-parties could expose such persons’ private information to the risk of financial or medical identity theft or expose us or such persons to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our brand and reputation or otherwise harm our business. Any of these disruptions or breaches of security could have ~~a material~~an adverse effect on our business, financial condition, and results of operations.

Our failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.

European Union member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the European Union, which was formerly governed by the provisions of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation, or the GDPR, in May 2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to €20 million or 4% of the annual global revenues of the non-compliant company, whichever is greater. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management’s attention and increase our cost of doing business.

On July 16, 2020, the Court of Justice of the European Union issued its long-awaited decision in the case Data Protection Commission v. Facebook Ireland, Schrems, or the Schrems II Decision. The Schrems II decision invalidates the European Commission’s adequacy decision for the EU-U.S. Privacy Shield Framework, calling into question personal data transfers from the EU to the U.S. While we have yet to determine the full impact of the invalidation of the EU-US Privacy Framework on our business, we anticipate increased legal and technological costs as we evaluate any trans-Atlantic transfers as well as the impact on any business that we may conduct in the EU.

Our employees and business partners may not appropriately secure and protect confidential information in their possession.

Each of our employees and business partners is responsible for the security of the information in our systems or under our control and to ensure that private and financial information is kept confidential. Should an employee or business partner not follow appropriate security measures, including those related to cyber threats or attacks or other tactics, as well as our privacy and security policies and procedures, the improper release of personal information, including PHI, or confidential business or financial information, or misappropriation of assets could result. The release of such information or misappropriation of assets could have ~~a material~~an adverse effect on our business, financial condition, and results of operations.

Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.

We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state ~~health care~~healthcare fraud and abuse laws and regulations, to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the ~~health care~~healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained during clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.

Another party could develop ~~hormone therapy~~competing pharmaceutical products and obtain FDA regulatory exclusivity in the ~~United States~~U.S. before we do, potentially preventing our ability to commercialize our ~~hormone therapy drug candidates~~pharmaceutical products and other products in development.

We plan to seek to obtain market exclusivity for our ~~hormone therapy drug candidates~~pharmaceutical products and any other ~~drug~~pharmaceutical product candidates we develop in the future. To the extent that patent protection is not available or has expired, FDA ~~marketing~~ exclusivity may be the only available form of exclusivity available for these proposed products. ~~Marketing exclusivity~~These FDA exclusivities can delay the submission or the approval of certain ~~marketing~~drug applications. Potentially competitive products may also be seeking ~~marketing exclusivity~~FDA exclusivities and may be in various stages of development, including some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted, nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It is possible that competing products may obtain FDA approval with ~~marketing exclusivity~~exclusivities before we do, which could delay our ability to submit ~~a marketing~~an application or obtain necessary regulatory approvals, result in lost market opportunities with respect to our ~~hormone therapy drug~~pharmaceutical product candidates, and ~~materially~~ adversely affect our business, financial condition, and results of operations.

If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy drug candidates and other products are not adequate, we may not be able to compete effectively in our market.

Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy drug candidates and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the United States, such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.

While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities’ applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our hormone therapy drug candidates. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.

If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our hormone therapy drugs may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.

~~Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.~~

If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our ~~drug~~pharmaceutical product candidates.

Our commercial success depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending applications that exist in the technical areas of ~~hormone therapy,~~our pharmaceutical products, including compounds, formulations, treatment methods, and synthetic processes, which may be applied towards the synthesis of ~~hormones.~~hormones, for example. Patent applications are confidential when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products or ~~drug~~product candidates. Therefore, we cannot ever know with certainty the nature or existence of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market our ~~drug~~product candidates as planned or that we or our licensors’ and partners’ patents will not be opposed or litigated by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of any of our ~~drug~~product candidates, the holders of any such patent may be able to block our ability to develop and commercialize the applicable ~~drug~~product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have ~~a material~~an adverse effect on our business.

There is a substantial amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe its patents or other proprietary rights, we could face many risks that could adversely affect our business, financial condition, results of operations, and prospects, including the following:

We are party from ~~time-to-time~~time to time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our ~~drug~~pharmaceutical product candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail or cease the development of some or all of our ~~drug~~pharmaceutical product candidates, which could adversely affect our business, financial condition, results of operations, and prospects.

We intend to submit NDAs for our hormone therapy drug candidates, assuming that the clinical data justify submission, under Section 505(b)(2), which was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. To the extent that a Section 505(b)(2) NDA relies on clinical trials conducted for a previously approved drug product or the FDA’s prior findings of safety and effectiveness for a previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications in its Section 505(b)(2) NDA with respect to any patents for the approved product on which the application relies that are listed in the FDA’s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. Specifically, the applicant must certify for each listed patent that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is not sought until after patent expiration; or (iv) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product’s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification.

If the Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA for 30 months beginning on the date the patent holder receives notice, or until a court deems the patent unenforceable, invalid or not infringed, whichever is earlier. The court also can shorten or lengthen the 30-month period if either party is found not to be reasonably cooperating in expediting the litigation. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its product only to be subject to significant delay and patent litigation before its product may be commercialized. Alternatively, if the NDA or relevant patent holder does not file a patent infringement lawsuit within the specified 45-day period, the FDA may approve the Section 505(b)(2) application at any time.

If we cannot certify that all of the patents listed in the Orange Book for the approved products referenced in the NDAs for each of our hormone therapy drug candidates have expired, we will be compelled to include a Paragraph IV certification in the NDA for such drug candidate. Our inability to certify that all of the patents listed in the FDA’s Orange Book for approved products referenced in the NDAs for each of our hormone therapy drug candidates could have significant adverse effects on the timing for obtaining approval of our hormone therapy drug candidates.

~~We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.~~

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.

In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the United States or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.

If we are unable to protect the confidentiality of certain information, the value of our products and technology could be ~~materially~~ adversely affected.

We also rely on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees, independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming, and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets, know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business, financial condition, results of operations, and prospects.

We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.

As is common in the pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and prospects.

The market price of our common stock may be highly volatile, and you could lose all or part of your investment.

The trading price of our common stock on Nasdaq is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:

In addition, the stock market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.

~~Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.~~

As of December 31, 2018, our executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 69% of our common stock on an as converted basis. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.

~~If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.~~

Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.

~~We do not intend to pay dividends on~~Future sales and issuances of equity securities, convertible securities or other securities could result in additional dilution of the percentage ownership of holders of our common ~~stock so any returns will be limited to the value of our~~ stock.

Our stockholders may experience dilution upon future equity issuances, including convertible debt or equity securities we may issue in the future, the exercise of stock options to purchase common stock granted to our employees, consultants and directors, including options to purchase common stock granted under our stock option and equity incentive plans or the issuance of common stock in settlement of previously issued awards under our stock option and equity incentive plans that may vest in the future.

We ~~have never declared or paid any cash dividends on our common stock. We currently anticipate~~expect that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholdersadditional capital will be ~~limited~~needed in the future to ~~the value of their stock.~~

~~Some provisions of~~continue our ~~charter documents~~planned operations. To raise capital, we may sell equity securities, convertible securities or other securities in one or more transactions at prices and ~~Nevada law~~in a manner we determine from time to time. If we sell equity securities, convertible securities or other securities current investors may ~~have anti-takeover effects that could discourage an acquisition of us~~be materially diluted by ~~others, even if an acquisition would be beneficial to our stockholders and~~subsequent sales. We may ~~prevent attempts by~~also need our stockholders to ~~replace or remove our current management.~~

~~Provisions in~~authorize the issuance of additional shares of common stock under our articles of incorporation if we do not have sufficient authorized shares to raise such additional capital or issue future awards under our stock option and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, andequity incentive plans. New investors could also ~~make it more difficult~~gain rights, preferences and privileges senior to ~~remove~~those of holders of our ~~current management. These provisions in our articles of incorporation and bylaws include the following:~~existing equity securities.

Our corporate headquarters is located in Boca Raton, Florida, where we lease 33,124 square feet of office space pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and was subsequently amended on February 18, 2015, April 26, 2016 and October 4, 2016 to lease additional administrative space. The lease expires on October 31, 2021. The primary functions performed at this location are executive, administrative, accounting, treasury, marketing, and human resources.

In October 2018, we entered into a lease for new corporate headquarter offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which the lease on 7,561 ~~has~~square feet commenced in 2018 and the lease on the remaining 48,651 square feet ~~will commence no earlier than June 1,~~commenced in August 2019, or the full premises commencement date. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We ~~believe that our current facility~~have the option to extend the term of the lease for two additional consecutive periods of five years. The extension option is not included in ~~good working order~~the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and ~~that our current facility~~free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and ~~new corporate headquarters are capable~~utility expenses. In June 2019, we entered into an agreement with the same lessors to lease additional 6,536 square feet of ~~supporting our operations for~~administrative office space in the ~~foreseeable future.~~same location, pursuant to an addendum to such lease, which commenced in May 2020.

We have been informed by the staff, or the Staff, of the Securities and Exchange Commission that the Staff is conducting a formal investigation concerning whether certain of our communications during 2017 regarding TX-004HR may have violated Regulation FD. We are cooperating with the Staff in connection with the investigation. Any determination that our actions violated Regulation FD could result in penalties or other remedies being imposed. While we believe that any such penalties and other remedies would be immaterial from a financial perspective, no assurance can be made about the ultimate outcome of the investigation, and there can be no assurance that any such penalties and remedies would not have a material adverse effect on our business.

From time to time, we are involved in litigation and proceedings in the ordinary course of our business.

On February 20, 2020, we received a Paragraph IV certification notice letter, or the IMVEXXY Notice Letter, regarding an ANDA submitted to the FDA by Teva Pharmaceuticals USA, Inc., or Teva. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of the 4 mcg and 10 mcg doses of IMVEXXY. In the IMVEXXY Notice Letter, Teva alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of IMVEXXY, or the IMVEXXY Patents, are invalid, unenforceable, and/or will not be infringed by Teva’s commercial manufacture, use, or sale of its proposed generic drug product. The IMVEXXY Patents identified in the IMVEXXY Notice Letter expire in 2032 or 2033. On April 1, 2020, we filed a complaint for patent infringement against Teva in the United States District Court for the District of New Jersey arising from Teva’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva’s ANDA would be a date no earlier than the expiration of the IMVEXXY Patents and equitable relief enjoining Teva from infringing the IMVEXXY Patents. Teva has filed its answer and counterclaim to the complaint, alleging that the IMVEXXY Patents are invalid and not ~~currently involved in any legal proceeding that we believe would have a material effect on our business or financial condition.~~infringed. A trial date has not been set.

On March 17, 2020, we received a Paragraph IV certification notice letter, or the BIJUVA Notice Letter, regarding an ANDA submitted to the FDA by Amneal Pharmaceuticals, or Amneal. The ANDA seeks approval from the FDA to commercially manufacture, use, or sell a generic version of BIJUVA. In the BIJUVA Notice Letter, Amneal alleges that TherapeuticsMD patents listed in the FDA’s Orange Book that claim compositions and methods of BIJUVA, or the BIJUVA Patents, are invalid, unenforceable, and/or will not be infringed by Amneal’s commercial manufacture, use, or sale of its proposed generic drug product. The BIJUVA Patents identified in the BIJUVA Notice Letter expire in 2032. On April 29, 2020, we filed a complaint for patent infringement against Amneal in the United States District Court for the District of New Jersey arising from Amneal’s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Amneal’s ANDA would be a date no earlier than the expiration of the BIJUVA Patents and equitable relief enjoining Amneal from infringing the BIJUVA Patents. Amneal has filed its answer and counterclaim to the complaint, alleging that the BIJUVA Patents are invalid and not infringed. A trial date has not been set. On February 25, 2021, the District Court entered an order temporarily staying all proceedings in the BIJUVA litigation. The District Court stay also extends the 30-month stay for the period in which the BIJUVA litigation has been stayed.

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

Since October 9, 2017, our common stock has been listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol “TXMD.” From April 23, 2013 to October 6, 2017, our common stock was listed on the NYSE American under the symbol “TXMD.” Before that time, our common stock was quoted on the OTCQB.

OnAs of February ~~15, 2019,~~1, 2021, there were approximately ~~208~~171 record holders and ~~as of February 8, 2019, there were approximately 24,155~~28,853 beneficial owners of our common stock.

Historically, we have not paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our board of directors. In addition, the ~~Credit~~Financing Agreement contains covenants that limit our ability to pay dividends or make other distributions on our common stock.

The following line graph compares cumulative total ~~shareholder~~stockholder return for the five years ended December 31, ~~2018~~2020 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, ~~2013~~2015 and includes reinvestment of dividends. Measurement points are at December 31, ~~2013~~2015 and the last trading day of the fiscal years ended December 31, ~~2014, 2015,~~ 2016, 2017, 2018, 2019, and ~~2018.~~2020. The stock price performance on the following graph is not necessarily indicative of future stock price performance.

The following line graph compares cumulative total ~~shareholder~~stockholder return for the five years ended December 31, ~~2018~~2020 for (i) our common stock; (ii) Nasdaq Pharmaceutical Index; and (iii) Nasdaq Stock Market (U.S. companies). The graph assumes $100 invested on December 31, ~~2013~~2015 and includes reinvestment of dividends. Measurement points are December 31, ~~2013~~2015 and the last trading day of the fiscal years ended December 31, 2020, 2019, 2018, 2017, ~~2016, 2015,~~ and ~~2014~~2016, and each of the following quarters ended therein. The stock price performance on the following graph is not necessarily indicative of future stock price performance.

The performance graphs shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act.

The following table sets forth selected consolidated financial and other data as of and for the periods indicated. You should read the following information together with the more detailed information contained in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes included elsewhere in this Annual Report. The consolidated statements of operations for the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016~~2018 and the consolidated balance sheet data as of December 31, ~~2018~~2020 and ~~2017~~2019 are derived from our audited consolidated financial statements included in this Annual Report. The consolidated statements of operations for the years ended December 31, ~~2015~~2017 and ~~2014,~~2016, and the consolidated balance sheet data as of December 31, ~~2016, 2015,~~2018, 2017, and ~~2014,~~2016 are derived from our audited consolidated financial statements not included in this Annual Report.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis in conjunction with the information set forth under “Selected Financial Data” and our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See “Statement Regarding Forward-Looking Information.” Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under “Risk Factors” elsewhere in this Annual Report.

~~We are~~TherapeuticsMD is a women’s healthcare company ~~focused on~~with a mission of creating and commercializing innovative products to support the lifespan of women ~~and championing awareness of women’s healthcare issues, specifically, for~~from pregnancy prevention ~~pregnancy, childbirth, nursing, pre-menopause, and~~through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical ~~products to patient-controlled, long-acting contraceptive.~~products. We also ~~manufacture and distribute~~have a portfolio of branded and generic prescription prenatal vitamins under the ~~vitaMedMD®~~vitaMedMD and ~~BocaGreenMD® brands.~~BocaGreenMD brands that furthers our women’s healthcare focus.

~~With our SYMBODA™ technology, we are developing and commercializing advanced hormone therapy pharmaceutical~~Our portfolio of products ~~to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization~~focused on women’s health allows us to efficiently leverage our sales and ~~grow our~~ marketing ~~and sales organization~~plan to ~~commercialize~~grow our recently approved products.

During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs.

We have also entered into ~~an exclusive~~ license ~~agreement, or the Population Council License Agreement,~~agreements with ~~the Population Council, Inc., or the Population Council,~~strategic partners to commercialize ~~ANNOVERA™ in~~IMVEXXY and BIJUVA outside of the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY® and BIJUVA™ in Canada and Israel.

We are focused on activities necessary for commercialization of ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA and ~~ANNOVERA™.~~ANNOVERA. We continue to manufacture and distribute our prescription prenatal vitamin product lines, consisting of branded prenatal vitamins under vitaMedMD^®and authorized generic formulations of some of our prescription prenatal vitamin products under ~~BocaGreenMD~~^®.BocaGreenMD. All of our prenatal vitamins are gluten-, sugar-, and lactose-free. A prenatal vitamin option that is both vegan and kosher is also available for women with special dietary needs. We believe our product attributes result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality and patented ingredients.

~~We submitted the New Drug Application, or NDA, for TX-001HR to the FDA on December 28, 2017. On~~In October ~~28,~~ 2018, the FDA approved ~~BIJUVA™~~BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved ~~bio-identical~~bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe VMS (commonly known as hot flashes or flushes) due to menopause in women with a uterus. The estrogen and progesterone in ~~BIJUVA™~~BIJUVA have the same chemical and molecular structure as the hormones that are naturally produced in a woman’s body. ~~With~~We launched BIJUVA in April 2019.

In late January 2020, we submitted a New Drug Application, or NDA, efficacy supplement for the ~~approval~~0.5/100 mg dose of ~~BIJUVA™,~~BIJUVA to the FDA ~~required a post-approval commitment to further develop~~for review and ~~validate~~potential approval. The NDA efficacy supplement used existing data from our ~~in-vitro dissolution method to show how BIJUVA™ is released from the capsule in an in-vitro setting~~Phase 3 REPLENISH trial for ~~quality control assessments. The development of this method and validation were completed and submitted to FDA as required in our approval.~~

~~On May 30, 2018,~~BIJUVA, for which we announced results in December 2016, together with additional information and analyses. In November 2020, we withdrew the NDA efficacy supplement. We currently intend to file a Formal Dispute Resolution Request, or FDRR, with the FDA that disputes the FDA’s requirement that the efficacy supplement meet approval standard that have not been required of other approved drugs in BIJUVA’s therapeutic class. There can be no assurance that we will prevail with respect to the FDRR, if filed, or that the 0.5/100 mg dose of BIJUVA will be approved.

In May 2018, the FDA ~~had~~ approved the ~~4 μg~~4-μg and ~~10 μg~~10-μg doses of ~~IMVEXXY®~~IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-μg formulation of ~~IMVEXXY®~~IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available. ~~IMVEXXY®~~IMVEXXY 10-μg became available for commercial distribution in ~~late~~ July 2018 and both doses were commercially available by September ~~2018.~~2018.

IMVEXXY is a small, digitally inserted, softgel vaginal insert that dissolves when inserted into the vagina. It is administered mess-free, without the need for an applicator, and can be used any time of day. IMVEXXY provides a mechanism of action and dosing that is comfortable for patients, with no patient education required for dose application or applicators. IMVEXXY demonstrated efficacy as early as two weeks (secondary endpoint) and maintained efficacy through week 12 in clinical studies, with no increase in systemic hormone levels beyond the normal postmenopausal range (the clinical relevance of systemic absorption rates for vaginal estrogen therapies is not known).

As part of the FDA’s approval of ~~IMVEXXY®,~~IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. In connection with the observational study, we are required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material.

In ~~addition, the FDA asked for post-approval information with respect to certain characteristics related to the product’s specifications, which we submitted to FDA in November 2018.~~

On July ~~30,~~ 2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ~~ANNOVERA™~~ANNOVERA (segesterone ~~acetate/~~acetate and ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive that can prevent pregnancy for up to a ~~full year,~~total of 13 cycles (one year), which was approved by the FDA onin August ~~10,~~ 2018. ~~ANNOVERA™~~ANNOVERA was classified by the FDA as ~~a “new chemical entity,” or~~an NCE and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act.

~~ANNOVERA™~~ANNOVERA is a one-year ring-shaped contraceptive vaginal system, or CVS. ~~ANNOVERA™~~ANNOVERA, which is made ofwith a silicone elastomer, ~~and~~ contains segesterone acetate, a 19-nor progesterone derivative also known as ~~Nestorone®, or NES,~~SA and ~~ethinyl estradiol, or~~ EE. EE is an approved active ingredient in many marketed hormonal contraceptive products. Segesterone acetate, ~~a new chemical entity~~an NCE, is a potent progestin ~~that~~and ANNOVERA is the only product with segesterone acetate. Segesterone acetate also does not ~~active orally but is active when administered via non-oral routes such as vaginal rings, implants,~~bind to the androgen or estrogen receptors and ~~transdermal systems. NES~~has no glucocorticoid effects at contraceptive doses. SA has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.

~~ANNOVERA™~~ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or OCs, ~~ANNOVERA™~~ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ~~ANNOVERA™~~ANNOVERA for 7seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (1(one year).

~~ANNOVERA™~~ANNOVERA releases daily vaginal doses of both active ingredients ~~(NES~~(SA and EE). The claimed release rate of 150 μg/day ~~NES~~SA and 13/day μg EE is supported by the calculated average release rate from an ex vivo analysis of ~~ANNOVERA™~~ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.

~~We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA™.~~

The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population Council.

Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20 million within 30 days following approval by the FDA of the NDA for ANNOVERA™ and will be required to pay the Population Council an additional $20 million within 30 days following the release of the first commercial batch of ANNOVERA™. The Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA™, as detailed below. We are required to pay the Population Council milestone payments of $40 million upon cumulative net sales of ANNOVERA™ in the U.S. by us and our affiliates and permitted sublicensees of each of $200.0 million, $400.0 million and $1.0 billion.

In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA™ in the U.S. by us and our affiliates and permitted sublicensees as follows:

The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ANNOVERA™ that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.

As part of the approval of ~~ANNOVERA™,~~ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism. AIn accordance with the post-marketing requirements, the full protocol ~~submission~~ for the study ~~is due~~was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed ~~$20 million,~~$20,000,000, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis. The Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA.

In October 2019, we began a “test and learn” market introduction phase of launch for ANNOVERA, with 36 of our existing sales representatives currently promoting ANNOVERA in addition to our other products, and our 23 regional sales managers and 12 compounding key account managers, or KAMs, introducing ANNOVERA to top targeted healthcare practitioners outside of these 36 territories. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed this initiative in July 2020.

We believe that the strong initial commercial net revenue per unit of ANNOVERA and commercial insurance adoption provide us with an opportunity to deploy additional financial resources to maximize ANNOVERA’s consumer-focused commercialization strategy and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when necessary. As part of this strategy, we are pursuing distribution opportunities for ANNOVERA to provide women with additional access to ANNOVERA, particularly during the COVID-19 pandemic, with multiple direct-to-consumer contraceptive platforms that extend the reach of our products.

In July 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a “test and learn” market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed the launch of ANNOVERA in July 2020.

Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA. The first commercial batch of ANNOVERA was released during the third quarter of 2019 and we paid the Population Council a second milestone payment of $20,000,000 as a result of the commercial batch release. The Population Council is eligible to receive additional milestone payments and royalties from commercial sales of ANNOVERA, as detailed below.

We assumed responsibility for marketing expenses related to the commercialization of ANNOVERA. We are required to pay the Population Council additional milestone payments of $40 million upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliated and permitted sublicensees of each of $200 million, $400 million and $1.0 billion.

In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees as follows:

The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of ANNOVERA that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate.

The Population Council has agreed to perform and pay the costs and expenses associated with two post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post-approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. We and the Population Council formed a joint product committee responsible for overseeing activities under the Population Council License Agreement. We are responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.

~~Pipeline for Our Hormone Therapy Drug Candidates~~License Agreement with Knight

TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bio-identical to – or having the same chemical and molecular structure as – the hormones that naturally occur in a woman’s body. In July ~~2014,~~2018, we ~~suspended enrollment~~entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in ~~October 2014 we stopped~~Canada and Israel. Pursuant to the ~~SPRY Trial, our phase 3 clinical trial~~terms of the Knight License Agreement, Knight paid us $2,000,000 in milestone fees upon the first regulatory approval in Canada for ~~TX-002HR,~~IMVEXXY and BIJUVA in the third quarter of 2020, and is required to ~~update the phase 3 protocol~~pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on ~~discussions~~aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.

In June 2019, we entered into the ~~FDA. Our Investigational New Drug Application,~~Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the Theramex Territory. Under the terms of the Theramex License Agreement, Theramex paid us EUR 14 million, or ~~IND,~~$15,506,400, in cash as an upfront fee in August 2019. Within thirty days of signing the Theramex License Agreement, we provided Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to ~~TX-002HR~~the upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments at a rate of 5% on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex is ~~currently inactive.~~responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Theramex Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. We ~~have suspended further development of this drug candidate~~may terminate the Theramex License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to ~~prioritize~~use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex challenges our ~~leading drugs.~~patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.

A significant portion of our historical operating expenses ~~to date~~ have been incurred in research and development activities. Research and development expenses relate primarily to the ~~discovery~~development, support and ~~development~~maintenance of our drug candidates. ~~Our business model is dependent upon our company continuing to conduct research and development.~~ Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, ~~investigative sites~~ and consultants that conduct our clinical ~~trials~~ and ~~a substantial portion of our~~ preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing, and controls capabilities, and costs associated with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with respect to drug candidates that have not received ~~IND application~~Investigational New Drug Application approval from the FDA.

We make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and development activities were $0, $0 and $228,933, at December 31, 2018, 2017, and 2016, respectively.

The following table indicates our research and development expense by project for the periods indicated:

Research and development expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical products. We will continue to be incurred as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur ongoing research and development costsdeploy limited resources as we develop our drug pipeline, continue stability testing and validation on our ~~drug candidates,~~pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on existing submissions.

During the year ended December 31, 2018 and since the project’s inception in February 2013, we have incurred approximately $11,790,000 and $127,187,000, respectively, in research and development costs with respect to BIJUVA™.

During the year ended December 31, 2018 and since the project’s inception in April 2013, we have incurred approximately $0 and $2,525,000, respectively, in research and development costs with respect to TX-002HR.

During the year ended December 31, 2018 and since the project’s inception in August 2014, we have incurred approximately $4,890,000 and $45,739,000, respectively, in research and development costs with respect to IMVEXXY®.

The costs of clinical trials may vary significantly over the life of a project owing to ~~factors that include, but are not limited to, the following: per patient trial costs; the number~~a variety of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial; the duration of patient follow-up; and the efficacy and safety profile of the drug candidate.factors. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work.

Comparison of Years Ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016:~~2018:

Year ended December 31, ~~2018~~2020 compared with year ended December 31, ~~2017~~2019

~~Revenue~~Product revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. ~~Revenue~~We launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019. We paused the planned full commercial launch of ANNOVERA in March 2020 due to the impact of the COVID-19 pandemic and resumed this initiative on July 1, 2020. Product revenue for the year ended December 31, ~~2018 decreased by~~2020 increased approximately ~~$679,000,~~$28,731,000, or 4%84%, to approximately ~~$16,099,000,~~$62,872,000, compared with approximately ~~$16,778,000~~$34,141,000 for the year ended December 31, ~~2017. Revenues, net decreased~~2019. Despite slower than anticipated growth of our product revenue due to the impact of the COVID-19 pandemic, product revenue increased primarily due to ~~a decrease in prenatal vitamin~~continued ramping of sales of ~~approximately $1,737,000 partially offset by sales of IMVEXXY® of approximately $1,058,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold~~IMVEXXY, BIJUVA and ~~higher utilization of coupons offered to customers~~ANNOVERA during the year ended December 31, ~~2018~~2020, as compared to the prior period, partially offset by a decrease in prenatal vitamins sales.

Sales of IMVEXXY increased approximately $10,887,000 as compared to the prior year and sales of BIJUVA increased approximately $4,517,000 as compared to the prior year due to a higher number of units sold and increased net product revenue per unit. Sales of ANNOVERA increased approximately $13,445,000 as compared to the prior year primarily due to a higher number of units sold, partially offset by slightly lower net revenue per unit. In addition, during the year ended December 31, 2020, our prenatal vitamin sales decreased approximately $118,000 due to decreased number of units sold partially offset by an increased net product revenue per unit as compared to the prior year. ~~We launched sales of IMVEXXY® in the third quarter of 2018. During this launch period, revenues, net related~~In addition to our ~~newly approved drug were greatly affected~~product revenue, during the year ended December 31, 2020, we recognized aggregate license revenue of $2,000,000 from two non-refundable milestone payments from Knight under the terms of the Knight License Agreement, which we recognized at the point in time upon the first regulatory approvals in Canada of each of IMVEXXY and BIJUVA. During the year ended December 31, 2019, we recognized license revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable payment, payable to us by Theramex under the terms of the Theramex License Agreement, which we recognized at the point in time when Theramex was able to use and benefit from the license, which was when the knowledge transfer of regulatory documents occurred.

During the launches of IMVEXXY and BIJUVA we introduced co-pay assistance ~~program that we introduced to launch IMVEXXY®,~~programs which ~~allowed~~allow eligible enrolled patients to access the ~~product~~products at a reasonable cost regardless of insurance coverage. We expect that our ~~revenues, net related to IMVEXXY® to~~product revenue will improve in the long term as commercial and Medicare payer coverage ~~for IMVEXXY® increases.~~increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA, and ANNOVERA prescriptions at pharmacies.

Cost of goods sold increased by approximately ~~$100,000,~~$9,640,000, or 4%152%, to approximately ~~$2,737,000~~$15,975,000 for the year ended December 31, ~~2018,~~2020, compared with approximately ~~$2,637,000~~ $6,335,000 for the year ended December 31, ~~2017~~2019. This increase is attributable to a 84% increase in product revenue as compared to the prior year, an increase in royalty fees of approximately $672,000, and an increase in amortization of our license fee related to ANNOVERA of approximately $2,246,000 as well as an increase of $4,085,000 inventory charge, primarily related to ~~product costs attributable~~BIJUVA, as compared to ~~IMVEXXY®, partially offset by lower royalty fees attributable to prenatal vitamins, and lower shipping costs.~~the prior year. Our gross margin related to prescription products was ~~83%~~approximately 75% and 81% for the ~~year~~years ended December 31, ~~2018 as compared to 84% for the year ended December 31, 2017.~~2020 and 2019, respectively. The ~~decrease~~change in our gross margin ~~percentage was~~between the two periods is primarily ~~attributable~~related to ~~higher utilization~~the change in product mix and its related costs including inventory charge, amortization of ~~coupons/co-pay assistance offered in 2018 as compared with 2017.~~license fee and royalty fees described above.

Our principal operating costs included the following items as a percentage of total operating expenses.

Operating expenses increased by approximately ~~$51,813,000,~~$9,920,000, or ~~56%~~5%, to approximately ~~$143,582,000~~$204,438,000 for the year ended December 31, ~~2018,~~2020, compared with approximately ~~$91,769,000~~$194,518,000 for the year ended December 31, ~~2017,~~2019, as a result of the following items:

Sales and marketing costs, ~~increased by approximately $42,231,000, or 215%, to approximately $61,845,000~~excluding human resources costs, for the year ended December 31, ~~2018,~~2020 increased by approximately $2,827,000, or 3%, to approximately $89,286,000, compared with approximately ~~$19,614,000~~$86,459,000 for the year ended December 31, ~~2017,~~2019. This increase was primarily due to higher expenses associated with advertising efforts to support the significant initiative related to the launch of ANNOVERA in March 2020, which was subsequently paused as a result of the COVID-19 pandemic and relaunched in July 2020, as well as continuing to support the commercialization of BIJUVA and IMVEXXY, which was partially offset by cost cutting initiatives put in place at the beginning of the COVID-19 pandemic, including reducing consulting and agency fees. In addition, we recorded product samples expense of approximately $7,100,000, during the year ended December 31, 2020, primarily related to BIJUVA. Sales and marketing costs, excluding human resources costs, also increased as compared to the prior year as a result of higher sales incentives due to the increase in product revenue, which was partially offset by lower physician education, training and travel expenses ~~associated with~~caused by restrictions on in-person speaker programs due to the COVID-19 pandemic. In addition, during the third quarter of 2020, we onboarded our outsourced sales personnel which decreased sales and marketing ~~efforts to support launch and commercialization of IMVEXXY® and BIJUVA™, including~~ costs, related to outsourced sales personnel and their related expenses, physician education and product samples, advertising and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA™, prepare for the launch of ANNOVERA™ and continue to support our growing business and commercialization of our products.excluding human resources costs.

Human ~~resource related~~resources costs, including salaries, benefits and ~~benefits increased by approximately $10,283,000, or 42%, to approximately $35,003,000~~taxes, for the year ended December 31, ~~2018,~~2020 increased by approximately $12,849,000, or 24%, to approximately $66,969,000, compared with approximately ~~$24,720,000~~$54,120,000 for the year ended December 31, ~~2017, primarily~~2019, as a result of an increase of approximately ~~$7,975,000~~$11,964,000 primarily related to higher employee count which increased from 348 in ~~personnel costs~~2019 to 400 in 2020 mostly in sales, marketing and regulatory areas to support commercialization of our ~~new drugs~~pharmaceutical products which included onboarding our outsourced sales personnel and an increase of approximately $885,000 in non-cash compensation expense included in this category ~~of approximately $2,308,000~~ related to employee ~~stock option amortization~~stock-based compensation during ~~2018~~2020 as compared to ~~2017.~~2019, partially offset by cost cutting measures implemented due to the COVID-19 pandemic.

Product research and development costs ~~decreased by approximately $6,554,000, or 19%, to approximately $27,299,000~~ for the year ended December 31, ~~2018,~~2020 decreased by approximately $9,360,000, or 47%, to approximately $10,432,000, compared with approximately ~~$33,853,000~~$19,792,000 for the year ended December 31, ~~2017, primarily as a result of the completion of the REPLENISH Trial for BIJUVA™~~2019. Product research and ~~FDA approval of IMVEXXY®~~development costs include costs related to manufacturing validation and ~~BIJUVA™, partially offset by scale-up and manufacturing activities for BIJUVA™ before FDA approval~~early development trials, as well as ~~increased pre-clinical work to support our product pipeline. Research~~salaries, wages, non-cash compensation, and ~~development costs~~benefits of personnel involved in 2017 included approximately $2,400,000 in NDA submission fees related to BIJUVA™ and a write-off of approximately $1,000,000 of prepaid manufacturing costs. Research and developments costs during the year ended December 31, 2018 included the following research and development ~~projects:~~activities. Product research and development expenditures have been reduced as we refocused our resources towards the commercialization of our approved pharmaceutical products. We continue to deploy limited resources as we develop our drug pipeline, continue stability testing and validation on our pharmaceutical products, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on existing submissions.

● Since the project’s inception in February 2013, we have incurred approximately ~~$11,790,000 and $127,187,000, respectively,~~$133,120,000 in research and development costs with respect to ~~BIJUVA™.~~BIJUVA.

~~During the year ended December 31, 2018 and since~~● Since the project’s inception in August 2014, we have incurred approximately ~~$4,890,000 and $45,739,000, respectively,~~$49,572,000 in research and development costs with respect to ~~IMVEXXY®.~~IMVEXXY.

For a discussion of the nature of efforts and steps necessary to complete these projects, see “Item 1. Business — Research and Development.” For a discussion of the risks and uncertainties associated with completing development of our products, see “Item 1A. Risk Factors — Risks Related to Our Business.” For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see “— Liquidity and Capital Resources.” For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see “Item 1. Business — ~~Our Hormone Therapy Drugs,” “Item 1. Business — Pipeline for Our Hormone Therapy Drug Candidates” and “Item 1. Business —~~ Pharmaceutical Regulation.” Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.

Professional fees and consulting costs ~~increased by approximately $1,802,000, or 31%,~~ for the year ended December 31, ~~2018,~~2020 decreased by approximately $653,000, or 5%, to approximately ~~$7,661,000~~$13,260,000, compared with approximately ~~$5,859,000~~$13,913,000 for the year ended December 31, ~~2017,~~2019, primarily as a result of reduced recruiting and consulting fees, partially offset by increased legal, accounting and other professional fees.

All other operating expenses for the year ended December 31, 2020 increased by approximately $4,257,000, or 21%, to approximately $24,491,000, compared with approximately $20,234,000 for the year ended December 31, 2019, primarily as a result of increased ~~legal, consulting~~insurance, dues and ~~recruiting fees.~~

~~All other costs increased~~subscriptions, rent, depreciation and amortization expenses, and write off of intangible assets and patents, partially offset by approximately $4,051,000, or 52%, to approximately $11,774,000 for the year ended December 31, 2018, compared with approximately $7,723,000 for the year ended December 31, 2017, as a result of increased information technology, travel, allowance for bad debt expense, insurance andlower other office and travel expenses ~~primarily~~due to ~~support commercialization of our new drugs.~~travel restrictions caused by the COVID-19 pandemic.

As a result of the foregoing, our operating loss increased approximately ~~$52,592,000,~~$4,335,000, or ~~68%~~3%, to approximately ~~$130,220,000~~$155,541,000 for the year ended December 31, ~~2018,~~2020, compared with approximately ~~$77,628,000~~$151,206,000 for the year ended December 31, ~~2017,~~2019, primarily as a result of ~~increased personnel costs, sales and marketing~~an increase in total operating expenses to support commercialization ~~of IMVEXXY®~~ and ~~BIJUVA™, including costs~~launch efforts related to ~~outsourced sales personnel and their related expenses, professional fees and other operating expenses, as well~~our pharmaceutical products, a decrease in our license revenue as well as write off of inventory and product samples due to the COVID-19 pandemic, as described above, partially offset by ~~a decrease in research and development costs.~~increased total net product revenue.

We anticipate that we will continue to have operating losses for the near future until we successfully commercialize ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™,~~ANNOVERA, although there is no assurance that any commercialization of ~~IMVEXXY®~~IMVEXXY, BIJUVA, and ~~BIJUVA™ and ANNOVERA™~~ANNOVERA will be successful.

Other non-operating ~~income changed~~expense, net increased by approximately ~~$3,100,000,~~$3,044,000, or ~~441%~~12%, to an expense of approximately ~~$2,397,000~~$27,983,000 for the year ended December 31, ~~2018~~2020, compared with an ~~income~~expense of approximately ~~$703,000~~$24,939,000 for ~~2017,~~the year ended December 31, 2019, primarily as a result of increased interest expense related to our ~~term loan that we obtained in 2018~~Financing Agreement partially offset by ~~increased interest income in 2018 as compared to 2017.~~the loss on extinguishment of debt of $10,058,000 incurred during the year ended December 31, 2019. For more information regarding our Financing Agreement, see “Liquidity and Capital Resources” below.

Because of the net effects of the foregoing, net loss increased by approximately ~~$55,692,000,~~$7,379,000, or ~~72%~~4%, to approximately ~~$132,617,000~~$183,524,000 for the year ended December 31, ~~2018,~~2020, compared with approximately ~~$76,925,000~~$176,145,000 for the year ended December 31, ~~2017.~~2019. Net loss per share of ~~common stock,~~Common Stock, basic and diluted, was ($~~0.59)~~0.67) and ($0.72) for the ~~year~~years ended December 31, ~~2018, compared with ($0.37) per share of common stock for the year ended December 31, 2017.~~2020 and 2019, respectively.

Year ended December 31, ~~2017~~2019 compared with year ended December 31, ~~2016~~2018

Product revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. ~~Revenue~~Product revenue for the year ended December 31, ~~2017 decreased by~~2019 increased approximately ~~$2,578,000,~~$18,042,000, or ~~13%~~112%, to approximately ~~$16,778,000,~~$34,141,000, compared with approximately ~~$19,356,000~~$16,099,000 for the year ended December 31, ~~2016. This decrease was attributable~~2018. Product revenue increased primarily due to ~~a decrease~~an increase in sales of approximately $15,194,000 of IMVEXXY in the ~~average net revenue per unit of our products, primarily related to higher coupons in 2017 due to implementation of a new point of sale coupon system,~~current period, partially offset by a ~~slight increase~~decrease in ~~the number~~prenatal vitamin sales of ~~units sold.~~

~~Cost of goods sold decreased by~~ approximately ~~$1,548,000, or 37%, to approximately $2,637,000~~$5,155,000. Product revenue for the year ended December 31, ~~2017,~~2019 also included sales of BIJUVA of approximately $1,836,000 and sales of ANNOVERA of approximately $6,167,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as compared ~~with~~to the prior year period. We launched IMVEXXY in the third quarter of 2018 and BIJUVA in the second quarter of 2019. We started selling ANNOVERA in the third quarter of 2019. Since the launches, revenues related to IMVEXXY and BIJUVA have been greatly affected by the co-pay assistance programs that we introduced to launch these products, which allow eligible enrolled patients to access the products at a reasonable cost regardless of insurance coverage. We expect our product revenue to improve as commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA and ANNOVERA prescriptions at pharmacies. In addition to our product revenue, during the year ended December 31, 2019, we recognized license revenue of approximately ~~$4,185,000~~$15,506,000 from the upfront fee, which was a non-refundable payment, paid to us by Theramex under the terms of the Theramex License Agreement, which we recognized at the point in time when Theramex was able to use and benefit from the license, which was when the knowledge transfer of regulatory documents occurred.

Cost of goods sold increased by approximately $3,598,000, or 131%, to approximately $6,335,000 for the year ended December 31, ~~2016, primarily related to lower distribution costs. Our gross margin was 84%~~2019, compared with approximately $2,737,000 for the year ended December 31, ~~2017~~2018, primarily related to product costs attributable to our prescription pharmaceutical products, as ~~compared~~well as royalty fees of $308,328 and the amortization of our license fee of $778,692 related to ~~78%~~ANNOVERA. Our gross margin related to our prescription pharmaceutical products was 81% for the year ended December 31, ~~2016.~~2019 as compared to 83% for the year ended December 31, 2018. The ~~increase~~change in our gross margin ~~percentage was~~is primarily ~~attributable~~related to the ~~centralization of~~change in product mix between the ~~distribution channel for both our retail pharmacy distributors and wholesale distributors which, among other things, lowered the cost to package, prepare and deliver our products to customers.~~two periods.

Our principal operating costs included the following items as a percentage of total operating expenses.

Operating expenses ~~decreased~~increased by approximately ~~$13,655,000,~~$50,936,000, or ~~13%~~35%, to approximately ~~$91,769,000~~$194,518,000 for the year ended December 31, ~~2017,~~2019, compared with approximately ~~$105,424,000~~$143,582,000 for the year ended December 31, ~~2016, because~~2018, as a result of the following items:

~~Research~~Sales and ~~development~~marketing costs increased by approximately $24,614,000 or 40%, to approximately $86,459,000 for the year ended December 31, ~~2017 decreased by~~2019, compared with approximately $20,090,000, or 37%, to approximately $33,853,000, primarily because of a decrease in costs related to our phase 3 clinical trials of BIJUVA™ and IMVEXXY®, partially offset by scale-up and manufacturing activities$61,845,000 for our phase 3 clinical trials of BIJUVA™ and IMVEXXY® and costs related to regulatory submission related to BIJUVA™. Research and development costs in 2017 included approximately a $2,400,000 in NDA submission fees related to BIJUVA™ and a write-off of approximately $1,000,000 of prepaid manufacturing costs. Research and developments costs during the year ended December 31, ~~2017 included~~2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of our pharmaceutical products, including an increase of $7.4 million related to advertising expenses related to our pharmaceutical products, an increase of $6.5 million in consulting projects including costs for outsourced sales personnel and their related expenses, an increase of $6.0 million in marketing initiatives related to the ~~following research~~launch of our pharmaceutical products as well as an increase in costs related to physician education, conferences and ~~development projects:~~travel expenses related to product commercialization.

~~During~~Human resource related costs, including salaries and benefits increased by approximately $19,117,000, or 55%, to approximately $54,120,000 for the year ended December 31, ~~2017~~2019, compared with approximately $35,003,000 for the year ended December 31, 2018, primarily as a result of an increase of approximately $16,844,000 primarily due to higher employee count which increased from 241 in 2018 to 348 in 2019 primarily in sales, marketing and ~~since~~regulatory areas to support commercialization of our pharmaceutical products and an increase in non-cash compensation expense included in this category of approximately $2,273,000 related to employee stock option amortization during 2019 as compared to 2018.

Research and development costs decreased by approximately $7,507,000, or 27%, to approximately $19,792,000 for the year ended December 31, 2019, compared with approximately $27,299,000 for the year ended December 31, 2018. Research and development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased primarily as a result of certain employees and activities that were previously classified as research and development being transferred into operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.

● Since the project’s inception in February 2013, we have incurred approximately ~~$19,381,000 and $115,397,000, respectively,~~$131,035,000 in research and development costs with respect to ~~BIJUVA™.~~BIJUVA.

During the year ended December 31, 2017 and since the project’s inception in April 2013, we have incurred approximately $0 and 2,525,000, respectively, in research and development costs with respect to TX-002HR.

~~During the year ended December 31, 2017 and since~~● Since the project’s inception in August 2014, we have incurred approximately ~~$8,043,000 and $40,849,000, respectively,~~$48,261,000 in research and development costs with respect to ~~IMVEXXY®.~~IMVEXXY.

For a discussion of the nature of efforts and steps necessary to complete these projects, see “Item 1. Business — Research and Development.” For a discussion of the risks and uncertainties associated with completing development of our products, see “Item 1A. Risk Factors — Risks Related to Our Business.” For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see “— Liquidity and Capital Resources.” For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see “Item 1. Business — ~~Our Hormone Therapy Drug,” “Item 1. Business — Pipeline for Our Hormone Therapy Drug Candidates” and “Item 1. Business —~~ Pharmaceutical Regulation.” Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.

Human resource related costs, including salaries and benefits, increased by approximately $121,000, or 0.5%, to approximately $24,720,000 for the year ended December 31, 2017, compared with approximately $24,599,000 for the year ended December 31, 2016, primarily as a result of an increase of approximately $5,750,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our hormone therapy drug candidates, partially offset by a decrease in non-cash compensation expense included in this category of approximately $5,629,000 related to employee stock option amortization during 2017 as compared to 2016.

Sales and marketing costs increased by approximately $6,861,000, or 54%, to approximately $19,614,000 for the year ended December 31, 2017, compared with approximately $12,753,000 for the year ended December 31, 2016, primarily as a result of increased expenses in the first half of 2017 associated with sales and marketing efforts to support commercialization of our hormone therapy drug candidates, which were curtailed in the third quarter of 2017 due to the status of the NDA for IMVEXXY®, higher costs related to outsourced sales personnel and their related expenses which started in the fourth quarter of 2016, together with an increase in employee incentives.

Professional and consulting costs increased by approximately ~~$558,000,~~$6,252,000, or ~~11%~~82%, for the year ended December 31, ~~2017,~~2019, to approximately ~~$5,859,000~~$13,913,000 compared with approximately ~~$5,301,000~~$7,661,000 for the year December 31, ~~2016,~~2018, primarily as a result of ~~result~~increased medical safety consulting fees to support commercialization of ~~increased legal and other professional expenses, partially offset by a decrease in consulting and accounting expenses.~~our pharmaceutical products.

All other costs ~~decreased~~increased by approximately ~~$1,105,000,~~$8,460,000, or ~~13%~~72%, to approximately ~~$7,723,000~~$20,234,000 for the year ended December 31, ~~2017,~~2019, compared with approximately ~~$8,828,000~~$11,774,000 for the year ended December 31, ~~2016, primarily~~2018, as a result of ~~a decrease in write-off of accounts receivable balances of approximately $2,200,000, which occurred in 2016, partially offset by an increase in rent,~~increased contract labor, dues and subscriptions, information technology, travel, insurance and other office expenses ~~in 2017.~~primarily to support commercialization of our new drugs.

As a result of the foregoing, our operating loss ~~decreased~~increased approximately ~~$12,625,000,~~$20,986,000, or ~~14%~~16%, to approximately ~~$77,628,000~~$151,206,000 for the year ended December 31, ~~2017,~~2019, compared with approximately ~~$90,253,000~~$130,220,000 for the year ended December 31, ~~2016,~~2018, primarily as a result of ~~decreased research and development~~an increase in total operating expenses ~~non-cash compensation expense and other expenses, partially offset by increased sales and marketing expenses associated with sales and marketing efforts~~ to support commercialization of our ~~hormone therapy drug candidates and higher personnel costs.~~pharmaceutical products, partially offset by increased total net revenue.

As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drugs are brought to market, although there is no assurance that our hormone therapy drugs will be successful.

Other non-operating ~~income increased~~expense, net changed by approximately ~~$325,000,~~$22,542,000, or ~~86%~~940%, to an expense of approximately ~~$703,000~~$24,939,000 for the year ended December 31, ~~2017~~2019 compared with an expense of approximately ~~$378,000~~$2,397,000 for ~~the comparable period~~2018, primarily as a result of a one-time charge of approximately $10,058,000 in ~~2016, primarily because~~loss on extinguishment of debt and increased interest ~~income.~~expense related to our Financing Agreement that we recorded in 2019 as compared to 2018.

Because of the net effects of the foregoing, net loss ~~decreased~~increased approximately ~~$12,950,000,~~$43,528,000, or ~~14%~~33%, to approximately ~~$76,925,000~~$176,145,000 for the year ended December 31, ~~2017,~~2019, compared with approximately ~~$89,875,000~~$132,617,000 for the year ended December 31, ~~2016.~~2018. Net loss per share of common stock, basic and diluted, was ($~~0.37)~~0.72) for the year ended December 31, ~~2017,~~2019, compared with ($~~0.46)~~0.59) per share of common stock for the year ended December 31, ~~2016.~~2018.

We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities. For the three-year period ~~ending~~ended December 31, ~~2018,~~2020, we received approximately ~~$293,344,000~~$198,642,000 in net proceeds from the issuance of shares of our common ~~stock.~~stock, par value $0.001 per share, or Common Stock. As of December 31, ~~2018,~~2020, we had a cash balance of approximately ~~$161,613,000, however, changing circumstances may cause us~~$80,486,000. Subsequent to ~~consume funds significantly faster than~~December 31, 2020, we ~~currently anticipate,~~received approximately $47,300,000 in net proceeds from sales of our Common Stock in January and ~~we may need~~February 2021 pursuant to ~~spend more money than currently expected because~~a Controlled Equity Offering^SM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, and approximately $97,100,000 in net proceeds from sales of ~~circumstances beyond~~ our ~~control.~~Common Stock pursuant to an underwritten public offering of our common stock in February 2021, each as described below.

On ~~August 1, 2018,~~November 10, 2020, we entered into an underwriting agreement with ~~Goldman Sachs & Co. LLC, as representative of the underwriters,~~Cantor Fitzgerald relating to an underwritten public offering of ~~12,745,098~~23,437,500 shares of our ~~common stock at a price~~Common Stock. We granted to the ~~public of $5.10 per share. We granted the underwriters~~underwriter an option, exercisable for a period of 30 days, to purchase up to ~~1,911,764~~3,515,625 additional shares of ~~common stock. On August 2, 2018, the underwriters~~Common Stock, which was exercised ~~the option~~ in full. The net proceeds ~~from~~ the offering ~~including the exercise of the option to purchase additional shares,~~ were approximately ~~$69,908,000,~~$31,703,000, after deducting the underwriting ~~discount~~discounts and commissions and estimated offering expenses payable by us. The offering closed on ~~August 6, 2018 and~~November 13, 2020.

On November 27, 2020, we ~~issued 14,656,862~~entered into the Sales Agreement with Cantor Fitzgerald relating to shares of our ~~common stock.~~Common Stock. In ~~connection~~accordance with the ~~Knight License Agreement, Knight entered into a subscription~~terms of the sales agreement, ~~with us, pursuant to which Knight purchased 3,921,568~~in January and February 2021 we offered and sold an aggregate of 28,600,689 shares of our ~~common stock concurrently~~Common Stock having an aggregate offering price of $50 million, resulting in estimated net proceeds to us of approximately $47.3 million. Sales of our Common Stock under the Sales Agreement were made in sales deemed to be “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. Cantor Fitzgerald was entitled to compensation at a fixed commission rate of 3.0% of the aggregate gross sales price per share sold.

On February 11, 2021, we entered into an underwriting agreement with ~~the closing of the~~Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of ~~common stock at~~59,459,460 shares of our Common Stock. Pursuant to the underwriting agreement, we granted to the underwriter an option, exercisable for a ~~price~~period of ~~$5.10, for~~30 days, to purchase up to 8,918,919 additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received from the exercise of ~~$20,000,000.~~the underwriter’s option to purchase additional shares, were approximately $97.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on February 16, 2021.

On ~~May 1, 2018,~~April 24, 2019, we entered into a ~~Credit~~Financing Agreement, byas amended, or the Financing Agreement, with Sixth Street Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to time party thereto, and ~~among us and~~certain of our subsidiaries party thereto from time to time ~~each~~ as guarantors, which provided us with up to a ~~borrower, MidCap Financial Trust,~~$300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provided for fund availability in multiple tranches: $200,000,000 was drawn upon entering into the Financing Agreement while an additional $50,000,000 was drawn on February 18, 2020. An additional $50,000,000 was previously available to us in the Administrative Agent’s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as ~~an agent~~the Administrative Agent may have consented to. Subsequent to the pause in the full launch of ANNOVERA caused by the COVID-19 pandemic, the undrawn $50,000,000 tranche under the Financing Agreement is no longer available.

On August 5, 2020, we and ~~as lender,~~our subsidiaries entered into Amendment No. 5 to the Financing Agreement, or Amendment No. 5, with the Administrative Agent and the ~~additional~~ lenders party thereto, ~~from time~~pursuant to ~~time,~~ which ~~provides a secured term loan facility in an aggregate principal amount of up to $200,000,000, or~~we modified the Term Loan. Under the terms of the Credit Agreement, the Term Loan will be made in three separate tranches, each, a Tranche, with each Tranche to be made available to us, at our option, upon our achievement of certain milestones. The first Tranche of $75,000,000, or Tranche 1, was drawn by us on June 7, 2018, following approval by FDA of the NDA for IMVEXXY®. We intend to use the proceeds from the first draw down to support the commercial launch of IMVEXXY®. The second Tranche of $75,000,000, or Tranche 2, may be drawn by us on or before May 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including (i) that Tranche 1 has been drawn, (ii) the approval by the FDA of the NDA for BIJUVA™ and (iii) we have consummated our first commercial sale in the United States of BIJUVA™. The third Tranche of $50,000,000, or Tranche 3, may be drawn by us on or before December 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including that (i) Tranche 2 has been drawn and (ii) we have generated at least $75,000,000 ofminimum consolidated net product revenue requirements attributable to commercial sales of ~~IMVEXXY®~~our IMVEXXY, BIJUVA, and ~~BIJUVA™ during~~ANNOVERA products, which requirements are effective beginning with the ~~twelve-month period~~fiscal quarter ending ~~immediately before~~December 31, 2020. In lieu of a cash amendment fee, to induce the ~~funding~~lenders to enter into Amendment No. 5, on August 5, 2020, we issued warrants, or the Lender Warrants, to the lenders under the Financing Agreement to purchase an aggregate of ~~Tranche 3.~~4,752,116 shares of Common Stock, pursuant to a subscription agreement among the parties, or the Subscription Agreement. The Warrants have an exercise price of $1.58 per share of Common Stock and an expiration date of August 5, 2030. The Warrants may also be exercised via cashless exercise pursuant to the terms thereof. No registration rights were issued pursuant to the Warrants or Subscription Agreement. On November 8, 2020, in connection with entering into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, we amended the Lender Warrants to provide for an adjustment to the exercise price if we conducted certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of our Common Stock for the fifteen trading days ending December 31, 2020 was lower than the then-current exercise price. The issuance of the shares of Common Stock in our November 2020 underwritten public offering at a price per share equal to $1.1856 triggered the automatic reduction in the exercise price of the Lender Warrants from $1.58 to $1.1856. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, or Amendment No. 7, the Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct certain dilutive issuances prior to March 31, 2021. In connection with entering into Amendment No. 7, we paid the Administrative Agent an amendment fee of $5.0 million.

As of the filing date of this Annual Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement. Based on our current projections, and recent equity financing, we anticipate that we will remain in compliance with the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the issuance of these financial statements. However, if we are unsuccessful with the commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if such commercialization is delayed, or if the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, among other circumstances, we may consume funds significantly faster than we currently anticipate and our existing cash reserves would be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA.

The Financing Agreement requires us to maintain certain minimum quarterly product net revenue requirements and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8, pursuant to which, among other amendments, the minimum quarterly product net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i) $17.0 million, $20.0 million, $23.0 million, and $26.5 million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million, $60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023, and (iv) $70.0 million for the first quarter of 2024. In connection with entering into Amendment No. 8, we repaid $15.0 million in principal under the Financing Agreement on such date and agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, in each case plus a 5.0% prepayment fee. Additionally, we have agreed to make quarterly repayments under the Financing Agreement commencing with the fiscal quarter ending March 31, 2022. See Note 8 – Debt for information regarding our debt maturity.

These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements or otherwise comply with any other covenant of the Financing Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which would have an adverse effect on our business, results of operations and financial condition.

Our net days sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts, chargebacks and payment discounts ~~divided~~ by the average daily net ~~revenues~~product revenue during the ~~fourth quarter of 2018.~~quarter. We also disclose gross DSO, which includes the calculation of gross accounts receivable divided by the average daily gross ~~revenues~~product revenue to distributors during the ~~fourth quarter of 2018.~~quarter. For the ~~quarter~~three months ended December 31, ~~2018,~~2020, our gross DSO was 7761 days compared to 6855 days for the ~~quarter~~three months ended December 31, ~~2017~~2019 and our net DSO was ~~200~~132 days for the ~~quarter~~three months ended December 31, ~~2018~~2020 compared to 97141 days for the ~~quarter~~three months ended December 31, 2017. The increase in our gross DSO as of December 31, 2018 was primarily related to extended terms given to our customers in connection with the launch of IMVEXXY®. Our net DSO was affected by extended terms and increased coupons and discounts given to our customers in connection with the launch of IMVEXXY®.2019. We anticipate that our DSO will fluctuate in the future based upon a variety of factors, including longer payment terms associated with the ~~launch~~launches of ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA, and ~~ANNOVERA™~~ANNOVERA and changes in the healthcare industry.

~~We believe that~~ Our exposure to credit losses may increase if our ~~existing cash~~customers are adversely affected by changes in healthcare laws, coverage, and ~~availability under~~reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the Term Loan will allow us to fund our operating plan through at least the next 12 months from the date of this Annual Report. However, if the commercialization of IMVEXXY®, BIJUVA™ or ANNOVERA™ is delayed, our existing cash and availability under the Term Loan, if we are able to access such funds, may be insufficient to satisfy our liquidity requirements until we are able to commercialize IMVEXXY®, BIJUVA™ and ANNOVERA™ and we may not be able to access funds under the Term Loan. If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other commercialization and pre-commercialization efforts and we may seek to sell additional equity or debt securities. Our ability to sell debt securities or obtain additional debt financing is restricted pursuant to the Credit Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, to the extent permitted under the Credit Agreement, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidationCOVID-19 pandemic, or other ~~preferences~~customer-specific factors. Although we have historically not experienced significant credit losses, it is possible that ~~adversely affect~~there could be a material adverse impact from potential adjustments of the ~~rights~~carrying amount of ~~our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, certain of which are restricted under~~trade receivables in the Credit Agreement, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products, if permitted under the Credit Agreement. Additionally, we may have to grant licenses on terms that may not be favorable to us.future.

We need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:

The principal use of cash in operating activities for the year ended December 31, ~~2018~~2020 and 2019 was to fund our current expenses primarily related to supporting commercialization activities for ~~IMVEXXY®, BIJUVA™~~IMVEXXY, BIJUVA and ~~ANNOVERA™,~~ANNOVERA, sales, marketing, scale-up and manufacturing activities and clinical development, adjusted for non-cash items. The ~~increase~~decrease of approximately ~~$30,656,000~~$6,227,000 in cash used in operating activities for the year ended December 31, ~~2018~~2020 in comparison to the year ended December 31, ~~2017~~2019 was primarily due ~~primarily~~ to ~~an increase in our net loss and non-cash compensation expense coupled with~~ changes in the components of working ~~capital.~~capital partially offset by an increase in non-cash items and an increase in our net loss.

The principal use of cash in operating activities for the year ended December 31, 2017 was to fund our current expenses primarily related to supporting clinical development, scale-up and manufacturing activities and commercial activities, adjusted for non-cash items. The increase of approximately ~~$7,013,000~~$58,886,000 in cash used in operating activities for the year ended December 31, ~~2017~~2019 in comparison to the year ended December 31, ~~2016~~2018 was primarily due to an increase in our net loss coupled with changes in the components of working capital which were primarily due to the launch and ~~lower non-cash compensation expense, as well as a decrease in net loss.~~commercialization of our pharmaceutical products.

During the year ended December 31, ~~2018,~~2020, a decrease in spending on fixed assets, patents and trademarks resulted in a decrease in cash used in investing activities for the year ended December 31, 2020 compared with the same period in 2019. In addition, during the year ended December 31, 2019, we paid $20,000,000 to the Population Council ~~upon FDA approval~~in connection with the commercial batch release of ANNOVERA,^™, based on the Population Council License Agreement.

During the year ended December 31, 2019, we paid $20,000,000 to the Population Council in connection with the commercial batch release of ANNOVERA, based on the Population Council License Agreement. In addition, an increase in spending on fixed assets, patents and trademarks resulted in an increase in cash used in investing activities for the year ended December 31, ~~2018~~2019 compared with the same period in ~~2017.~~2018.

The decrease of approximately $428,000 in cash used in investing activities for the year ended December 31, 2017 compared with the year ended December 31, 2016 was primarily due to a decrease in patent costs and costs relating to the purchase of fixed assets.

Our financing activities for the year ended December 31, ~~2018~~2020 provided net cash of approximately ~~$162,787,000.~~$80,724,000 which consisted of the funding from our Financing Agreement of $50,000,000, approximately $31,703,000 in proceeds from the sale of our common stock and the exercise of options to purchase common stock of approximately $271,000, partially offset by the payment of deferred financing fees of $1,250,000.

On November 10, 2020, we entered into an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of 23,437,500 shares of our common stock. We granted to the underwriter an option, exercisable for a period of 30 days, to purchase up to 3,515,625 additional shares of common stock, which was exercised in full. The net proceeds the offering were approximately $31,703,000, after deducting the underwriting discounts and commissions and offering expenses paid by us. The offering of 23,437,500 shares closed on November 13, 2020 and the offering of 3,515,625 shares closed on November 20, 2020.

Our financing activities for the year ended December 31, 2019 provided net cash of approximately $188,827,000. The cash provided by financing activities during the year ended December 31, ~~2018~~2019 included approximately ~~$89,908,000~~$77,031,000 in proceeds from the sale of our common stock and approximately ~~$1,666,000~~$109,000 in proceeds from the exercise of options as well as funding from our ~~Term Loan~~Financing Agreement of approximately ~~$75,000,000~~$200,000,000 partially offset by the payment of financing fees of approximately ~~$3,787,000.~~

~~On August 1, 2018, we entered into an underwriting agreement~~$6,652,000 in connection with ~~Goldman Sachs & Co. LLC, as representative~~the Financing Agreement and the repayment of the ~~underwriters, relating to~~MidCap Agreement of $81,661,000.

On October 29, 2019, we closed an underwritten public offering of ~~14,656,862~~29,900,000 shares of our common stock at a price to the public of ~~$5.10~~$2.75 per ~~share. The net proceeds from the offering, including the exercise~~share, inclusive of the underwriters’ option to purchase additional shares, were approximately $69,908,000, after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018 and we issued 14,656,862 shares of our common stock. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased 3,921,568 shares of our common stock concurrently with the closing of the underwritten public offering of common stock at a price of $5.10, for proceeds of $20,000,000.

Our financing activities for the year ended December 31, 2017 provided net cash of approximately $72,584,000. The cash provided by financing activities during the year ended December 31, 2017 included approximately $68,573,000 in proceeds from sale of our common stock and approximately $4,011,000 in proceeds from the exercise of options and warrants.

On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of 12,400,000 shares of our common stock at a price of $5.55 per share. The net proceeds to us from the offering were approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued 12,400,000 shares of our common stock.

Our financing activities for the year ended December 31, 2016 provided net cash of approximately $137,226,000. The cash provided by financing activities during the year ended December 31, 2016 included approximately $134,864,000 in proceeds from sale of our common stock and approximately $2,362,000 in proceeds from the exercise of options and warrants.

On January 6, 2016, we entered into an underwriting agreement with Goldman, Sachs & Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or Underwriters, relating to an underwritten public offering of 15,151,515 shares of our common stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of common stock, which option was exercised in full. ~~The~~We received net proceeds ~~to us~~ from the offering ~~were~~of approximately ~~$134,864,000,~~$77,031,000, after deducting underwriting discounts and commissions and ~~other estimated~~ offering expenses ~~payable~~paid by us. ~~The offering closed on January 12, 2016 and we issued 17,424,242 shares of our common stock.~~

The preparation of financial statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate to be critical if:

We base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in the industry, information provided by our customers, and information available from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as those that we believe are most critical to our financial condition and results of operations and that require our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense and income taxes.

Revenue Recognition. ~~We recognize revenue on arrangements in accordance with ASC 606, Revenue Recognition. In accordance with ASC 606, revenue is recognized when a customer obtains control~~As of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.

~~Our~~December 31, 2020, our products ~~consist~~consisted primarily of prescription vitamins and ~~IMVEXXY®,~~our FDA-approved products: IMVEXXY, which we began selling during the third quarter of ~~2018.~~ 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed the launch of ANNOVERA in July 2020.

We sell our name brand and generic prescription products primarily through wholesale distributors and retail ~~pharmacy distributors.~~pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a ~~customer,~~distributor, and two performance obligations related to products sold through retail ~~pharmacy distributors,~~pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer’s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. ~~All of our performance obligations, and associated revenue, are transferred to customers at a point in time.~~ Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.

The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). ToIn order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract’s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.

~~Research and Development Expenses.~~ Research and development, or R&D, expenses include internal R&D activities, services of external CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&D expenses include professional research and advice regarding R&D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to expense in the period in which the facts that give rise to the revision become known.

Share-Based Compensation. We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements ~~may~~ include options, restricted stock, restricted stock units, performance-based awards, ~~and~~ share appreciation ~~rights.~~rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation,, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Before January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to our company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with ~~two~~the other peer entities whose stock prices were publicly available that were similar to our ~~company.~~company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. ~~The average~~On January 1, 2020, we began calculating the expected ~~life~~term of ~~warrants is based on~~our stock-based awards, which represents the ~~contractual terms of~~period that the ~~awards. The~~stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average expected life of options iswas based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of ~~share-based~~stock-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.

~~Equity instruments (“instruments”) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505,~~ ~~Equity - Based Payments to Non-Employees~~, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505. We recognize the compensation expense for ~~all~~ share-based compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period. ~~We adopted ASU 2016-09, effective~~Effective January 1, 2017, ~~electing to~~we account for forfeitures when they occur. ~~Before that,~~On January 1, 2019, we ~~estimated~~adopted ASU 2018-07 which simplified the ~~forfeiture rate~~accounting for share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.

We grant performance-based stock units and restricted stock units for shares of common stock to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price on the date of grant. We recognize compensation expense for restricted stock units based on ~~our historical experience~~a straight-line basis over the requisite service period of ~~forfeitures.~~the entire award. We recognize performance-based restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and through the date the restricted stock vests. The number of target shares that vest are determined based on the level of attainment of the targets. If a minimum level of performance is attained for the awards, restricted stock is issued based on the level of attainment.

Income Taxes. We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

In accordance with ASC 740, Income Taxes, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur. We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, ~~2018~~2020 and ~~2017,~~2019, we had no tax positions relating to open tax returns that were considered to be uncertain. Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.

The determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which is reflected in our provision for income taxes and recorded tax assets and liabilities.

Segment Reporting. We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single ~~management~~executive leadership team that ~~reports to~~is chaired by the ~~President~~Chief Executive Officer of our ~~Company.~~Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.

New Accounting Pronouncements. In ~~August 2018,~~March 2020, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally, contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022. Our Financing Agreement currently include the use of alternate rates when LIBOR is not available. We do not expect the change from LIBOR to an alternate rate will have a material impact on our financial statements and, to the extent we enter into modifications of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.

In August 2018, the FASB issued ASU 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We ~~are currently evaluating the effect of~~adopted this ~~guidance on our disclosures.~~

In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We do not expect that the adoption of this standard ~~will have a material effect on our consolidated financial statements and disclosures.~~

In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We plan to adopt ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11. While we are still finalizing the quantitative and qualitative impact of adopting this new standard and the subsequent amendments, the most significant impact is expected to be the recognition of a right of use asset and lease liability on our statement of financial position related to the operating leases for our new and existing office space. We elected the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we will not assess 1) whether existing or expired contracts contain leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We will not separate lease components from non-lease components for our specified asset classes. Based on our preliminary calculations, we currently expect to recognize right-of-use asset and corresponding lease liability between $4 million to $5 million on our Consolidated Balance Sheet based on the present value of future minimum lease payments under operating leases in effect on January 1, 2019. Additionally, the adoption of the new standard will result in increased disclosure requirements in our quarterly and annual filings.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. This may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. In 2016, the FASB issued final amendments to clarify the implementation guidance for principal versus agent considerations (ASU 2016-08), accounting for licenses of intellectual property and identifying performance obligations (ASU 2016-10), narrow-scope improvements and practical expedients (ASU 2016-12) and technical corrections and improvements to topic 606 (ASU 2016-20) in its new revenue standard. We adopted this standard under the modified retrospective method to all contracts not completed as of January 1, 20182020, and the adoption did not have a material effect on our disclosures.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendments in this update require a financial ~~statements however~~asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative and qualitative disclosures about the Company’s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our ~~disclosures related to contracts with customers.~~credit losses.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.

As of December 31, ~~2018, 2017,~~2020, 2019, and ~~2016,~~2018, we had no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our drugs or drug candidates, use of such drugs or drug candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is sometimes unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, ~~2018, 2017,~~2020, 2019, and ~~2016.~~2018.

In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.

For each of the fiscal years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016,~~2018, our business and operations have not been materially affected by inflation.

A summary of contractual obligations as of December 31, ~~2018~~2020 is as follows:

We have license agreements with third parties that provide for minimum royalty, license, and exclusivity payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note 6, Intangible Assets, to these consolidated financial statements.

~~From time to time,~~ In addition, we have a manufacturing and supply agreement whereby we are ~~involved in litigation and proceedings in the ordinary course~~required to purchase a minimum number of ~~business. We are not currently involved in any legal proceeding that~~units of ANNOVERA during a contract year. As of December 31, 2020, we ~~believe would~~ have ~~a material effect on~~met our ~~consolidated financial condition, results of operations, or cash flows.~~minimum purchase commitments with our manufacturers related to fiscal year 2020.

We have entered into employment agreements with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.

The specialty pharmaceutical industry component of women’s health is not subject to seasonal sales ~~fluctuation.~~fluctuation, however, we anticipate that high deductible and annual prescription copay resets under commercial insurance plans at the beginning of the calendar year will affect our first quarter net revenue.

We had a cash balance of approximately ~~$161,613,000~~$80,486,000 as of December 31, ~~2018~~ . 2020. We hold certain portions of our cash balances in overnight money market placements all of which are fully available to us to support our cash flow requirements. The primary objective of our investment policy is to preserve principal and maintain proper liquidity to meet operating ~~needs~~ . needs. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of ~~investment~~ . investment.

Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest ~~rates~~ . rates. To minimize this risk, we intend to maintain aan investment portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity ~~dates~~ . dates. Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.

~~We are also subject to market risk in connection with borrowings under our Term Loan.~~ Amounts borrowed under ~~our Term Loan bear~~the Financing Agreement accrue interest at ~~a rate equal to the sum of~~either (i) ~~one-month~~3-month LIBOR ~~(subject~~plus 7.75%, subject to a LIBOR floor of ~~1.50%)~~2.70% or (ii) the prime rate plus ~~(ii) 7.75% per annum. At December 31, 2018, the outstanding principal balance on our Term Loan, net~~6.75%, subject to a prime rate floor of ~~issuance costs, was approximately $73,381,000.~~5.20%. Considering the total outstanding principal balance under the Financing Agreement of ~~approximately $75,000,000, as of~~$250,000,000 at December 31, ~~2018,~~2020, a 1.0% change in interest rates would result in an impact to ~~income~~loss before income taxes of ~~approximately $750,000~~$2,500,000 per year.

Reference is made to the financial statements, the notes thereto, and the reports thereon, commencing on page F-1 of this Annual Report, which financial statements, notes, and reports are incorporated herein by reference.

~~None.~~Item 9. Change in and Disagreements With Accountants on Accounting and Financial Disclosure

We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, ~~2018,~~2020, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate because of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, ~~2018.~~2020. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control—Integrated Framework (2013). Management’s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on management’s assessment, we believe that our internal controls over financial reporting were effective as of December 31, ~~2018.~~2020.

~~The effectiveness~~This Annual Report on Form 10-K does not include an attestation report of ~~our~~the Company’s registered public accounting firm regarding internal control over financial ~~reporting as of December 31, 2018 has been audited~~reporting. Management’s report was not subject to attestation by ~~Grant Thornton LLP, an independent~~the Company’s registered public accounting firm ~~as stated in their Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting as of December 31, 2018, which appears below.~~

~~We have audited~~pursuant to the ~~internal control over financial reporting of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the “Company”) as of December 31, 2018, based on criteria established in the 2013~~ ~~Internal Control—Integrated Framework~~ ~~issued by the Committee of Sponsoring Organizations~~rules of the ~~Treadway Commission (“COSO”). In our opinion,~~SEC that permit the Company ~~maintained,~~to provide only management’s report in ~~all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in the 2013~~ ~~Internal Control—Integrated Framework~~ ~~issued by COSO.~~

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated financial statements of the Company as of and for the year ended December 31, 2018, and our report dated February 27, 2019 expressed an unqualified opinion on those financial statements.

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’sthis Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.Form 10-K.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

On March 1, 2021, we entered into Amendment No. 8, pursuant to which, among other amendments, the minimum quarterly product net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised, the amortization and prepayment terms of the borrowings under the Financing Agreement were revised, and the Administrative Agent consented to a framework for our potential disposition of our vitaCare prescription services business. The minimum quarterly product net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised pursuant to Amendment No. 8 to (i) $17.0 million, $20.0 million, $23.0 million, and $26.5 million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million, $60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023, and (iv) $70.0 million for the first quarter of 2024. With respect to amortization and prepayment terms of the borrowings under the Financing Agreement, in connection with Amendment No. 8, we (i) repaid $15.0 million in principal under the Financing Agreement on such date, plus a 5.0% prepayment fee, (ii) agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, plus a 5.0% prepayment fee, and (iii) agreed to make additional principal repayments as follows: (x) $5.0 million on each of March 31, 2022, June 30, 2022 and September 30, 2022; (y) $10.0 million on each of December 31, 2022 and March 31, 2023; and (z) $41.25 million on each of June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees described in the following sentence. In connection with Amendment No. 8, the prepayment fees on principal amounts being prepaid under the Financing Agreement were revised as follows: (i) 30.0% of the principal amount being repaid through March 31, 2022 (excluding the scheduled $5.0 million principal repayment on such date, which is subject to a 5.0% prepayment fee); (ii) 5.0% of the principal amount being repaid from April 1, 2022 through March 31, 2023; (iii) 3.0% of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv) thereafter, none, in each case subject to certain limited exceptions, including with respect to a repayment in full of the obligations under the Financing Agreement. The foregoing summary of Amendment No. 8 does not purport to be complete and is subject to, and qualified in its entirety by, the full text of Amendment No. 8, a copy of which is filed as Exhibit 10.25 to this Annual Report on Form 10-K and is incorporated herein by reference.

The information required by this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our ~~2019~~2021 Annual Meeting of Stockholders.

The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our ~~2019~~2021 Annual Meeting of Stockholders.

The information required by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the Exchange Act for our ~~2019~~2021 Annual Meeting of Stockholders.

The information required by this Item is incorporated herein by reference to the definitive Proxy ~~Statement~~Statements to be filed pursuant to Regulation 14A of the Exchange Act for our ~~2019~~2021 Annual Meeting of Stockholders.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.

~~F- 1~~

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and ~~Shareholders~~
Stockholders

TherapeuticsMD, Inc.

Opinion on the financial statements

We have audited the accompanying consolidated balance sheets of TherapeuticsMD, Inc. (a Nevada corporation) and subsidiaries (the “Company”) as of December 31, ~~2018~~2020 and ~~2017,~~2019, the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, ~~2018,~~2020, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, ~~2018~~2020 and ~~2017,~~2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, ~~2018,~~2020, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in the 2013 ~~Internal Control—Integrated Framework~~ ~~issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), and our report dated February 27, 2019 expressed an unqualified opinion.~~

Basis for opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the ~~PCAOB~~Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence ~~supporting~~regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical audit matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Calculation of variable consideration related to sales deductions

As described further in Note 2 to the financial statements, the transaction price of the Company’s revenue contracts is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees (collectively “sales deductions”). We identified the calculation of variable consideration related to sales deductions as a critical audit matter.

The principal consideration for our determination that the calculation of variable consideration related to sales deductions was a critical audit matter is that auditing the estimation of variable consideration requires significant judgement and the amounts are material to the financial statements taken as a whole. These estimates require the consideration of key assumptions such as expected return rates, estimated level of inventory in the distribution channel, expected coupon utilization, and expected insurance coverage levels, all of which have estimation uncertainty.

Our audit procedures related to testing the calculation of variable consideration related to sales deductions included the following, among others:

●

We evaluated the design and tested the operating effectiveness of controls over management’s calculation and review of variable consideration related to sales deductions by verifying management’s controls over the completeness of the input data, mathematical accuracy of the calculations and evaluating the reasonableness of key assumptions used in the calculation.

●

We tested management’s estimates by performing one of the following procedures based on the sales deduction being tested (1) developing independent expectations to corroborate the reasonableness of management’s estimate, (2) testing management’s process to develop the estimate, or (3) reviewing subsequent events or transactions. Our procedures included reviewing subsequent information related to coupon and rebate settlements. We used historical sales and return data in developing our independent expectations and in testing management’s process. We tested the completeness and accuracy of the historical sales and return data used in the calculations by agreeing total sales to accounting records and tracing a sample of individual sale transactions to supporting audit evidence, such as purchase orders, shipping documents and invoices. We also evaluated the average assistance paid in the co-pay assistance program by vouching a sample of transactions settled during the year to source documentation.

Forecasted debt covenant compliance and going concern

As described further in Note 2 to the consolidated financial statements, the Company’s Financing Agreement contains covenants that, among other items, require the Company to maintain a minimum cash balance and meet certain minimum quarterly product revenue requirements. The principal assumptions used in management’s cash flow and product net revenue analyses used to estimate future covenant compliance consisted of the forecasts related to revenue growth, gross profit margins, and sales and marketing expenses. We identified the evaluation of management’s forecasted debt covenant compliance and going concern analysis as a critical audit matter.

The principal considerations for our determination that the evaluation of management’s forecasted debt covenant compliance and going concern analysis was a critical audit matter are the significant judgment by management when evaluating the uncertainty related to the Company’s forecasts and a high degree of auditor judgment in evaluating management’s forecasts for at least the next twelve months.

Our audit procedures related to the evaluation of management’s forecasted debt covenant compliance and going concern analysis included the following, among others, (i) testing management’s process for forecasting financial results for one year after the date the financial statements are issued; and (ii) testing the completeness and accuracy of underlying data used in the forecast; and (iii) evaluation of management’s covenant compliance assessment and their disclosure in the consolidated financial statements regarding having the ability of the Company to continue to maintain liquidity and meet the Company’s financial covenants for at least the next twelve months.

/s/ ~~Grant Thornton~~GRANT THORNTON LLP

We have served as the Company’s auditor since 2015.

~~Fort Lauderdale,~~Miami, Florida

~~February 27, 2019~~March 3, 2021

F-3

~~F- 2~~

THERAPEUTICSMD, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31,
2018 2017
ASSETS
Current Assets:
Cash $ 161,613,077 $ 127,135,628
Accounts receivable, net of allowance for doubtful accounts of $596,602 and $380,580, respectively 11,063,821 4,328,802
Inventory 3,267,670 1,485,358
Other current assets 10,834,693 6,604,284
Total current assets 186,779,261 139,554,072

Fixed assets, net 472,683 437,055

Other Assets:
License rights 20,000,000 —
Intangible assets, net 4,092,679 3,099,747
Other assets 324,855 —
Security deposit 314,446 139,036
Total other assets 24,731,980 3,238,783
Total assets $ 211,983,924 $ 143,229,910
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable $ 22,743,841 $ 4,097,600
Accrued expenses and other current liabilities 18,334,948 9,223,595
Total current liabilities 41,078,789 13,321,195

Long-Term Liabilities:
Long-term debt 73,381,014 —
Total liabilities 114,459,803 13,321,195

Commitments and Contingencies - See Note 13

Stockholders’ Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding — —
Common stock - par value $0.001; 350,000,000 shares authorized: 240,462,439 and 216,429,642 issued and outstanding, respectively 240,463 216,430
Additional paid-in capital 616,559,938 516,351,405
Accumulated deficit (519,276,280 ) (386,659,120 )
Total stockholders’ equity 97,524,121 129,908,715
Total liabilities and stockholders’ equity $ 211,983,924 $ 143,229,910


	December 31,
	2020			2019
ASSETS
Current Assets:
Cash	$	80,485,784		$	160,829,713
Accounts receivable, net of allowance for doubtful accounts of $1,117,854 and $904,040, respectively		32,381,701			24,395,958
Inventory		7,993,087			11,860,716
Other current assets		7,543,397			11,329,793
Total current assets		128,403,969			208,416,180

Fixed assets, net		1,942,224			2,507,775

Other Assets:
License rights, net		36,196,916			39,221,308
Intangible assets, net		5,247,723			5,258,211
Right of use assets		9,565,700			10,109,154
Other assets		253,121			473,009
Total other assets		51,263,460			55,061,682
Total assets	$	181,609,653		$	265,985,637

LIABILITIES AND STOCKHOLDERS’ (DEFICIT) EQUITY
Current Liabilities:
Accounts payable	$	21,068,327		$	19,181,212
Other current liabilities		38,169,869			33,823,613
Total current liabilities		59,238,196			53,004,825

Long-Term Liabilities:
Long-term debt		237,697,531			194,634,643
Operating lease liability		8,675,477			9,145,049
Total long-term liabilities		246,373,008			203,779,692
Total liabilities		305,611,204			256,784,517

Commitments and Contingencies - See Note 14

Stockholders’ (Deficit) Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock - par value $0.001; 600,000,000 and 350,000,000 shares authorized: 299,765,396 and 271,177,076 issued and outstanding, respectively		299,765			271,177
Additional paid-in capital		754,644,100			704,351,222
Accumulated deficit		(878,945,416	)		(695,421,279	)
Total stockholders’ (deficit) equity		(124,001,551	)		9,201,120
Total liabilities and stockholders’ (deficit) equity	$	181,609,653		$	265,985,637

The accompanying footnotes are an integral part of these consolidated financial statements.

F-4

~~F- 3~~

THERAPEUTICSMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

Year Ended December 31,
2018 2017 2016
Revenues, net $ 16,099,460 $ 16,777,713 $ 19,356,450

Cost of goods sold 2,737,652 2,636,943 4,185,708

Gross profit 13,361,808 14,140,770 15,170,742

Operating expenses:
Sales, general, and administrative 115,988,954 57,703,370 51,348,414
Research and development 27,299,138 33,852,993 53,943,477
Depreciation and amortization 293,886 213,117 132,451
Total operating expenses 143,581,978 91,769,480 105,424,342

Operating loss (130,220,170 ) (77,628,710 ) (90,253,600 )

Other (expense) income
Miscellaneous income 2,280,844 695,631 367,317
Interest expense (4,677,834 ) — —
Accreted interest — 7,699 10,824
Total other (expense) income (2,396,990 ) 703,330 378,141

Loss before income taxes (132,617,160 ) (76,925,380 ) (89,875,459 )

Provision for income taxes — — —

Net loss $ (132,617,160 ) $ (76,925,380 ) $ (89,875,459 )

Loss per share, basic and diluted:

Net loss per share, basic and diluted $ (0.59 ) $ (0.37 ) $ (0.46 )

Weighted average number of common shares outstanding, basic and diluted 225,026,300 205,523,288 196,088,196


	Year Ended December 31,
	2020			2019			2018

Product revenues, net	$	62,872,280		$	34,140,537		$	16,099,460
License revenue		2,000,000			15,506,400			—
Total revenue, net		64,872,280			49,646,937			16,099,460

Cost of goods sold		15,974,977			6,334,585			2,737,652

Gross profit		48,897,303			43,312,352			13,361,808

Operating expenses:
Sales, general, and administrative		192,963,967			174,112,612			115,988,954
Research and development		10,431,907			19,792,212			27,299,138
Depreciation and amortization		1,042,170			612,786			293,886
Total operating expenses		204,438,044			194,517,610			143,581,978

Operating loss		(155,540,741	)		(151,205,258	)		(130,220,170	)

Other (expense) income
Loss on extinguishment of debt		—			(10,057,632	)		—
Miscellaneous income		597,647			2,500,106			2,280,844
Interest expense		(28,581,043	)		(17,382,215	)		(4,677,834	)
Total other expense		(27,983,396	)		(24,939,741	)		(2,396,990	)

Loss before income taxes		(183,524,137	)		(176,144,999	)		(132,617,160	)

Provision for income taxes		—			—			—

Net loss	$	(183,524,137	)	$	(176,144,999	)	$	(132,617,160	)

Loss per share, basic and diluted:

Net loss per share, basic and diluted	$	(0.67	)	$	(0.72	)	$	(0.59	)

Weighted average number of common shares outstanding, basic and diluted		275,648,552			246,353,318			225,026,300

The accompanying footnotes are an integral part of these consolidated financial statements.

~~F- 4~~

THERAPEUTICSMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

FOR THE YEARS ENDED DECEMBER 31, ~~2018, 2017~~2020, 2019 AND ~~2016~~2018

Common Stock Additional
Paid in Accumulated
Shares Amount Capital Deficit Total
Balance, January 1, 2016 177,928,041 $ 177,928 $ 282,712,078 $ (219,826,860 ) $ 63,063,146
Shares issued in offerings, net of cost 17,424,242 17,424 134,846,051 — 134,863,475
Shares issued for exercise of options, net 722,744 723 1,372,277 — 1,373,000
Shares issued for exercise of warrants, net 613,195 613 988,447 — 989,060
Share-based compensation — — 17,076,199 — 17,076,199
Net loss — — — (89,875,459 ) (89,875,459 )
Balance, December 31, 2016 196,688,222 196,688 436,995,052 (309,702,319 ) 127,489,421
Shares issued in offerings, net of cost 12,400,000 12,400 68,560,235 — 68,572,635
Shares issued for exercise of warrants, net 7,238,874 7,239 3,791,760 — 3,798,999
Shares issued for exercise of options, net 102,546 103 212,512 — 212,615
Share-based compensation — — 6,760,425 — 6,760,425
Adoption of ASU 2016-09 — — 31,421 (31,421 ) —
Net loss — — — (76,925,380 ) (76,925,380 )
Balance, December 31, 2017 216,429,642 216,430 516,351,405 (386,659,120 ) 129,908,715
Shares issued in offerings, net of cost 18,578,430 18,578 89,889,219 89,907,797
Shares issued for exercise of options, net 5,454,367 5,455 1,660,753 1,666,208
Share-based compensation 8,658,561 8,658,561
Net loss — — — (132,617,160 ) (132,617,160 )

Balance, December 31, 2018 240,462,439 $ 240,463 $ 616,559,938 $ (519,276,280 ) $ 97,524,121

					Additional
	Common Stock				Paid in			Accumulated
	Shares		Amount		Capital			Deficit			Total
Balance, December 31, 2017		216,429,642	$	216,430	$	516,351,405		$	(386,659,120	)	$	129,908,715

Shares issued in offerings, net of cost		18,578,430		18,578		89,889,219			—			89,907,797
Shares issued for exercise of options and warrants, net		5,454,367		5,455		1,660,753			—			1,666,208
Share-based compensation		—		—		8,658,561			—			8,658,561
Net loss		—		—		—			(132,617,160	)		(132,617,160	)
Balance, December 31, 2018		240,462,439		240,463		616,559,938			(519,276,280	)		97,524,121

Shares issued in offerings, net of cost		29,900,000		29,900		77,001,358			—			77,031,258
Shares issued for exercise of options and warrants, net		814,637		814		107,842			—			108,656
Share-based compensation		—		—		10,682,084			—			10,682,084
Net loss		—		—		—			(176,144,999	)		(176,144,999	)
Balance, December 31, 2019		271,177,076		271,177		704,351,222			(695,421,279	)		9,201,120

Shares issued in offerings, net of cost		26,953,125		26,953		31,675,682			—			31,702,635
Shares issued for exercise of options and warrants, net		1,182,195		1,182		270,496			—			271,678
Issuance of shares from release of restricted stock		453,000		453		(453	)		—			—
Warrant granted in relation to Financing Agreement		—		—		7,668,161			—			7,668,161
Share-based compensation		—		—		10,678,992			—			10,678,992
Net loss		—		—		—			(183,524,137	)		(183,524,137	)
Balance, December 31, 2020		299,765,396	$	299,765	$	754,644,100		$	(878,945,416	)	$	(124,001,551	)

The accompanying footnotes are an integral part of these consolidated financial statements.

~~F- 5~~

THERAPEUTICSMD, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

Year Ended December, 31,
2018 2017 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss $ (132,617,160 ) $ (76,925,380 ) $ (89,875,459 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of fixed assets 181,412 141,601 77,906
Amortization of intangible assets 112,474 71,516 54,545
Provision for doubtful accounts 216,022 4,206 2,524,909
Share-based compensation 8,661,967 6,889,323 17,411,021
Amortization of deferred financing costs 269,859 — —
Changes in operating assets and liabilities:
Accounts receivable (6,951,041 ) 167,691 (3,975,893 )
Inventory (1,782,312 ) (409,037 ) (386,168 )
Other current assets (2,332,335 ) (4,434,130 ) 709,907
Other assets (324,855 ) — —
Accounts payable 18,646,241 (3,260,914 ) 4,232,340
Accrued expenses and other current liabilities 9,107,947 1,599,510 84,559
Net cash used in operating activities (106,811,781 ) (76,155,614 ) (69,142,333 )

CASH FLOWS FROM INVESTING ACTIVITIES
Payment for intellectual property license (20,000,000 ) — —
Patent costs (1,105,407 ) (765,291 ) (845,266 )
Purchase of fixed assets (217,040 ) (61,817 ) (396,154 )
Payment of security deposit (175,410 ) — (14,036 )
Net cash used in investing activities (21,497,857 ) (827,108 ) (1,255,456 )

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of common stock, net of costs 89,907,797 68,572,635 134,863,475
Proceeds from term loan 75,000,000 — —
Payment of deferred financing fees (3,786,918 ) — —
Proceeds from exercise of options 1,666,208 212,615 989,060
Proceeds from exercise of warrants — 3,798,999 1,373,000
Net cash provided by financing activities 162,787,087 72,584,249 137,225,535

Increase (decrease) in cash 34,477,449 (4,398,473 ) 66,827,746
Cash, beginning of period 127,135,628 131,534,101 64,706,355
Cash, end of period $ 161,613,077 $ 127,135,628 $ 131,534,101

Supplemental disclosure of cash flow information
Interest paid $ 1,890,166 $ — $ —


	Year Ended December, 31,
	2020			2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(183,524,137	)	$	(176,144,999	)	$	(132,617,160	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of fixed assets		772,624			415,193			181,412
Amortization of intangible assets		269,546			197,593			112,474
Write off of patent and trademark cost		1,131,776			78,864			—
Write off of deferred financing fees		275,379			—			—
Non-cash operating lease expense		1,405,443			1,062,318			—
Provision for doubtful accounts		213,814			307,438			216,022
Lease impairment		136,832			—			—
Inventory charge		7,204,818			—			—
Loss of extinguishment of debt		—			10,057,632			—
Share-based compensation		10,678,992			10,693,662			8,661,967
Amortization of intellectual property license fee		3,024,391			778,692			—
Amortization of deferred financing costs		2,256,429			856,302			269,859
Changes in operating assets and liabilities:
Accounts receivable		(8,199,558	)		(13,639,575	)		(6,951,041	)
Inventory		(3,337,189	)		(8,593,046	)		(1,782,312	)
Other assets		3,429,443			(1,880,048	)		(2,657,190	)
Accounts payable		1,887,115			(3,562,629	)		18,646,241
Accrued expenses and other liabilities		2,903,947			13,675,008			9,107,947

Net cash used in operating activities		(159,470,335	)		(165,697,595	)		(106,811,781	)

CASH FLOWS FROM INVESTING ACTIVITIES
Payment for intellectual property license		—			(20,000,000	)		(20,000,000	)
Patent costs		(1,390,834	)		(1,441,989	)		(1,105,407	)
Purchase of fixed assets		(207,073	)		(2,450,285	)		(217,040	)
Payment of security deposit		—			(20,420	)		(175,410	)

Net cash used in investing activities		(1,597,907	)		(23,912,694	)		(21,497,857	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of options and warrants		271,678			108,656			1,666,208
Proceeds from sale of common stock, net of costs		31,702,635			77,031,258			89,907,797
Proceeds from Financing Agreement		50,000,000			200,000,000			—
Proceeds from Credit Agreement		—			—			75,000,000
Payment of deferred financing fees		(1,250,000	)		(6,652,270	)		(3,786,918	)
Repayment of Credit Agreement		—			(81,660,719	)		—

Net cash provided by financing activities		80,724,313			188,826,925			162,787,087

(Decrease) increase in cash		(80,343,929	)		(783,364	)		34,477,449
Cash, beginning of period		160,829,713			161,613,077			127,135,628
Cash, end of period	$	80,485,784		$	160,829,713		$	161,613,077

Supplemental disclosure of cash flow information
Interest paid	$	25,849,236		$	17,787,903		$	1,890,166

Non-cash investing activity
Warrant granted in relation to Financing Agreement	$	7,668,161		$	—		$	—

The accompanying footnotes are an integral part of these consolidated financial statements.

~~F- 6~~

THERAPEUTICSMD, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – THE COMPANY

TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has ~~three~~3 wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or ~~VitaMed;~~vitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, ~~VitaMed,~~vitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as “our company,” “we,” “our,” or “us.” TherapeuticsMD^®, vitaMedMD^®, BocaGreenMD^®, IMVEXXY^®, BIJUVA^® and ANNOVERA^® are registered trademarks of our company.

Nature of Business

We are a women’s healthcare company ~~focused on~~with a mission of creating and commercializing innovative products to support the lifespan of women ~~and championing awareness of women’s healthcare issues, specifically, for~~from pregnancy prevention ~~pregnancy, childbirth, nursing, pre-menopause, and~~through menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from a patient-controlled, long-lasting contraceptive to advanced hormone therapy pharmaceutical ~~products to patient-controlled, long-acting contraceptive.~~products. We also manufacture and distribute branded and generic prescription prenatal vitamins under the ~~vitaMedMD®~~vitaMedMD and ~~BocaGreenMD®~~BocaGreenMD brands.

~~With our SYMBODA™ technology, we are developing and commercializing advanced hormone therapy pharmaceutical~~ Our portfolio of products ~~to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization~~focused on women’s health allows us to efficiently leverage our sales and ~~grow our~~ marketing ~~and sales organization~~plan to ~~commercialize~~grow our recently approved products.

During 2018, the U.S. Food and Drug Administration, or FDA, approval of our ~~drugs~~pharmaceutical products has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our ~~drugs.~~pharmaceutical products. In July 2018, we launched our ~~recently FDA approved~~FDA-approved product, ~~IMVEXXY®~~IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. ~~We are also focused on commercialization activities necessary for launch of BIJUVA™~~In April 2019, we launched our FDA-approved product BIJUVA (estradiol and ~~ANNOVERA™. BIJUVA™ is~~progesterone) capsules, our hormone therapy combination of bio-identical 17ß-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a ~~uterus, which was approved by the FDA on~~uterus. In October ~~28, 2018. ANNOVERA™~~2019, we began a test and learn market introduction for our FDA-approved product ANNOVERA (segesterone ~~acetate/~~acetate and ethinyl estradiol vaginal system), is the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive ~~that can prevent unintended pregnancy~~option for upwomen. Although we expected to commence the full commercial launch of ANNOVERA in the first quarter of 2020, as a ~~full year, which was approved by~~result of the ~~FDA~~uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA and deferred sales and marketing initiatives into subsequent quarters as the pandemic began to negatively affect our revenue growth. We resumed the commercial launch of ANNOVERA on ~~August 10, 2018.~~July 1, 2020. On July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize ~~IMVEXXY®~~IMVEXXY and ~~BIJUVA™~~BIJUVA in Canada and Israel. ~~In addition, on July 30, 2018,~~On June 6, 2019, we entered into an exclusive license and supply agreement, or the ~~Council~~Theramex License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of the ~~Population Council, Inc.~~U.S., excluding Canada and Israel, or the ~~Population Council, to commercialize ANNOVERA™ in the U.S.~~ Theramex Territory.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, ~~VitaMed,~~vitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.

Risks and Uncertainties

We continue to be subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the future impact of the COVID-19 pandemic on our business continues to be highly uncertain and difficult to predict. We continue to provide an uninterrupted supply of our portfolio of products for patients. We have sufficient inventory of finished product to meet anticipated demand in the near future. Additionally, we currently do not foresee any interruption in our ability to continue to manufacture additional product to be used beyond this period and have sufficient active pharmaceutical ingredients on hand for the continued manufacture of our products. During the year ended December 31, 2020, we recorded an inventory charge of $7,204,818 which was primarily related to BIJUVA and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.

Since the early phase of the COVID-19 pandemic, we have been using substantial virtual options to ensure business continuity. Our VitaCare Prescription Services patient model assists patients in obtaining easy and convenient access to their prescriptions for products at a retail pharmacy of their choice, including via home delivery retail pharmacy options. We have also partnered with independent community pharmacies and multiple third-party online pharmacies and telemedicine providers that focus on contraception or menopause to ensure patients have real-time access to both diagnosis and treatment. We continue to support prescribers’ needs with samples and product materials through our sales force. If access is restricted, we have mailing options in place for these materials. We also have business continuity plans and infrastructure in place that allows for live virtual e-detailing of our products.

As part of our response to the COVID-19 pandemic, we implemented measures to reduce marketing expenses for 2020. We also implemented cost saving measures, which included negotiating lower fees or suspending services from third party vendors; implementing a company-wide hiring restriction; delaying or cancelling non-critical information technology projects; and eliminating non-essential travel, entertainment, meeting, and event expenses.

The full impact of the COVID-19 pandemic continues to evolve. However, we remain committed to the execution of our corporate goals, despite the ongoing COVID-19 pandemic, as demonstrated in part by the increase in product revenue throughout 2020. As of the date of issuance of these consolidated financial statements, the future extent to which the COVID-19 pandemic may continue to materially impact our financial condition, liquidity, or results of operations remains uncertain. We are continuing to assess the effect the COVID-19 pandemic on our operations by monitoring the spread of COVID-19 and the various actions implemented to combat the pandemic throughout the world. Even after the COVID-19 pandemic has subsided, we may continue to experience adverse impacts to our business as a result of any economic recession or depression that has occurred or may occur in the future.

Liquidity

As of the filing date of this Annual Report on Form 10-K, our cash balance was above the required balance by the Financing Agreement (as defined in Note 8 - Debt). On November 8, 2020, we and our subsidiaries entered into Amendment No. 6 to the Financing Agreement, or Amendment No. 6, with the Administrative Agent (as defined in Note 8 - Debt) and the lenders party thereto, pursuant to which we temporarily lowered the minimum required cash balance from $60 million to $45 million through December 31, 2020. After December 31, 2020, the minimum cash balance reverted to $60 million. Based on our current projections, and recent equity financings, we anticipate that we will remain in compliance with the minimum cash balance covenant for the next twelve months from the issuance of these financial statements. In addition, we have reviewed numerous potential scenarios in connection with the impact of COVID-19 pandemic on our business and we believe that our existing cash reserves are sufficient to meet our cash needs arising in the ordinary course of business for the next twelve months from the issuance of these financial statements.

However, if we are unsuccessful with the commercialization of IMVEXXY, BIJUVA, or ANNOVERA, if commercialization is delayed, or if the continued impact of the COVID-19 pandemic on our business is worse than we anticipate, our existing cash reserves may be insufficient to maintain compliance with the Financing Agreement covenants or satisfy our liquidity requirements until we are able to successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA. The Financing Agreement also requires us to maintain certain minimum quarterly product net revenue requirements and several other restrictive covenants. On March 1, 2021, we entered into Amendment No. 8 to the Financing Agreement, or Amendment No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised. See Note 8 – Debt – for a description of these covenants. These and other terms in the Financing Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. If we are unable to maintain the minimum unrestricted cash balance, achieve any of the total minimum net revenue requirements, or otherwise comply with the covenants of the Financing Agreement, all or a portion of our obligations under the Financing Agreement may be declared immediately due and payable, which would have a material adverse effect on our business, results of operations and financial condition.

Cash

We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation, or the FDIC, insured limits of ~~$250,000~~$250,000 per bank. We have never experienced any losses related to these funds.

~~F- 7~~

Trade Accounts Receivable and Allowance for Doubtful Accounts

Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card ~~charge-backs~~chargebacks and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, reasonable supportable forecasts, and existing economic ~~conditions.~~conditions and we record an allowance that presents the net amount expected to be collected. We ~~consider~~evaluate trade accounts receivable ~~past due~~ for ~~more than 90 days to be delinquent.~~delinquency. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does not accurately reflect bad debts, adjustments to these reserves may be required. Our exposure to credit losses may increase if our customers are adversely affected by changes in healthcare laws, coverage, and reimbursement, economic pressures or uncertainty associated with local or global economic recessions, disruption associated with the current COVID-19 pandemic, or other customer-specific factors. Although we have historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables in the future. At December 31, ~~2018, three~~2020, four different customers represented ~~42%~~25%, ~~24%~~19%, 17% and ~~13%~~11% of our gross accounts receivable. At December 31, ~~2017,~~2019, four different customers represented ~~27%~~36%, ~~23%~~21%, ~~22%~~16% and ~~11%~~11% of our gross accounts receivable.

The opening balance of the allowance for doubtful accounts is reconciled to the closing balance for expected credit losses as follows:


Allowance for Doubtful Accounts
Balance - January 1, 2020	$	904,040
Increase in allowance		422,137
Recoveries		(181,514	)
Write-offs		(26,809	)
Balance - December 31, 2020	$	1,117,854

Inventories

Inventories represent ~~hormone therapy drugs,~~pharmaceutical products, packaged vitamins ~~nutritional products and supplements~~ and raw materials which are valued at the lower of cost or net realizable ~~value~~value. Our pharmaceutical products are valued using first in first out method and our vitamins are valued using the average-cost method. We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring, or product improvements rendering previous versions ~~obsolete.~~obsolete, or decreases in demand for our products.

Pre-Launch Inventory

~~Inventory~~Pre-launch inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.

Inventory Write-Off

We evaluate inventory quarterly for short dated and excess inventory. During the years ended December 31, 2020 and December 31, 2019, we recorded an inventory charge of $7,204,818 and $0, respectively. The charge recorded during the year ended December 31, 2020 was primarily related to BIJUVA and resulted from the impact of the COVID-19 pandemic on our business, which decreased demand for our products.

Cost of Sales

Cost of sales includes the cost of inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. The Population Council License Agreement requires payment of royalties based on the sale of future products. Such royalties are recorded as a component of cost of sales. Additionally, the amortization of license fees or milestone payments related to licensed products are classified as components of cost of sales to the extent such payments become due in the future.

Fixed Assets

We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven ~~years.~~years. Leasehold improvements are depreciated over the shorter of their useful life or the term of the lease.

We capitalize software and software development costs incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize software development costs when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five to seven ~~years.~~years.

Intangible Assets

~~Intangible Assets~~

We have adopted the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, 350, Intangibles - Goodwill and Other, or ASC 350. Capitalized patent costs, net of accumulated amortization, include outside legal costs incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, ~~2018,~~2020, we had 2138 issued domestic, or U.S., patents and 2439 issued foreign patents (See Note 6). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.

~~F- 8~~

Impairment of Long-Lived Assets

We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:

●

significant declines in an asset’s market price;

●

significant deterioration in an asset’s physical condition;

●

significant changes in the nature or extent of an asset’s use or operation;

●

significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;

●

accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;

●

current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and

●

expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. ~~In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production.~~ If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. ~~There was no impairment of long-lived assets to be held and used during the years ended December 31, 2018, 2017, and 2016.~~

We perform impairment tests for intangible assets with indefinite useful lives annually, in the fourth quarter, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess.

We also evaluate the remaining useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset’s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.

The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. During the years ended December 31, 2020 and 2019, we wrote off $1,131,776 and $78,864, respectively, in costs related to trademarks and patents. There was no impairment of ~~indefinite lived~~ intangible assets during the ~~years~~year ended December 31, ~~2018, 2017, and 2016.~~2018.

Fair Value of Financial Instruments

Our financial instruments consist primarily of cash, accounts receivable, accounts payable, accrued expenses and ~~long term~~long-term debt. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of December 31, 2020 and 2019 (as disclosed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).

~~F- 9~~

We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, Fair Value ~~Measurements.~~Measurements, or ASC 820. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1

unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2

quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

Level 3

unobservable inputs for the ~~asset~~assets or ~~liability.~~liabilities.

At December 31, ~~2018~~2020 and ~~2017,~~2019, we had no assets or liabilities that were valued at fair value on a recurring basis.

The carrying amount for the long term debt as of December 31, 2018 (as discussed in Note 8) approximates fair value based on market activity for other debt instruments with similar characteristics and comparable risk (Level 2).

Income Taxes

We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, ~~2018~~2020 and ~~2017,~~2019, we had no tax positions relating to open tax returns that were considered to be uncertain.

Our U.S. federal and state tax returns since 2011, which was the first year we generated net operating losses, remain open to examination.

Share-Based Compensation

We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options. Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Prior to January 1, 2017, the expected volatility of share options was estimated based on a historical volatility analysis of peer entities whose stock prices were publicly available that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other peer entities whose stock prices were publicly available that were similar to our ~~company.~~company and in 2019 we started using only our own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over a period equal to the expected term of the awards. ~~The~~On January 1, 2020, we began calculating the expected term of our stock-based awards, which represents the period that the stock-based awards are expected to be outstanding. Prior to January 1, 2020, the average expected life isof options was based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. ~~Calculating share-based compensation expense requires~~In addition, the ~~input of highly subjective judgment and assumptions: estimates of expected life~~terms of the ~~share-based award, stock price volatility~~Financing Agreement (See Note 8) preclude us from paying dividends, and ~~risk-free interest rates.~~any future debt agreements may also preclude us from paying dividends. The assumptions used in calculating the fair value of ~~share-based~~stock-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.

~~F- 10~~

We recognize the compensation expense for ~~all~~ share-based compensation granted ~~to employees~~ based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee’s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.

~~Revenue Recognition~~

~~We adopted ASC 606 on~~Effective January 1, ~~2018 using~~2017, we account for forfeitures when they occur. On January 1, 2019, we adopted ASU 2018-07 which simplified the ~~modified retrospective method~~accounting for ~~all contracts not completed~~share-based payments to non-employees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and superseded the guidance in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required by ASC 505, Equity - Based Payments to Non-Employees.

We grant restricted stock units and performance-based stock units for shares of common stock, par value $0.001 per share, or Common Stock, to employees. We value our restricted stock units and our performance-based stock units by reference to our stock price on the date of ~~adoption. ASC 606 states that~~grant. We recognize compensation expense for restricted stock units based on a ~~contract is considered “completed” if all (or substantially all)~~straight-line basis over the requisite service period of the ~~revenue was recognized in accordance with revenue guidance that was in effect before~~entire award. We recognize performance-based restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and through the date the performance restricted stock vests. The number of ~~initial application. Because all (or substantially all)~~target shares that vest are determined based on the level of attainment of the ~~revenue related to sales~~targets. If a minimum level of ~~our products has been recognized under ASC 605 prior to~~performance is attained for the ~~date~~awards, restricted stock is issued based on the level of initial application of the new standard, the contracts are considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary upon implementation of ASC 606 on January 1, 2018.attainment.

Revenue Recognition

In accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.

Prescription Products

~~Our~~As of December 31, 2020, our products ~~consist~~consisted primarily of prescription vitamins and our ~~recently approved product IMVEXXY®,~~FDA-approved products: IMVEXXY, which we began selling during the third quarter of ~~2018.~~ 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed the commercial launch of ANNOVERA on July 1, 2020.

We sell our name brand and generic prescription products primarily through wholesale distributors and retail ~~pharmacy distributors.~~pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors, which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail ~~pharmacy distributors,~~pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription product revenue only when we satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to be transferred when the customer receives the goods or service or obtains control. Control refers to the customer’s ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. ~~All of our performance obligations, and associated revenue, are transferred to customers at a point in time.~~ Based on our contracts, we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.

~~F- 11~~

The transaction price of a contract is the amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer. Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative product revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration to include in a contract’s transaction price, we rely on our historical experience and other evidence that supports our qualitative assessment of whether product revenue would be subject to a significant reversal. We consider all the facts and circumstances associated with both the risk of a product revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such changes in estimates become known.

We accept returns of unsalable prescription products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product expiration. ANNOVERA cannot be returned before the expiration date and expired ANNOVERA can be returned up to 12 months past the expiration date. Our prescription ~~products~~vitamins, IMVEXXY and BIJUVA currently have a shelf life of 24 months from the date of manufacture and ANNOVERA currently has a shelf life of 18 months from the date of manufacture. We do not allow product returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be returned by our customers and record this estimate as a reduction of product revenue in the period the related product revenue is recognized. Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers. For our newly launched products, for which the right of return exists but for which we currently do not have history of product returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory remaining in the distribution channel. At the end of each reporting period, we may decide to constrain product revenue for product returns based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We recognize the amount of expected returns as a refund liability, representing the obligation to return the customer’s consideration. Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of product revenue is deferred due to the anticipated return). Return estimates are recorded in ~~the accrued expenses and~~ other current liabilities on the consolidated balance sheet.

We offer various rebate and discount programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product ~~revenues~~revenue at the time the ~~revenues are~~product revenue is recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates and distributor fees are recorded in ~~accrued expenses and~~ other current liabilities on the consolidated balance sheet. We estimate chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience. Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 7. We provide invoice discounts to our customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product ~~revenues~~revenue at the time the ~~revenues are~~product revenue is recognized.

As part of ~~the~~ commercial ~~launch~~launches for ~~IMVEXXY® during the third quarter of 2018,~~our FDA-approved prescription products, we introduced a co-pay assistance program ~~where~~for eligible enrolled patients ~~do not pay~~whose out of pocket costs are reduced to a more ~~than $35 for up to 12 IMVEXXY® prescription fills.~~affordable price. This allows patients to access the product at a reasonable cost ~~regardless of insurance coverage.~~and is in line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We consider these payments as consideration paid to the customer and reflect such payments as a reduction of the transaction price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by patients’ insurance. Payers may change coverage levels for ~~IMVEXXY®~~our prescription products positively or negatively, at any time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of ~~IMVEXXY®~~our prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a result, we constrain ~~revenue recognized~~variable consideration for ~~IMVEXXY®~~our prescription products to an amount that will not result in a significant product revenue reversal in future periods. Our ability to estimate the net transaction price for ~~IMVEXXY®~~our prescription products is constrained by our estimates of the amount to be paid for the co-pay assistance program ~~for IMVEXXY®~~ which is directly related to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate ~~any constraint~~variable consideration each reporting period.

~~F- 12~~

~~OTC Products~~

Our over the counter, or OTC, and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. As of January 1, 2017, we decided to focus on selling our prescription vitamins and ceased manufacturing and distributing our OTC product lines, except for Iron 21/7 which we ceased manufacturing in October 2017. We generated OTC revenue from product sales primarily to retail consumers. We recognized revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We included outbound shipping and handling fees, if any, in revenues, net, and bill them upon shipment. We included shipping expenses in cost of goods sold. A majority of our OTC customers paid for our products with credit cards, and we usually received the cash settlement in two to three banking days. Credit card sales minimized accounts receivable balances relative to OTC sales. We provided an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognized revenue from OTC sales, net of estimated returns and sales discounts.

Disaggregation of revenue

The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016:~~2018:


	For the Years Ended December 31,						For the Years Ended December 31,
	2018		2017		2016		2020		2019		2018
Prescription vitamins	$	15,041,259	$	16,744,831	$	18,854,984	$	9,767,644	$	9,885,493	$	15,041,259
IMVEXXY®		1,058,201		—		—
OTC products		—		32,882		501,466
IMVEXXY								27,139,387		16,252,045		1,058,201
BIJUVA								6,353,963		1,836,443		—
ANNOVERA								19,611,286		6,166,556		—
License revenue								2,000,000		15,506,400		—
Net revenue	$	16,099,460	$	16,777,713	$	19,356,450	$	64,872,280	$	49,646,937	$	16,099,460

License Revenue

License arrangements may consist of non-refundable upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones and future product royalty payments. Some of these arrangements may include multiple performance obligations. Non-refundable up-front fees that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized as revenue when the right to use functional intellectual property is transferred to the customer.

License Agreement with the Population Council

On July 30, 2018, we entered into the Population Council License Agreement to commercialize ANNOVERA in the U.S. We began selling ANNOVERA in a “test and learn” market introduction in the third quarter of 2019. As a result of the uncertainty surrounding the COVID-19 pandemic, we paused the commercial launch of ANNOVERA in the first quarter of 2020 and deferred sales and marketing initiatives into subsequent quarters. We resumed the commercial launch of ANNOVERA on July 1, 2020.

Under the terms of the Population Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following the approval by the FDA of the new drug application, or NDA, for ANNOVERA and $20,000,000 within 30 days following the first commercial batch release of ANNOVERA. Both milestone payments of $20,000,000 were recorded as license rights in the consolidated balance sheets. We started amortizing license rights in the third quarter of 2019 once ANNOVERA became commercially available for use. The cost is amortized over the remaining useful life over which the license rights will contribute directly or indirectly to our cash flows, which is estimated to be the remaining patent life of the product, which expires as early as December 2032. The cost is amortized using the straight-line method as the pattern of economic benefit cannot be reliably determined. During the years ended December 31, 2020 and 2019 we recorded $3,024,391 and $778,692, respectively, in amortization expense related to the license fee which was recorded as a component of cost of sales.

The Population Council is also eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We are responsible for marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $50,000,000, a royalty of 5% of net sales; (ii) for annual net sales greater than $50,000,000 and less than or equal to $150,000,000, a royalty of 10% of such net sales; and (iii) for net sales greater than $150,000,000, a royalty of 15% of such net sales. The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate. We are required to pay the Population Council milestone payments of $40 million upon cumulative net sales of ANNOVERA in the U.S. by us and our affiliates and permitted sublicensees of each of $200 million, $400 million and $1 billion. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. We and the Population Council have agreed to form a joint product committee responsible for overseeing activities under the Population Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. The Population Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population Council.

Unless earlier terminated, the Population Council License Agreement will remain in effect until the later of the expiration of the last-to-expire of the Population Council’s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months during which we and our affiliates have not made a commercial sale of ANNOVERA in the U.S. The Population Council License Agreement may also be terminated for certain breach and bankruptcy-related events and by us on 180 days’ prior notice to the Population Council.

License Agreement with Knight Therapeutics Inc.

In July 2018, we entered into the Knight License Agreement pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight paid us $2,000,000 in milestone fees upon the first regulatory approval in Canada for IMVEXXY and BIJUVA in the third quarter of 2020, and is required to pay us sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each of IMVEXXY and BIJUVA in Canada and Israel. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters. As part of the Knight License Agreement, Knight is prohibited from exporting IMVEXXY and BIJUVA to the United States.

License Agreement with Theramex

On June 6, 2019, we entered into the Theramex License Agreement with Theramex to commercialize BIJUVA and IMVEXXY in the Theramex Territory. Under the terms of the Theramex License Agreement, Theramex paid us EUR 14 million, or $15,506,400, in cash as an upfront fee on August 5, 2019. Within thirty days of signing the Theramex License Agreement, we provided Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Theramex Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments at a rate of 5% on net sales of BIJUVA and IMVEXXY in the Theramex Territory. Theramex is responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Theramex Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Theramex Territory, except for certain specified markets. We may terminate the Theramex License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the Theramex License Agreement if Theramex challenges our patents. Either party may terminate the Theramex License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.

Segment Reporting

We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single ~~management~~executive leadership team that ~~reports to~~is led by the ~~President~~Chief Executive Officer of our ~~company.~~Company, who oversees all operations. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.

Shipping and Handling Costs

We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.

~~F- 13~~

Advertising Costs

We expense advertising costs when incurred. Advertising costs were ~~$1,682,746, $448,288,~~$35,799,313, $9,045,571 and ~~$752,611~~$1,682,746 during the years ended December 31, 2020, 2019, and 2018, ~~2017, and 2016,~~ respectively.

Research and Development Expenses

Research and development, or R&D, expenses include internal R&D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and ~~legal fees and~~other costs. The activities undertaken by our regulatory consultants that were classified as R&D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. ~~Legal activities that were classified as R&D expenses include professional research and advice regarding R&D, patents and regulatory matters.~~ These consulting ~~and legal~~ expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions to ~~expense~~expenses in the period in which the facts that give rise to the revision become known.

Earnings Per Share

We calculate earnings per share, or EPS, in accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of ~~common stock, par value $0.001 per share, or~~ Common Stock outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options, warrants and restricted stock ~~awards~~units and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us. The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.


	As of December 31,						As of December 31,
	2018		2017		2016		2020		2019		2018
Stock options		20,872,824		23,365,225		21,767,854		23,781,930		25,030,234		20,872,824
Warrants		3,007,571		3,115,905		12,060,071		6,534,687		1,832,571		3,007,571
Restricted stock awards		1,040,000		—		—
Performance stock units								2,403,951		—		—
Restricted stock units								7,061,024		1,240,000		1,040,000
		24,920,395		26,481,130		33,827,925		39,781,592		28,102,805		24,920,395

Concentration of Credit Risk and other Risks and Uncertainties

Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. We have not experienced any historical losses on ~~its~~our deposits of cash.

Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacy distributors. Credit is extended to our customers based on an evaluation of a customer’s financial condition, and collateral is not required.

~~F- 14~~

Use of Estimates

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.

Recently Issued Accounting Pronouncements

In March 2020, the FASB issued Accounting Standards Update, or ASU, 2020-04: Reference Rate Reform (Topic 848) Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides optional guidance for a limited period of time to ease potential accounting impacts associated with transitioning away from reference rates that are expected to be discontinued, such as London Interbank Offered Rate (LIBOR). This ASU includes practical expedients for contract modifications due to reference rate reform. Generally, contract modifications related to reference rate reform may be considered an event that does not require remeasurement or reassessment of a previous accounting determination at the modification date. This ASU is effective March 12, 2020 through December 31, 2022. Our debt agreements currently include the use of alternate rates when LIBOR is not available. We do not expect the change from LIBOR to an alternate rate will have a material impact to our financial statements and, to the extent we enter into modifications of agreements that are impacted by the LIBOR phase-out, we will apply such guidance to those contract modifications.

In August 2018, the FASB issued ~~Accounting Standards Update, or~~ ASU 2018-13, which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to Accounting Standards Codification, or ASC, 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We ~~are currently evaluating the effect of~~adopted this ~~guidance on our disclosures.~~

In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets but recognize expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. Early adoption is permitted for all entities. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We plan to adopt ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11. While we are still finalizing the quantitative and qualitative impact of adopting this new standard and the subsequent amendments, the most significant impact is expected to be the recognition of a right of use asset and lease liability on our statement of financial position related to the operating leases for our new and existing office space. We elected the optional transition method of recognizing a cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2019. Therefore, comparative financial information will not be adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we will not assess 1) whether existing or expired contracts contain leases, 2) lease classification for any existing or expired leases, and 3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We will not separate lease components from non-lease components for our specified asset classes. Based on our preliminary calculations, we currently expect to recognize right-of-use asset and corresponding lease liability between $4 million to $5 million on our Consolidated Balance Sheet based on the present value of future minimum lease payments under operating leases in effect on January 1, 2019. ~~Additionally, the adoption of the new standard will result in increased disclosure requirements in our quarterly and annual filings.~~

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. The amendments in this update require a financial ~~statements but~~asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected based on historical experience, current conditions, and reasonable supportable forecasts. The amendments in this update are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted no sooner than the first quarter of 2019. A modified retrospective approach is required for all investments, except debt securities for which an other-than-temporary impairment had been recognized prior to the effective date, which will require a prospective transition approach and should be applied either prospectively or retrospectively depending on the nature of the disclosure. The adoption of ASU 2016-13 requires expanded quantitative and qualitative disclosures about the Company’s expected credit losses. Effective January 1, 2020, we adopted ASU 2016-13 under a modified retrospective approach for all financial assets measured at amortized cost. There was no adjustment recorded for the cumulative effect of adopting ASU 2016-13. The adoption expanded disclosures about our ~~disclosures related to contracts with customers.~~credit losses.

~~F- 15~~

NOTE 3 – INVENTORY

Inventory consists of the following:


	December 31,				December 31,
	2018		2017		2020		2019
Finished products	$	2,908,958	$	1,485,358	$	3,350,580	$	4,976,910
Work in process		339,312		—		219,918		1,182,059
Raw materials		19,400		—		4,422,589		5,701,747
TOTAL INVENTORY	$	3,267,670	$	1,485,358	$	7,993,087	$	11,860,716

NOTE 4 – OTHER CURRENT ASSETS

Other current assets consist of the following:


	December 31,				December 31,
	2018		2017		2020		2019
Prepaid sales and marketing costs	$	5,148,789	$	5,335,936	$	4,308	$	1,583,698
Debt financing fees (Note 8)		1,898,074		—
Debt financing fees on undrawn tranches (Note 8)						—		550,757
Prepaid insurance		790,465		680,243		2,568,269		1,812,135
Prepaid manufacturing						1,331,100		2,595,721
Other prepaid costs		2,997,365		588,105		3,639,720		4,787,482
TOTAL OTHER CURRENT ASSETS		10,834,693	$	6,604,284	$	7,543,397	$	11,329,793

NOTE 5 – FIXED ASSETS, NET

Fixed assets, net consist of the following:


	December 31,						December 31,
	2018			2017			2020			2019
Accounting system	$	301,096		$	301,096		$	411,550		$	301,096
Equipment		490,576			273,536			1,704,931			1,619,646
Furniture and fixtures		116,542			116,542			1,406,858			1,406,858
Computer hardware		80,211			80,211			80,211			80,211
Leasehold improvements		37,888			37,888			80,121			68,788
TOTAL FIXED ASSETS		1,026,313			809,273			3,683,671			3,476,599
Accumulated depreciation		(553,630	)		(372,218	)		(1,741,447	)		(968,824	)
TOTAL FIXED ASSETS, NET	$	472,683		$	437,055		$	1,942,224		$	2,507,775

Depreciation expense for the years ended December 31, 2020, 2019, and 2018 ~~2017,~~was $772,624, $415,193, and ~~2016 was $181,412, $141,601, and $77,906,~~$181,412, respectively.

~~F- 16~~

NOTE 6 – INTANGIBLE ASSETS, NET

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, ~~2018~~2020 and ~~2017:~~2019:

December 31, 2018
Gross
Carrying
Amount Accumulated
Amortization Net
Amount Weighted-
Average
Remaining
Amortization
Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent $ 31,951 $ (10,484 ) $ 21,467 10.75
Development costs of corporate website 91,743 (91,743 ) — n/a
Approved hormone therapy drug candidate patents 2,234,129 (282,485 ) 1,951,644 14
Hormone therapy drug candidate patents (pending) 1,855,279 — 1,855,279 n/a
Non-amortizable intangible assets:
Multiple trademarks 264,289 — 264,289 indefinite
TOTAL $ 4,477,391 $ (384,712 ) $ 4,092,679


	December 31, 2017									December 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)		Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
OPERA^®software patent	$	31,951	$	(8,487	)	$	23,464		11.75
Development costs of corporate website		91,743		(91,743	)		—		n/a
Approved hormone therapy drug candidate patents		1,293,614		(171,911	)		1,121,703		15	$	4,044,552	$	(748,627	)	$	3,295,925		12
Hormone therapy drug candidate patents (pending)		1,721,305		—			1,721,305		n/a		1,628,457		—			1,628,457		n/a
Non-amortizable intangible assets:
Multiple trademarks		233,275		—			233,275		indefinite		323,341		—			323,341		indefinite
TOTAL	$	3,371,888	$	(272,141	)	$	3,099,747			$	5,996,350	$	(748,627	)	$	5,247,723


	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents	$	3,463,082	$	(478,983	)	$	2,984,099		13
Hormone therapy drug candidate patents (pending)		1,979,299		—			1,979,299		n/a
Non-amortizable intangible assets:
Multiple trademarks		294,813		—			294,813		indefinite
TOTAL	$	5,737,194	$	(478,983	)	$	5,258,211

We capitalize external costs, consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized patent costs at that time. Trademarks are perpetual and are not amortized. During the years ended December 31, ~~2018~~2020 and ~~2017, there~~2019, we wrote off $1,131,776 and $78,864, respectively, in costs related to trademarks and patents. There was no impairment ~~recognized related to~~of intangible ~~assets.~~assets during the year ended December 31, 2018.

~~F- 17~~

As of December 31, ~~2018,~~2020, we had 2138 issued domestic ~~or U.S.~~ patents and 2439 issued foreign patents, including:

●

1115 domestic patents and ~~five~~9 foreign patents that relate to ~~BIJUVA™~~BIJUVA as well as 3 domestic patents that relate to ~~non-approved doses of BIJUVA™.~~estradiol and progesterone product candidates. These patents establish an important intellectual property foundation ~~for BIJUVA™~~ and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to ~~BIJUVA™~~BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;

●

~~Three~~12 domestic patents (10 utility and 2 design) and 18 foreign patents that relate to our progesterone-only candidate, which are owned by us. The foreign patent will expire no earlier than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;

●

~~Three domestic patents (two~~(8 utility and ~~one design) and 12 foreign patents (three utility and nine~~10 design) that relate to ~~IMVEXXY®.~~IMVEXXY. These patents establish an important intellectual property foundation for ~~IMVEXXY®~~IMVEXXY and are owned by us. ~~These~~The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain ~~jurisdictions,~~countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to ~~IMVEXXY®~~IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;

●

~~One~~NaN domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;

2035;

●

~~One~~NaN domestic utility patent and ~~four~~8 foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have a pending patent ~~applications~~application with respect to our transdermal-patch candidates in Brazil;

●

NaN domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037;

●

NaN domestic and 4 foreign patents that relate to formulations containing progesterone, which are owned by us. The domestic patents will expire between 2032 and 2036. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect formulations containing progesterone in the U.S., Australia, ~~Brazil,~~ Canada, Europe, ~~Mexico, Japan,~~ and ~~South Africa;~~

Mexico; and

	●	~~One~~NaN domestic utility patent that relates to our ~~OPERA®~~OPERA information-technology platform, which is owned by us and will expire in ~~2029; and~~

●	One domestic utility patent that relates to TX-009HR, a progesterone and estradiol product candidate, which is owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.2031.

Amortization expense was ~~$112,474, $71,516,~~$269,546, $197,593, and ~~$54,545~~$112,474 for the years ended December 31, 2020, 2019, and 2018, ~~2017, and 2016,~~ respectively.

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Year Ending
December 31, Estimated
Amortization
2019 $ 139,410
2020 $ 139,410
2021 $ 139,410
2022 $ 139,410
2023 $ 139,410
Thereafter $ 1,276,061

Year Ending December 31,	Estimated Amortization
2021	$	274,669
2022	$	274,669
2023	$	274,669
2024	$	274,669
2025	$	274,669

~~License Agreement with~~

NOTE 7– OTHER CURRENT LIABILITIES

Other current liabilities consist of the ~~Population Council~~following:


	December 31,
	2020		2019
Accrued payroll, bonuses and commission costs	$	8,758,073	$	8,040,278
Allowance for coupons and returns		6,770,206		10,316,298
Accrued sales and marketing costs		227,500		3,285,662
Accrued compensated absences		2,353,996		1,463,878
Allowance for wholesale distributor fees		2,632,432		2,347,122
Accrued legal and accounting expense		898,568		422,336
Accrued research and development		925,314		1,049,603
Operating lease liability		2,253,994		1,501,539
Accrued rebates		11,010,588		3,916,672
Other accrued expenses		2,339,198		1,480,225
TOTAL OTHER CURRENT LIABILITIES	$	38,169,869	$	33,823,613

NOTE 8 – DEBT

On ~~July 30, 2018,~~April 24, 2019, we entered into a Financing Agreement, as amended, or the ~~Council License~~Financing Agreement, with Sixth Street Specialty Lending, Inc., as administrative agent, or the Administrative Agent, various lenders from time to ~~commercialize~~time party thereto, and certain of our subsidiaries party thereto from time to time as guarantors, which provided us with up to a $300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provided for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into the ~~U.S. ANNOVERA™. We currently estimate that ANNOVERA™ will be commercially available as early as~~Financing Agreement; (ii) $50,000,000 was drawn on February 18, 2020 following our achievement of more than $11,000,000 in net revenues from IMVEXXY, BIJUVA, and ANNOVERA for the ~~third~~fourth quarter of 2019 and (iii) $50,000,000 was previously available to us in the Administrative Agent’s sole and absolute discretion either contemporaneously with the delivery of our financial statements for the quarter ended June 30, 2020 or at such earlier date as the Administrative Agent may have consented to. Subsequent to the pause in the successful full launch of ANNOVERA caused by the COVID-19 pandemic, the undrawn $50,000,000 tranche under the Financing Agreement is no longer available. Borrowings under the Facility accrue interest at either (i) 3-month LIBOR plus 7.75%, subject to a ~~planned~~LIBOR floor of 2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.2% as selected by us. Interest on amounts borrowed under the Facility is payable quarterly. Prior to entering into Amendment No. 8, the outstanding principal amount of the Facility was payable in 4 equal quarterly installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. In connection with Amendment No. 8 we, among other things, (i) repaid $15.0 million in principal under the Financing Agreement on such date, plus a 5.0% prepayment fee, (ii) agreed to repay an additional $35.0 million in principal by no later than March 31, 2021, plus a 5.0% prepayment fee, and (iii) agreed to make additional principal repayments as follows: (x) $5.0 million on each of March 31, 2022, June 30, 2022 and September 30, 2022; (y) $10.0 million on each of December 31, 2022 and March 31, 2023; and (z) $41.25 million on each of June 30, 2023, September 30, 2023, December 31, 2023 and March 31, 2024, plus the prepayment fees described in the following sentence. We have the right to prepay borrowings under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid, which was revised in connection with Amendment No. 8, of (i) 30.0% of the principal amount being repaid through March 31, 2022 (excluding the scheduled $5.0 million principal repayment on such date, which is subject to a 5.0% prepayment fee); (ii) 5.0% of the principal amount being repaid from April 1, 2022 through March 31, 2023; (iii) 3.0% of the principal amount being repaid from April 1, 2023 through March 31, 2024; and (iv) thereafter, none, in each case subject to certain limited exceptions, including with respect to a repayment in full of the obligations under the Financing Agreement. In connection with the initial borrowing under the Facility, we paid, for the benefit of the lenders, a facility fee equal to 2.5% of the initial amount borrowed and were required to pay such a facility fee in connection with subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments, restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are required to (i) maintain a minimum unrestricted cash balance of $60,000,000, and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial ~~launch by~~sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ended December 31, 2020. Pursuant to Amendment No. 8, the minimum consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA were revised to (i) $17.0 million, $20.0 million, $23.0 million, and $26.5 million for the first, second, third, and fourth quarters of 2021, respectively, (ii) $30.0 million, $35.0 million, $40.0 million and $45.0 million for the first, second, third, and fourth quarters of 2022, respectively, (iii) $50.0 million, $55.0 million, $60.0 million and $65.5 million for the first, second, third, and fourth quarters of 2023, respectively, and (iv) $70.0 million for the first quarter of 2024. Pursuant to Amendment No. 6 (as defined below), the minimum required cash balance was lowered to $45 million from November 8, 2020 through December 31, 2020. As of December 31, 2020, we were in compliance with all covenants under the Financing Agreement. The Financing Agreement also includes other representations, warranties, indemnities, restrictions on the payment of dividends, and events of default that are customary for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement. The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after acquired assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our future direct and indirect subsidiaries, subject to certain exceptions. Also pursuant to Amendment No. 8, the Administrative Agent consented to a framework for our potential disposition of our vitaCare prescription services business.

~~F- 18~~

~~Under~~On August 5, 2020, we entered into Amendment No. 5 to the ~~terms~~Financing Agreement, or Amendment No. 5. Amendment No. 5 adjusted the covenant in the Financing Agreement regarding our achievement of ~~the Council License Agreement, we paid the Population Council a milestone payment of $20,000,000 within 30 days following approval by the FDA of the NDA for ANNOVERA™ and will be required~~minimum consolidated net revenue attributable to pay the Population Council $20,000,000 within 30 days following the release of the first commercial batch of ANNOVERA™. The Population Council is also eligible to receive milestone payments and royalties from commercial sales of ~~ANNOVERA™. We will assume responsibility for marketing expenses related~~our IMVEXXY, BIJUVA, and ANNOVERA products to reflect the impact of COVID-19 on our business. The covenant was effective beginning with the fiscal quarter ending December 31, 2020. In connection with Amendment No. 5 and in lieu of a cash amendment fee, we issued to the ~~commercialization of ANNOVERA™. The milestone payment of $20,000,000 upon~~Administrative Agent and the FDA’s approval of ANNOVERA™ in the third quarter of 2018 was recorded as a finite-lived intangible asset in the consolidated balance sheet and will be amortized on a straight-line basis once it becomes available for use which is expected to be upon release of first commercial batch of ANNOVERA^TM. In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA™ in the U.S. by the Company and its affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to $50,000,000, a royalty of 5% of net sales; (ii) for annual net sales greater than $50,000,000 and less than or equal to $150,000,000, a royalty of 10% of such net sales; and (iii) for net sales greater than $150,000,000, a royalty of 15% of such net sales. The annual royalty rate will be reduced to 50% of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will be reduced to 20% of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four post-approval studies required by the FDA for ANNOVERA™ and we have agreed to perform and pay the costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20,000,000, half of such excess will be offset against royalties or other payments owed by us to the Population Councillenders under the ~~Council License Agreement. We~~Financing Agreement warrants to purchase an aggregate of 4,752,116 shares of Common Stock with an exercise price of $1.58 per share and a ten-year term, or the ~~Population Council have agreed~~Lender Warrants. The Lender Warrants were issued pursuant to ~~form a joint product committee responsible for overseeing activities~~an exemption from registration under the ~~Council License Agreement. We will be responsible for all aspects~~Securities Act of ~~promotion, product positioning, pricing, education programs, publications, sales messages~~1933, as amended, and ~~any additional desired clinical studies for~~no registration rights were issued. The Company concluded that the ~~one-year vaginal contraceptive system, subject~~modification accounting model is applicable to ~~oversight~~this transaction and decisions made by the joint product committee. The Council License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal contraceptive systems in development by the Population Council.

We assess our intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, we would determinerecognized the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining useful life of intangible assets subject to amortization onwarrants as a ~~periodic basis to determine whether events and circumstances would indicate impairment or warrant a revision~~debt discount.

On November 8, 2020, in connection with entering into Amendment No. 6 to the ~~remaining useful life. If~~Financing Agreement, or Amendment No. 6, we amended the ~~estimate of~~Lender Warrants to provide for an ~~intangible asset’s remaining useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining useful life.~~

~~License Agreement with Knight Therapeutics Inc.~~

On July 30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY® and BIJUVA^TM ~~in Canada and Israel. Pursuant~~adjustment to the ~~terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of IMVEXXY® and BIJUVA~~^TM~~, sales milestone fees based upon~~exercise price if we conduct certain ~~aggregate annual sales in Canada and Israel of each of IMVEXXY® and BIJUVA~~^TM ~~and royalties based on aggregate annual sales of each of IMVEXXY® and BIJUVA~~^TM~~in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related~~dilutive issuances prior to ~~IMVEXXY® and BIJUVA~~^TM. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY® and BIJUVA^TMin Canada and Israel within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified time periodsDecember 31, 2020, or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight purchased 3,921,568 of sharesvolume-weighted average price of our Common Stock ~~concurrently with~~for the ~~closing~~fifteen trading days ending December 31, 2020 is lower than the then-current exercise price. Pursuant to Amendment No. 6, the issuance of Common Stock by the Company in the underwritten public offering ~~of Common Stock~~ at a price ~~of $5.10, for proceeds of $20,000,000, on August 6, 2018.~~

~~F- 19~~

~~NOTE 7– ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES~~

~~Accrued expenses and other current liabilities consist~~per share equal to $1.1856 triggered the automatic reduction in the exercise price of the ~~following:~~

December 31,
2018 2017
Accrued payroll, bonuses and commission costs $ 6,854,002 $ 4,240,379
Allowance for coupons and returns 5,294,120 1,432,846
Accrued sales and marketing costs 2,288,028 420,162
Accrued compensated absences 1,178,110 945,457
Allowance for wholesale distributor fees 792,891 172,973
Accrued legal and accounting expense 385,824 600,350
Accrued research and development 388,675 366,933
Accrued rent 365,155 327,099
Accrued rebates 412,570 76,917
Accrued royalties — 114,480
Other accrued expenses 375,573 525,999
TOTAL $ 18,334,948 $ 9,223,595

~~NOTE 8 – DEBT~~Lender Warrants from $1.58 to $1.1856.

On May 1, 2018, we entered into a Credit and Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders).

On July 30, 2018, we entered into Amendment No. 1 to the Credit Agreement in order to permit our entry into the Council License Agreement. Pursuant to the amendment, we were required to receive aggregate net cash proceeds of at least $75,000,000 from the issuance of our equity securities within thirty days of entering into the Council License Agreement, which we did in connection with the August 2018 underwritten public offering.

, as amended. The Credit Agreement ~~provides~~provided a secured term loan facility in an aggregate principal amount of up to ~~$200,000,000,~~$200,000,000, or the Term Loan. Under the terms of the Credit Agreement, the Term Loan ~~will~~was available to be made in ~~three~~3 separate tranches, with each tranche to be made available to us, at our option, upon our achievement of certain milestones. The first tranche of $75,000,000, or Tranche 1, was drawn by us on June 7, 2018, following approval by the FDA of the NDA for IMVEXXY®. The second tranche of $75,000,000, or Tranche 2, may be drawn by us on or before May 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including (i) that Tranche 1 has been drawn, (ii) the approval by the FDA of the NDA for BIJUVA^TM~~and (iii) we have consummated our first commercial sale in the United States of BIJUVA~~^TM. The third tranche of $50,000,000, or Tranche 3, may be drawn by us on or before December 31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including that (i) Tranche 2 has been drawn and (ii) we have generated at least $75,000,000 of consolidated net revenue attributable to commercial sales of BIJUVA^TM ~~and IMVEXXY® during the twelve-month period ending immediately prior to the funding of Tranche 3.~~

Amounts borrowed under the Term Loan ~~bear~~bore interest at a rate equal to the sum of (i) one-month LIBOR (subject to a LIBOR floor of ~~1.50%~~1.50%) plus (ii) ~~7.75%~~7.75% per annum. ~~Interest on amounts borrowed~~

On April 24, 2019, we terminated the Credit Agreement. A portion of the initial tranche of borrowing under the ~~Term Loan is due~~Financing Agreement in the amount of approximately $81,661,000 was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of 4%, a repayment fee of 4% and other fees and expenses payable ~~monthly~~to the lenders under the Credit Agreement. As a result of the termination of the Credit Agreement, we recorded $10,057,632 in ~~arrears. Principal~~loss on ~~each Tranche is payable~~extinguishment of debt in ~~36 equal monthly installments beginning May 1, 2020 until paid in full on May 1, 2023, or~~ the ~~Maturity Date. However, if we generate at least $95,000,000~~second quarter of ~~consolidated net revenue attributable to commercial sales of BIJUVA~~^TM~~and IMVEXXY® by~~2019. Interest expense for the years ended December 31, 2019 ~~we may extend the interest-only period by an additional 12 months to May 1, 2021. Interest expense~~and 2018 related to ~~this Term Loan for~~the Credit Agreement was $1,816,747 and $4,407,975, respectively. During the year ended December 31, ~~2018 was $4,407,975.~~

~~F- 20~~

~~The Term Loan may be prepaid, in whole or in part, subject~~2019, and prior to ~~a prepayment fee on~~ the amount being prepaid (or required to be prepaid, if such amount is greater) of (i) 4.0% for the first year following the Tranche 1 funding date, (ii) 3.0% for the second year following the Tranche 1 funding date and (iii) 2.0% thereafter. Upon repayment of the Term Loan at the Maturity Date or prepayment on any earlier date, we will be required to pay a termination payment based on the principal amount paid or prepaid. In connection with the execution of the Credit Agreement, we ~~paid the Agent, for the benefit~~amortized $120,146 of all Lenders, an origination fee equal to 1.00% of the maximum potential amount of the Term Loan. We are also required to pay the Agent an annual administration fee of 0.25% based on the amounts borrowed under the Term Loan, in addition to other fees and expenses.

Our obligations under the Credit Agreement are secured, subject to customary permitted liens and other agreed upon exceptions, by a first priority perfected security interest in all of our existing and after-acquired assets. Our obligations under the Credit Agreement are guaranteed by each of our future direct and indirect subsidiaries (other than certain non-U.S. subsidiaries of ours and certain U.S. subsidiaries substantially all of whose assets consist of equity interests in non-U.S. subsidiaries, subject to certain exceptions). The Credit Agreement contains customary restrictions and covenants. Among other requirements, we must (i) maintain a minimum cash balance of $50,000,000 and (ii) achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our products. As of December 31, 2018, we were in compliance with the covenants under the Credit Agreement.

The Credit Agreement also contains customary covenants that limit, among other things, our ability to (i) incur indebtedness, (ii) incur liens on our property, (iii) pay dividends or make other distributions, (iv) sell our assets, (v) make certain loans or investments, (vi) merge or consolidate, (vii) voluntarily repay or prepay certain permitted indebtedness and (viii) enter into transactions with affiliates, in each case subject to certain exceptions. The Credit Agreement contains customary representations and warranties and events of default relating to, among other things, payment defaults, breaches of covenants, the occurrence of any fact, event or circumstance that could reasonably be expected to result in a Material Adverse Effect (as defined in the Credit Agreement), delisting of our common stock, par value $0.001 per share, or Common Stock, bankruptcy and insolvency, cross defaults with certain material indebtedness and certain material contracts, judgments and inaccuracies of representations and warranties. Upon or after an event of default, the agent and the Lenders may declare all or a portion of our obligations under the Credit Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Credit Agreement.

As of December 31, 2018, we had $75,000,000 in borrowings outstanding under the Term Loan, which are classified as long-term debt in the accompanying consolidated financial statements. We incurred $3,786,918 in debt issuance costs related to the Term Loan. Debt financing fees related to the entire Term Loan have been allocated pro rata between the funded and unfunded portions of each tranche. Allocated debt financing fees related to Tranche 1 of $1,888,844 have been reclassified to debt discount and are accreted to interest expense using the effective interest method. Debt financing fees associated with unfunded tranches are deferred as assets until Tranche 2 and Tranche 3 milestones have been met. As of December 31, 2018, deferred financing fees ~~related to Tranche 2 and Tranche 3 are included in other current assets~~as interest expense in the accompanying consolidated financial statements. During the year ended December 31, 2018, we amortized ~~$269,859,~~$269,859 of ~~debt issuance costs related to Tranche 1~~deferred financing fees as interest expense in ~~our~~the accompanying consolidated financial statements.

As of December 31, 2020, we had $250,000,000 in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying consolidated financial statements. Since the inception of the Financing Agreement, we have incurred $7,902,270 in deferred financing fees related to the Financing Agreement. Deferred financing fees related to the entire Financing Agreement were allocated pro rata between the funded and unfunded tranches. Allocated deferred financing fees related to the two tranches of borrowings that we received of $7,626,891 have been reflected as debt discount upon each draw and are amortized to interest expense using the effective interest method. In addition, during the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of $7,428,178 as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value to the debt discount of $239,983, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. The public offering in November 2020 triggered the down round provision underlying the warrants granted in August 2020, as modified in November 2020, which was immaterial.

During the third quarter of 2020, we concluded that the undrawn $50,000,000 tranche under the Financing Agreement is no longer available to us. As such, we wrote off $275,379 of deferred financing fees associated with the unfunded tranche, which were previously deferred as assets until such tranche had been drawn.

During the years ended December 31, 2020 and 2019, we amortized $2,256,428 and $736,156, respectively, of deferred financing fees related to the Financing Agreement as interest expense in the accompanying consolidated financial statements. Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears. Interest expense for the years ended December 31, 2020 and 2019 was $26,049,236 and $14,709,166, respectively. The overall effective interest rate under the Financing Agreement was approximately ~~11%~~12.5% as of December 31, ~~2018.~~ 2020.

As of December 31, ~~2018,~~2020 and 2019, the carrying value of our debt ~~consists~~consisted of the following:

	December 31, 2018
Term Loan	$	75,000,000
				As of December 31,
				2020			2019
Financing Agreement				$	250,000,000		$	200,000,000
Debt discount and financing fees		(1,618,986	)		(12,302,469	)		(5,365,357	)
TOTAL LONG-TERM DEBT	$	73,381,014		$	237,697,531		$	194,634,643

The following table reflects our aggregate future principal payments under the Financing Agreement for the next five years, as amended by Amendment No. 8:

Year Ending December 31,
2021	$	50,000,000
2022	$	25,000,000
2023	$	133,750,000
2024	$	41,250,000
2025	$	0

NOTE 9 – STOCKHOLDERS’ EQUITY

Preferred Stock

At December 31, ~~2018,~~2020, we had 10,000,000 shares of preferred stock, par value ~~$0.001,~~$0.001 per share, or Preferred Stock, authorized for issuance, of which no0 shares of ~~preferred stock~~Preferred Stock were issued or outstanding.

~~F- 21~~

Common Stock

At December 31, ~~2018,~~2020, we had ~~350,000,000~~600,000,000 shares of Common Stock authorized for issuance, of which ~~240,462,439~~299,765,396 shares of Common Stock were issued and outstanding.

Issuances During 2020

During the year ended December 31, 2020, stock options to purchase an aggregate of 1,182,195 shares of Common Stock were exercised for $271,678 in cash.

On November 10, 2020, we entered into an underwriting agreement with Cantor Fitzgerald & Co., or Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of 23,437,500 shares of Common Stock at a public offering price of $1.1856 per share. We granted to the underwriter an option, exercisable for a period of 30 days, to purchase up to 3,515,625 additional shares of Common Stock, which was exercised in full. The net proceeds the offering were approximately $31,703,000, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The offering of 23,437,500 shares closed on November 13, 2020 and the offering of 3,515,625 shares closed on November 20, 2020.

In November 2020, we entered into a Controlled Equity Offering^SM Sales Agreement, or sales agreement, with Cantor Fitzgerald relating to shares of our Common Stock. In accordance with the terms of the sales agreement, we were permitted to offer and sell shares of our Common Stock having an aggregate offering price of up to $50 million from time to time through or to Cantor Fitzgerald, acting as sales agent. Cantor Fitzgerald was entitled to compensation at a fixed commission rate of 3.0% of the aggregate gross sales price per share sold. No shares of Common Stock were ~~issued~~sold under the sales agreement during the year ended December 31, 2020. As further described in Note 16 - Subsequent Events, on February 8, 2021, our “at the market” offering with Cantor Fitzgerald terminated following the sale of the maximum $50 million of shares of Common Stock in January 2021 and ~~outstanding.~~February 2021 pursuant to the sales agreement.

Issuances During 2019

On October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters, relating to an underwritten public offering of 26,000,000 shares of our Common Stock at a public offering price of $2.75 per share. We granted the underwriters an option, exercisable for a period of 30 days, to purchase up to 3,900,000 additional shares of Common Stock, which was exercised in full. The net proceeds to us from the offering were approximately $77,031,000, after deducting the underwriting discount and offering expenses payable by us. The offering closed on October 29, 2019.

During the year ended December 31, 2019, certain individuals exercised stock options to purchase an aggregate of 331,619 shares of Common Stock for $108,656 in cash. Also, during the year ended December 31, 2019, stock options to purchase an aggregate of 12,097 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, which resulted in 11,834 shares of Common Stock being issued.

Issuances During 2018

On August 1, 2018, we entered into an underwriting agreement with Goldman Sachs & Co. LLC, as representative of the underwriters, relating to an underwritten public offering of 12,745,098 shares of our Common Stock at a price of ~~$5.10~~$5.10 per share. We granted the underwriters an option, exercisable for a period of 30 days, to purchase up to 1,911,764 additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds to us from the offering, including the exercise of the option to purchase additional shares, were approximately ~~$69,908,000,~~$69,908,000, after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018.

In connection with the Knight License Agreement, on August 6, 2018, Knight entered into a subscription agreement with us, pursuant to which Knight purchased 3,921,568 of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock at a price of ~~$5.10,~~$5.10, for proceeds to us of ~~$20,000,000.~~

~~Issuances During 2018~~$20,000,000.

During the year ended December 31, 2018, certain individuals exercised stock options to purchase an aggregate of 5,444,526 shares of Common Stock for ~~$1,666,208~~$1,666,208 in cash. Also, during the year ended December 31, 2018, stock options to purchase an aggregate of 10,000 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, wherein 9,841 shares of Common Stock were issued.

~~Issuances During 2017~~

On September 25, 2017, we entered into an underwriting agreement with J.P. Morgan Securities LLC relating to an underwritten public offering of 12,400,000 shares of our Common Stock at a price of $5.55 per share. The net proceeds to us from the offering were approximately $68,573,000, after deducting estimated offering expenses payable by us. The offering closed on September 28, 2017 and we issued 12,400,000 shares of Common Stock.

~~During the year ended December 31, 2017, certain individuals exercised stock options to purchase 102,546 shares of Common Stock for $212,615 in cash.~~

~~Issuances During 2016~~

On January 6, 2016, we entered into an underwriting agreement with Goldman Sachs & Co. and Cowen and Company, LLC, as the representatives of the several underwriters relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which the option was exercised in full. The net proceeds to us from the offering were approximately $134,864,000, after deducting underwriting discounts and commissions and other expenses payable by us. The offering closed on January 12, 2016 and we issued 17,424,242 shares of our Common Stock.

During the year ended December 31, 2016, certain individuals exercised stock options to purchase 525,362 shares of Common Stock for $989,060 in cash. Also, during the same period, stock options to purchase 127,109 shares of Common Stock were exercised pursuant to the options’ cashless exercise provisions, wherein 87,833 shares of Common Stock were issued.

~~F- 22~~

Warrants to Purchase Common Stock

As of December 31, ~~2018,~~2020, we had warrants outstanding to purchase an aggregate of ~~3,007,571~~6,534,687 shares of Common Stock with a weighted-average contractual remaining life of approximately ~~1.6~~7.25 years, and exercise prices ranging from ~~$0.24~~$0.24 to ~~$8.20~~$8.20 per share, resulting in a weighted average exercise price of ~~$2.78~~$1.55 per share.

The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate, dividend yield and the term of the warrant.

~~During~~In connection with Amendment No. 5 and in lieu of a cash amendment fee, we issued to the ~~year ended December 31, 2018, we granted warrants to purchase 175,000 shares of Common Stock to outside consultants at an exercise price of $5.16 per share.~~Administrative Agent and the lenders under the Financing Agreement the Lender Warrants. The fair value for ~~these warrants~~the Lender Warrants was determined by using the Black-Scholes Model on the date of the grant using a term of ~~five years;~~ten years, volatility of ~~62.1%; risk free~~68.8%, risk-free interest rate of ~~2.36%;~~0.34% and dividend yield of 0%0%. The grant date fair value of the warrants was ~~$2.79~~$1.56 per share. The warrants ~~vest ratably~~vested upon issuance. We concluded that the modification accounting model is applicable to this warrant issuance and recognized the fair value of the warrants as a debt discount. As a result, the fair value of the Lender Warrants is being amortized to interest expense over ~~a 12-month period and have~~the term of the Financing Agreement.

On November 8, 2020, in connection with entering into Amendment No. 6, we amended the Lender Warrants to provide for an ~~expiration date~~adjustment to the exercise price if we conducted certain dilutive issuances prior to December 31, 2020, or if the volume-weighted average price of ~~March 15, 2023.~~our Common Stock for the fifteen trading days ending December 31, 2020 was lower than the then-current exercise price. Pursuant to Amendment No. 6, the issuance of the shares of Common Stock in the November 2020 underwritten public offering triggered the automatic reduction in the exercise price of the Warrants from $1.58 to $1.1856. Based on Amendment No. 6 to the Financing Agreement, we recognized additional value to the debt discount of $239,983.

During the year ended December 31, ~~2017,~~2019, we granted warrants to purchase ~~125,000~~an aggregate of 75,000 shares of Common Stock to outside consultants at an exercise price of $6.83 per share. The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of five years; volatility of 63.24%; risk free rate of 1.47%; and dividend yield of 0%. The grant date fair value of the warrants was $3.67 per share. The warrantswhich vest ratably over a ~~12-month~~12-month period and have an expiration date of ~~March 15, 2022.~~

February 13, 2024. During the year ended December 31, ~~2016,~~2018, we granted warrants to purchase ~~245,000~~an aggregate of 175,000 shares of Common Stock to outside consultants at the weighted average price of $7.90 per share. These warrants vest and have expiration dates as follows: warrants to purchase 75,000 shares of Common Stock vested on April 21, 2016 and have an expiration date of April 21, 2021, warrants to purchase 50,000 shares of Common Stockwhich vest ratably over a ~~24-month~~12-month period and have an expiration date of ~~April 21, 2021, and warrants to purchase 120,000 shares of Common Stock vest ratable over a 12-month period and have an expiration date of January 21, 2021.~~ March 15, 2023.

We recorded share-based compensation expense related to warrants previously issued of ~~$494,136, $313,271~~$26,446, $254,970, and ~~$936,974~~$494,136 for the years ended December 31, ~~2018, 2017~~2020, 2019 and ~~2016,~~2018, respectively, in the accompanying consolidated financial statements. At December 31, ~~2018, total~~2020, there was no unrecognized ~~estimated~~ compensation expense remaining related to unvested ~~warrants was approximately $106,000 which is expected to be recognized over weighted-average period of 0.2 years.~~warrants.

Summary of our Warrant activity during the year ended December 31, ~~2018:~~2020:

Number of
Shares Under
Warrants Weighted
Average
Exercise
Price Weighted
Average
Remaining
Contractual
Life in
Years Aggregate
Intrinsic
Value
Balance at December 31, 2017 3,115,905 $ 2.58 1.8 $ 11,348,273
  Granted 175,000 $ 5.16
  Exercised —
  Expired (283,334 ) $ 2.01
  Cancelled/Forfeited —
Balance at December 31, 2018 3,007,571 $ 2.78 1.58 $ 4,826,403
Vested and Exercisable at December 31, 2018 2,963,818 $ 2.75 1.54 $ 4,826,403
Unvested at December 31, 2018 43,753 $ 5.16 4.21 $ 0

~~F- 23~~

	Number of Shares Under Warrants			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2019		1,832,571		$	2.62		1.95	$	2,447,929
Granted		4,752,116		$	1.19
Exercised		—			—				—
Expired		—			—
Cancelled/Forfeited		(50,000	)	$	6.35
Balance at December 31, 2020		6,534,687		$	1.55		7.25	$	1,041,219
Vested and Exercisable at December 31, 2020		6,534,687		$	1.55		7.25	$	1,041,219
Unvested at December 31, 2020		—			—		—		—

The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016~~2018 are set forth in the table below.

	2018			2017			2016			2020			2019			2018
Weighted average exercise price	$	5.16		$	6.83		$	7.90		$	1.19		$	5.63		$	5.16
Weighted average grant date fair value	$	2.79		$	3.67		$	4.78		$	1.56		$	3.00		$	2.79
Risk-free interest rate		2.36	%		1.47	%	��	1.04-1.28	%		0.34	%		2.52	%		2.36	%
Volatility		62.12	%		63.24	%		74.10-74.15	%		68.8	%		60.8	%		62.12	%
Term (in years)		5			5			5			10			5			5
Dividend yield		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%		0.00	%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the instrument. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of the instrument. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the instrument. The expected volatility of warrants was estimated based on a historical volatility analysis of our Company as well as peers that were similar to the Company with respect to industry, stage of life cycle, market capitalization, and financial leverage.

In May 2013, we entered into a consulting agreement with Sancilio and Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain FDA approval for our drug candidates, including a vaginal capsule for the treatment of VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:

283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013. These shares were exercised in 2017 and are included in the warrant exercise details below;

283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of five years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the years ended December 31, 2017, 2016, and 2015, we recorded $0, $0, and $77,026, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of December 31, 2017 this warrant was fully amortized. These shares were exercised in 2017 and are included in the warrant exercise details below; and

283,334 shares were going to vest upon the receipt by us, prior to the warrant expiration date of April 30, 2018, of any final FDA approval of a drug candidate that SCI helped us design. Since the receipt of such approval did not occur before warrant’s expiration date, the warrant expired on April 30, 2018.

~~F- 24~~

In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to SCI for services to be rendered over approximately five years beginning in May 2012. The warrants vested upon issuance. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain new drug approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. During the years ended December 31, 2018, 2017, and 2016, we recorded $0, $128,898, and $257,796, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements. As of December 31, 2017, the SCI warrants issued in 2013 and 2012 were fully amortized. This warrant was fully exercised, of which 800,000 shares were exercised in 2017 and 500,000 shares were exercised in 2016.

Warrant exercises

During the year ended December 31, ~~2018, no~~2020, 0 warrants were exercised.

During the year ended December 31, ~~2017, certain individuals exercised~~2019, warrants to purchase ~~2,476,666~~an aggregate of 1,250,000 shares of Common Stock ~~for $3,798,999 in cash, which included SCI warrants issued in 2012 and 2013. In addition, during the year ended December 31, 2017, certain individuals~~were exercised ~~warrants to purchase 6,590,000 shares of Common Stock~~ pursuant to the warrants’ cashless exercise provisions, ~~wherein 4,762,208~~which resulted in 471,184 shares of Common Stock ~~were~~being issued.

During the year ended December 31, ~~2016, certain individuals exercised~~2018, 0 warrants ~~to purchase 722,744 shares of Common Stock for $1,373,000 in cash, of which 500,000 shares related to SCI warrant issued in 2012.~~were exercised.

Options to Purchase Common Stock of the Company

In 2009, we adopted the 2009 ~~Long Term~~Long-Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. As of December 31, 2020, there were non-qualified stock options to purchase an aggregate of 13,285,205 shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009 Plan.

On June 20, 2019, we adopted the 2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the ~~2009~~2019 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the ~~2009~~2019 Plan. ~~There are 25,000,000 shares authorized for issuance thereunder.~~ Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued.

As of December 31, ~~2018,~~2020, there were 2,583,565 shares of Common Stock available for issuance under the 2019 Plan, consisting of (i) new shares, (ii) unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding “Awards” (as defined in the 2012 Plan), and (iii) unallocated shares previously available for issuance under the 2009 Plan that were not then subject to outstanding “Awards” (as defined in the 2009 Plan). Any shares subject to outstanding options or other equity “Awards” under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again be available for delivery with respect to Awards under the 2019 Plan. As of December 31, 2020, there were non-qualified stock options to purchase ~~14,594,350~~4,190,751 shares of Common Stock outstanding under the ~~2009 Plan. As~~2019 Plan and an aggregate of ~~December 31, 2018, there were 866,912 shares available to be issued under 2009 Plan.~~

In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock,6,171,024 restricted stock units ~~performance stock, performance units,~~ and other stock or cash awards as described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of December 31, 2018, there were non-qualified stock options to purchase 6,278,474 shares of Common Stock outstanding and 1,040,000 restricted2,403,951 performance stock units outstanding under the ~~2009~~2019 Plan. ~~As of December 31, 2018, there were 2,433,333 shares available to be issued under 2012 Plan.~~

~~F- 25~~

The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016~~2018 are set forth in the table below.

2018 2017 2016
Weighted average exercise price $ 5.45 $ 6.60 $ 6.22
Weighted average grant date fair value $ 3.24 $ 3.82 $ 3.94
Risk-free interest rate 2.38-2.89 % 1.84-2.05 % 1.13-1.90 %
Volatility 59.45-64.04 % 61.56-64.25 % 70.26-73.34 %
Term (in years) 5.1-6.25 5.5-6.25 5.5-6.25
Dividend yield 0.00 % 0.00 % 0.00 %

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the stock price is expected to fluctuate each year during the term of an award. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. The expected volatility of share options was estimated based on a historical volatility analysis of our Company as well as peers that were similar to us with respect to industry, stage of life cycle, market capitalization, and financial leverage. The average expected life is based on the contractual terms of the stock option using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have no current intention to pay cash dividends. Future stock-based compensation may significantly differ based on changes in the fair value of our Common Stock and our estimates of expected volatility and the other relevant assumptions.

	2020			2019			2018
Weighted average exercise price	$	1.58		$	3.10		$	5.45
Weighted average grant date fair value	$	0.95		$	1.82		$	3.24
Risk-free interest rate		0.34-1.68%			1.64-2.54%			2.38-2.89%
Volatility		63.53-67.92%			61.25-64.49%			59.45-64.04%
Term (in years)		6-6.8			5.5-6.5			5.1-6.25
Dividend yield		0.00	%		0.00	%		0.00	%

A summary of activity under the 2009, 2012 and ~~2012~~2019 Plans and related information during the year ended December 31, ~~2018~~2020 is as follows:

	Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value		Number of Shares Under Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2017		23,365,225		$	3.78		5.13	$	64,664,821
Balance at December 31, 2019											25,030,234		$	4.65		5.84	$	3,668,171
Granted		3,264,500		$	5.45						736,500		$	1.58
Exercised		(5,454,526	)	$	0.31			$	27,534,623		(1,182,195	)	$	0.23			$	1,738,740
Expired		(25,000	)	$	7.76						(386,609	)	$	3.76
Cancelled/Forfeited		(277,375	)	$	5.47						(416,000	)	$	3.80
Balance at December 31, 2018		20,872,824		$	4.93		5.94	$	12,239,876
Vested and Exercisable at December 31, 2018		16,068,991		$	4.61		5.09	$	12,239,876
Unvested at December 31, 2018		4,803,833		$	5.99		8.8	$	0
Balance at December 31, 2020											23,781,930		$	4.80		5.20	$	152,253
Vested and Exercisable at December 31, 2020											19,862,681		$	5.06		4.59	$	117,443
Unvested at December 31, 2020											3,919,249		$	3.53		8.29	$	34,810

At December 31, ~~2018,~~2020, our outstanding options had exercise prices ranging from ~~$0.10~~$0.38 to ~~$8.92~~$8.92 per share. Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016~~2018 was approximately ~~$8,091,294, $6,447,154,~~$5,235,585, $8,798,707, and ~~$16,139,225,~~$8,091,294, respectively, and it is based on awards vested. At December 31, ~~2018,~~2020, total unrecognized estimated compensation expense related to unvested options was approximately ~~$12,175,000,~~$5,238,000, which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of ~~2.01~~1.9 years. No tax benefit was realized due to a continued pattern of operating losses.

Restricted Stock

Restricted stock ~~awards~~units granted under our 2009, 2012 and ~~2012~~2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock. Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.

Performance stock units will vest if certain performance targets are achieved. If minimum performance thresholds are achieved, each award will convert into Common Stock at a defined ratio depending on the degree of achievement of the performance target designated by each individual award. If minimum performance thresholds are not achieved, then no shares will be issued. We recognize performance-based restricted stock as compensation expense based on the most likely probability of attaining the prescribed performance and over the requisite service period beginning at its grant date and through the date the restricted stock vests. The expected levels of achievement are reassessed over the requisite service periods and, to the extent that the expected levels of achievement change, stock-based compensation is adjusted and recorded on the consolidated statements of income and the remaining unrecognized stock-based compensation is recognized over the remaining requisite service period.

~~F- 26~~

~~On December 13, 2018, we granted 1,040,000 restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair value was $4.06 per unit.~~ During the ~~year~~years ended December 31, 2020, 2019 and 2018 we recorded ~~$73,132~~$5,399,472, $1,628,407 and $73,132, respectively, in share-based compensation expense related to restricted stock units and performance stock units. As of December 31, 2020, we recognized performance-based compensation expense using our assessment of the most likely probability of attaining quarterly EBITDA break-even which would result in vesting 1.5 times the base number of performance stock units. At December 31, ~~2018,~~2020, total unrecognized estimated compensation expense related to unvested restricted stock units and performance stock units was approximately ~~$4,149,000,~~$9,989,000, which may be adjusted if certain performance targets are achieved or for future changes in forfeitures. This cost is expected to be recognized over a weighted-average period of ~~2.95~~1.6 years. ~~At December 31, 2018, 1,040,000~~

Schedule of restricted stock ~~awards remained outstanding.~~units and performance stock units

	Restricted Stock Units					Performance Stock Units
	Number of Shares			Weighted Average Grant Date Fair Value		Number of Shares			Weighted Average Grant Date Fair Value
Balance at December 31, 2019		1,240,000		$	3.56		—		$	—
Granted		6,152,818		$	1.39		2,585,745		$	1.08
Vested/Released		(301,500	)	$	1.78		(151,500	)	$	1.14
Forfeited		(30,294	)	$	1.07		(30,294	)	$	1.07
Balance at December 31, 2020		7,061,024		$	1.76		2,403,951	*	$	1.08

~~Cash-Settled~~

The number of performance stock units (PSUs) represents the base number of PSUs that may vest. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the Company’s achievement of break-even quarterly EBITDA.

Employee Stock ~~Appreciation Rights (SARs)~~Purchase Plan

On ~~July 1, 2018, we issued cash-settled SARs~~June 18, 2020, our stockholders approved the TherapeuticsMD, Inc. 2020 Employee Stock Purchase Plan, or the ESPP, which reserved 5,400,000 shares of Common Stock for purchase. The ESPP permits eligible employee participants to ~~certain consultants and employees. The SARs plan year begins on July 1 and ends on or immediately following June 30, 2019. SARs are granted with~~purchase Common Stock at a ~~grant~~ price per share which is equal to ~~the market value of a share of our Common Stock on the date of grant. Cash-settled SARs provide for the cash payment~~85% of the ~~excess~~lesser of (a) the fair market value of ~~our Common Stock~~the shares on ~~June 30, 2019 over~~ the ~~grant price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over the grant price is paid in cash and not in Common Stock.~~

~~Cash settled SARs are recorded in our consolidated balance sheets as a liability until the~~offering date of ~~exercise. The fair value of each SAR award is estimated using~~ the ~~Black-Scholes valuation model. In accordance with ASC Topic 718, “Stock Compensation,”~~offering period or (b) the fair value of each SAR award is recalculated at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested. At December 31, 2018, we had 103,000 SARs outstanding and the liability related to SAR calculation was $3,406. The assumptions used to determine the fairmarket value of the ~~cash settled SAR awards at~~shares on the purchase date. During the year ended December 31, ~~2018~~2020, no shares were ~~life~~issued under the ESPP. We recorded $17,489 of ~~6 months, 49.7% volatility, 2.7% risk-free rate, and zero annual dividends. As of~~non-cash compensation expense related to the ESPP during the year ended December 31, ~~2018, the fair value of SARs outstanding was $0.07 per award.~~2020.

NOTE 10 – EMPLOYEE BENEFIT PLAN

The Company maintains a voluntary defined contribution 401(k) plan covering all eligible employees as defined in the plan documents. The plan provides for discretionary matching contribution, which is equal to up to 4 percent of each eligible contributing participant’s elective deferral not to exceed $2,000 per year. Employees who elect to participate in the plan are generally fully vested in any existing matching contribution after five years of service with the Company. Contributions by the Company under the plan amounted to approximately $487,000 and $403,000 for the years ended December 31, 2020 and 2019, respectively.

NOTE 11 – INCOME TAXES

For financial reporting purposes, (loss) income before taxes includes the following components:

	2018			2017			2016			2020			2019			2018
United States		(132,617,160	)		(76,925,380	)		(89,875,459	)	$	(183,524,137	)	$	(176,144,999	)	$	(132,617,160	)
Total		(132,617,160	)		(76,925,380	)		(89,875,459	)	$	(183,524,137	)	$	(177,144,999	)	$	(132,617,160	)

For the years ended December 31, ~~2018, 2017,~~2020, 2019, and ~~2016,~~2018, there was no provision for income taxes, current or deferred. At December 31, ~~2018,~~2020, we had a federal net operating loss carry forward of approximately ~~$481,365,550.~~$761,701,546 available to offset future taxable income through 2038. Approximately ~~$338,668,076~~$338,775,332 of the federal net operating loss carry forward can be carried forward for 20 years and will begin to expire in ~~2031.~~2031. The remaining ~~$142,697,474~~$422,926,214 can be carried forward indefinitely.

A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:

2018 2017 2016
Federal statutory tax rate 21.0 % 34.0 % 34.0 %
State tax rate, net of federal tax benefit 5.2 % 5.0 % 5.4 %
Adjustment in valuation allowances (31.2 )% 22.6 % (40.3 )%
Excess stock benefit 5.3 % 0.0 % 0.0 %
Federal income tax rate change 0.0 % (60.8 )% — %
Permanent and other differences (0.3 )% (0.8 )% 0.9 %
Provision (benefit) for income taxes — — —

~~F- 27~~

	2020			2019			2018
Federal statutory tax rate		21.0	%		21.0	%		21.0	%
State tax rate, net of federal tax benefit		5.1	%		4.0	%		5.2	%
Adjustment in valuation allowances		(27.0	)%		(22.5	)%		(31.2	)%
Excess stock benefits		0.1	%		0.2	%		5.3	%
Federal income tax rate change		0	%		0	%		0	%
Permanent and other differences		0.8	%		(2.7	)%		(0.3	)%
Provision (benefit) for income taxes		0			0			0

Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes.

The components of the net deferred income tax asset as of December 31, ~~2018, 2017,~~2020, 2019, and ~~2016~~2018 are as follows:

	2018			2017			2016			2020			2019			2018
Deferred Income Tax Assets:
Net operating losses	$	140,891,764		$	99,596,321		$	111,730,450		$	195,008,131		$	157,555,975		$	126,419,113
R&D Credit		186,347			186,347			186,347
Share based compensation											17,251,900			13,913,568			11,640,464
Interest expense limitation											12,991,716			5,389,129			1,173,614
Other, net											4,818,935			3,662,037			1,658,573
R&D credit											186,347			186,347			186,347
Total deferred income tax asset		141,078,111			99,782,668			111,916,797			230,257,029			180,707,056			141,078,111
Valuation allowance		(141,078,111	)		(99,782,668	)		(111,916,797	)		(230,257,029	)		(180,707,056	)		(141,078,111	)
Deferred income tax assets, net	$	—		$	—		$	—		$	0		$	0		$	0

We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, ~~2018.~~2020.

The change in valuation allowance was $49,549,973, $39,628,945, and $41,295,443 for the years ended December 31, 2020, 2019, and 2018, respectively.

Unrecognized Tax Benefits

As of ~~the period ended~~ December 31, ~~2018,~~2020 and 2019, we have no unrecognized tax benefits.

NOTE 1112 – RELATED PARTIES

In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our ~~company~~Company, or a committee consisting of independent directors of our company, since July 2015. During the years ended December 31, ~~2018, 2017~~2020, 2019 and ~~2016~~2018, we were billed by Catalent approximately ~~$4,111,000, $3,646,000~~$3,036,000, $6,101,000 and ~~$3,647,000,~~$4,111,000, respectively, for ~~inventory related to our products,~~ manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of December 31, ~~2018~~2020 and ~~2017,~~2019, there were amounts due to Catalent of approximately ~~$88,000~~$0 and ~~$523,000,~~$35,000, respectively. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note ~~13,~~14, Commitments and Contingencies.

In April 2020, Karen L. Ling, Executive Vice President and Chief Human Resources Officer of American International Group, Inc., or AIG, was appointed to our board of directors. From time to time, we have entered into agreements with AIG in the normal course of business. Agreements with AIG have been reviewed by independent directors of our Company, or a committee consisting of independent directors of our Company, since April 2020. During the year ended December 31, 2020, we were billed by AIG approximately $209,000 for various insurance coverage for our Company.

~~F- 28~~

NOTE 1213 - BUSINESS CONCENTRATIONS

We purchase our prescription products from several suppliers with approximately ~~43%~~36%, ~~33%~~30% and ~~24%~~25% of our purchases ~~were~~ supplied by three vendors each, respectively, during the year ended December 31, ~~2018,~~2020, 24%, 27% and ~~100% and 98%~~35% of our purchases ~~were~~ supplied by ~~one vendor~~three vendors each, ~~for~~respectively, during the ~~years~~year ended December 31, ~~2017~~2019, and ~~2016, respectively.~~43%, 33% and 24% of our purchases supplied by 3 vendors each, respectively, during the year ended December 31, 2018.

We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2020, 3 customers each accounted for more than 10% of our total product revenue. During each of the years ended December 31, 2019 and 2018, ~~2017 and 2016, four, four and three~~4 customers each ~~respectively,~~ accounted for more than ~~10%~~10% of our total ~~net revenues. Net~~product revenue. Product revenue from the ~~four~~3 customers combined accounted for approximately ~~76%~~63% of our ~~net recognized~~product revenue for the year ended December 31, ~~2018 and approximately 59% of our recognized revenue for the year ended December 31, 2017. Net~~2020. Product revenue from ~~three~~the 4 customers combined accounted for approximately ~~41%~~73% and 76% of our ~~net~~product revenue ~~during~~for the ~~year~~years ended December 31, ~~2016.~~2019 and 2018, respectively.

During the year ended December 31, ~~2018, McKesson Corporation~~2020, Cardinal Health accounted for approximately ~~$1,610,000~~$17,489,000 of our product revenue, Pillpack, Inc. accounted for approximately ~~$5,075,000~~$13,228,000 of our product revenue, and McKesson Corporation accounted for approximately $9,862,000 of our product revenue. During the year ended December 31, 2019, Pillpack, Inc. accounted for approximately $12,676,000 of our product revenue, Cardinal Health accounted for approximately $4,551,000 of our product revenue, AmerisourceBergen accounted for approximately ~~$3,246,000~~$3,927,000 of our product revenue and McKesson Corporation accounted for approximately $3,911,000 of our product revenue. During the year ended December 31, 2018, Pillpack, Inc. accounted for approximately $5,075,000 of our product revenue, AmerisourceBergen accounted for approximately $3,246,000 of our product revenue and Cardinal Health accounted for approximately ~~$2,308,000~~$2,308,000 of our ~~revenue. During the year ended December 31, 2017, AmerisourceBergen accounted for approximately $2,667,000 of our revenue;~~product revenue, and McKesson Corporation accounted for approximately ~~$1,959,000~~$1,610,000 of our ~~revenue; Cardinal Health accounted for approximately $2,559,000 of our revenue and Pharmacy Innovations PA accounted for approximately $2,715,000 of our~~product revenue. During the year ended December 31, 2016, Woodstock Pharmaceutical and Compounding accounted for approximately $2,247,000 of our revenue; Medical Center Pharmacy accounted for approximately $3,700,000 of our revenue and Pharmacy Innovations PA accounted for approximately $2,040,000 of our revenue.

NOTE 1314 – COMMITMENTS AND CONTINGENCIES

Operating Leases

We adopted ASC 842, Leases, effective January 1, 2019. Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used to conduct our business. Upon adoption, we recognized a right-of-use asset and a lease liability for all leases that have commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability.

We lease administrative office space in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided for a ~~63-month~~63-month term. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May 1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum isbecame effective beginning November 1, 2016. ~~As of December 31, 2018, future minimum rental payments on non-cancelable operating leases are as follows:~~

Years Ending December 31,
2019 $ 1,094,116
2020 1,113,069
2021 943,127
Thereafter —
Total minimum lease payments $ 3,150,312

~~F- 29~~

In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes 56,212 rentable square feet, or the full premises, of which the lease on 7,561 square feet ~~has~~ commenced in 2018 and the lease on the remaining 48,651 square feet ~~will commence no earlier than June 1,~~commenced in August 2019, or the full premises commencement date. The lease will expire 11 years after the full premises commencement date, unless terminated earlier in accordance with the terms of the lease. We have the option to extend the term of the lease for ~~two~~2 additional consecutive periods of five ~~years.~~years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating costs under the lease, including electricity and utility expenses. In ~~addition,~~June 2019, we ~~will be entitled~~entered into an agreement with the same lessors to ~~reimbursement from~~lease additional 6,536 square feet of administrative office space in the ~~landlord of up~~same location, pursuant to ~~$1,800,000~~an addendum to such lease, which commenced in May 2020.

Supplemental lease information as of:	December 31, 2020			December 31, 2019
Right-of-use asset	$	9,565,700		$	10,109,154
Short-term operating lease liability (included in Other current liabilities)	$	2,253,994		$	1,501,539
Long-term operating lease liability	$	8,675,477		$	9,145,049
Weighted average remaining term		8.9 years			9 years
Weighted average discount rate		8.30	%		8.25	%

Supplemental cash flow information for the year ended:	December 31, 2020			December 31, 2019
Cash paid for amounts included in the measurement of lease liabilities for operating lease	$	1,617,645		$	1,164,234
Right-of-use assets obtained in exchange for lease obligation	$	998,821		$	11,171,471

The following table reconciles the undiscounted cash flows for ~~tenant improvements. As of~~all operating leases at December 31, ~~2018, future minimum rental payments~~2020 to the operating lease liabilities recorded on ~~full premises~~the balance sheet:

Years Ending December 31,
2021	$	2,334,582
2022		1,413,289
2023		1,443,143
2024		1,476,534
2025		1,513,458
Thereafter		7,434,412
Total undiscounted lease payments		15,615,418
Less: imputed interest		(4,685,947	)
Present value of lease payments	$	10,929,471

During the year ended December 31, 2020, operating lease expense related to our real estate leases was $2,325,844, and variable lease expense was $423,578. During the ~~new~~year ended December 31, 2019, operating lease expense related to our real estate leases ~~are as follows, of which approximately $2.7 million relates to the~~was $1,558,794, and variable lease ~~on the suite that has commenced in 2018:~~

Years Ending December 31,
2019 $ 48,288
2020 984,756
2021 1,779,384
2022 1,808,312
2023 1,837,963
Thereafter 12,390,298
Total minimum lease payments $ 18,849,001

expense was insignificant. The rental expense during the ~~years~~year ended December 31, 2018 ~~2017 and 2016~~ was ~~approximately $1,068,275, $1,029,205 and $709,483, respectively.~~$1,068,275.

Intellectual Property Licenses

~~We have license agreements with third parties that provide~~The Population Council License Agreement provides for ~~minimum royalty, license, and exclusivity~~future milestone payments to be paid by us for access to certain technologies. In addition, we pay royalties as a percent of revenue as described in Note ~~6, Intangible Assets,~~2, Summary of Significant Accounting Policies to these consolidated financial statements.

Purchase Commitments

We have a manufacturing and supply ~~agreement~~agreements whereby we are required to purchase from Catalent a minimum of number of softgels during the first contract year and a higher number orof softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to pay Catalent ~~50%~~50% of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and the sum of all purchases of our products from Catalent during the contract year. ~~At December 31, 2018, we had~~The minimum purchase ~~obligations related to this agreement of approximately $2,600,000 over~~commitments for Catalent for the next five ~~years. This amount represents~~years are as follows: 2021 - $3,458,000, 2022 - $2,150,000, 2023 - $2,991,000, 2024 - $3,347,000, and 2025 - $3,786,000. In addition, we have a manufacturing and supply agreement whereby we are required to purchase a minimum number of units of ANNOVERA during a contract year. The minimum purchase commitment for ANNOVERA for 2021 is approximately $1,526,000. As of December 31, 2020, we have met our ~~estimate of the~~ minimum ~~required payments under the agreement.~~purchase commitments with our manufacturers.

Legal Proceedings

From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.

Off-Balance Sheet Arrangements

As of December 31, ~~2018, 2017,~~2020, 2019, and ~~2016,~~2018, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effects on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Employment Agreements

~~F- 30~~

NOTE 1415 – SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

Summarized quarterly financial data for fiscal years ~~2018~~2020 and ~~2017~~2019 is as ~~follows:~~follows:

2018 Quarter
(In thousands, except per share) 1st 2nd 3rd 4th
Revenues $ 3,773 $ 3,763 $ 3,474 $ 5,089
Gross profit $ 3,139 $ 3,309 $ 2,775 $ 4,139
Net loss $ (24,402 ) $ (33,219 ) $ (35,605 ) $ (39,391 )

Loss per common share, basic and diluted $ (0.11 ) $ (0.15 ) $ (0.16 ) $ (0.17 )

2017 Quarter
(In thousands, except per share) 1st 2nd 3rd 4th
Revenues $ 3,985 $ 4,250 $ 4,418 $ 4,125
Gross profit $ 3,326 $ 3,568 $ 3,717 $ 3,530
Net loss $ (21,156 ) $ (19,677 ) $ (14,665 ) $ (21,427 )

Loss per common share, basic and diluted $ (0.11 ) $ (0.10 ) $ (0.07 ) $ (0.10 )

~~F- 31~~


	2020
(In thousands, except per share)	First Quarter			Second Quarter			Third Quarter ^(1)(2)(3)(4)			Fourth Quarter ⁽⁵⁾
Revenues	$	12,251		$	10,701		$	19,343		$	22,577
Gross profit	$	9,536		$	6,301		$	16,064		$	16,996
Net loss	$	(56,849	)	$	(51,976	)	$	(32,611	)	$	(42,088	)

Loss per common share, basic and diluted	$	(0.21	)	$	(0.19	)	$	(0.12	)	$	(0.15	)


	2019
(In thousands, except per share)	First Quarter			Second Quarter ⁽⁶⁾			Third Quarter ⁽⁷⁾			Fourth Quarter
Revenues	$	3,947		$	6,079		$	23,719		$	15,902
Gross profit	$	3,184		$	4,830		$	22,275		$	13,023
Net loss	$	(39,506	)	$	(55,237	)	$	(31,967	)	$	(49,435	)

Loss per common share, basic and diluted	$	(0.16	)	$	(0.23	)	$	(0.13	)	$	(0.19	)

(1)

During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

(2)

During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately $7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. Refer to discussion in Note 8-Debt.

(3)

During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.

(4)

During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

(5)

During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.

(6)

During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.

(7)

During the third quarter of 2019, we recorded approximately $15. 5 million in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

(1)

During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

(2)

(3)

During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.

(4)

During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

(5)

During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.

(6)

During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.

(7)

During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.

NOTE 16 – SUBSEQUENT EVENTS

During the period from January 1, 2021 through February 8, 2021 in accordance with the terms of the sales agreement described in Note 9- Stockholders’ Equity, we sold 28,600,689 shares of Common Stock for net proceeds of approximately $47.3 million through Cantor Fitzgerald who acted as our sales agent.

On January 13, 2021, we entered into Amendment No. 7 to the Financing Agreement, or Amendment No. 7, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA for the fiscal quarters ending March 31, 2021 and June 30, 2021 were reduced to $18.0 million and $22.0 million, respectively. On January 13, 2021, in connection with entering into Amendment No. 7 to the Financing Agreement, the Lender Warrants were further amended to provide for an additional adjustment to the exercise price if we conduct certain dilutive issuances prior to March 31, 2021.

On March 1, 2021, we entered into Amendment No. 8, pursuant to which, among other amendments, the minimum consolidated net revenue requirements attributable to commercial sales of IMVEXXY, BIJUVA, and ANNOVERA. See Note 8 – Debt for information regarding Amendment No. 8.

On February 11, 2021, we entered into an underwriting agreement with Cantor Fitzgerald, as underwriter, relating to an underwritten public offering of 59,459,460 shares of Common Stock. Pursuant to the underwriting agreement, we granted to the underwriter an option, exercisable for a period of 30 days, to purchase up to 8,918,919 additional shares of Common Stock. The net proceeds to us from the offering, excluding any proceeds that may be received from the exercise of the underwriter’s option to purchase additional shares, are expected to be approximately $97.1 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The offering closed on February 16, 2021.

F-32

Nevada		87-0233535
(State or Other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

Large accelerated filer ☒☐	Accelerated filer ☐
Non-accelerated filer ☐☒	Smaller reporting company ☐☒
	Emerging growth ~~Company~~ company ☐

	PART I

Item 1.	Business	4
Item 1A.	Risk Factors	26
Item 1B.	Unresolved Staff Comments	52 54
Item 2.	Properties	52 54
Item 3.	Legal Proceedings	52 54
Item 4.	Mine Safety Disclosures	52 55

	PART II

Item 5.	Market for ~~the~~ Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	53 55
Item 6.	Selected Financial Data	55 57
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	56 58
Item 7A.	Quantitative and Qualitative Disclosures ~~about~~About Market Risk	71 73
Item 8.	Financial Statements and Supplementary Data	71 74
Item 9.	Changes in and Disagreements ~~with~~With Accountants on Accounting and Financial Disclosure	71 74
Item 9A.	Controls and Procedures	71 74
Item 9B.	Other Information	74 75

	PART III

Item 10.	Directors, Executive Officers and Corporate Governance	74 75
Item 11.	Executive Compensation	74 75
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	74 75
Item 13.	Certain Relationships and Related Transactions, and Director Independence	74 75
Item 14.	Principal ~~Accounting~~Accountant Fees and Services	74 75

	PART IV

Item 15.	Exhibits and Financial Statement Schedules	75
Item 16.	Form 10-K Summary	77 78

Annual Net Sales	Royalty Rate
Less than or equal to $50.0 million	5	% 5%
Greater than $50.0 million and less than or equal to $150.0 million	10	% 10%
Greater than $150.0 million	15	% 15%


●	~~Three~~●	12 domestic patents (ten utility and two design) and 18 foreign patents that relate to our progesterone-only candidate, which are owned by us. The foreign patents will expire no earlier than 2033. In addition, we have pending patent applications with respect to our progesterone-only candidate in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;

●	~~Three domestic patents (two~~(eight utility and ~~one design) and 12 foreign patents (three utility and nine~~ten design) that relate to ~~IMVEXXY®.~~IMVEXXY. These patents establish an important intellectual property foundation for ~~IMVEXXY®~~IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain ~~jurisdictions,~~countries, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to ~~IMVEXXY®~~IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;

☒	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the fiscal year ended December 31, 2020

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from ______________________ to ________________________

	●
	●	Our contraceptive product is the only ~~long acting~~long-lasting, reversible contraceptive option that is patient-controlled and procedure-free.

	●	We believe the attributes of our prenatal vitamins will result in greater consumer acceptance and satisfaction than competitive products while offering ~~the highest quality~~high-quality products ~~such as Quatrefolic~~^®~~, FOLMAX®, FePlus®, and pur-DHA™. All our prenatal vitamins are gluten-, sugar-, and lactose-free.~~

	●	with differentiating ingredients. We ~~strive to improve our existing products and develop new products to generate additional revenue through our existing sales channels.~~

	●	We believe health care providers, or HCPs, can offer alternatives to patients that meet the patient’s individual nutritional requirements and provide patients a cost that is competitive in the marketplace.

	●	~~Improved~~focus on improved patient education, a high level of patient compliance, and ~~reduced~~a competitive cost of products, ~~all~~which can result in lower cost of care for payers and improved outcomes for patients.

	●
	●	~~help~~ Help HCPs and payers by delivering information on patient compliance and satisfaction.


	●	One domestic utility patent and ~~four~~eight foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have a pending patent ~~applications~~application with respect to our transdermal-patch candidates in Brazil;

	●
	●	~~The Ethics in Patient Referrals Act of 1989, commonly referred to as~~ federal civil and criminal false claims laws and civil monetary penalty laws, including, for example, the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.

	●	~~The~~ federal civil False Claims Act, ~~imposes~~which impose criminal and civil penalties, ~~and authorizes~~including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment ~~involving federally funded programs~~ that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money ~~with respect~~ to athe federal ~~program.~~government;

	●
	●	the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, ~~imposes~~which created additional federal criminal statutes that prohibit knowingly and ~~civil liability for~~willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private), knowingly and ~~also imposes~~willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

	●
	●	~~The~~ the federal ~~false statements statute prohibits knowingly~~physician sunshine requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and ~~willfully falsifying, concealing,~~medical supplies for which payment is available under Medicare or ~~covering up a material fact or making any materially false statement~~Medicaid to report annually to the Centers for Medicare & Medicaid Services information related to payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. In 2022, the Sunshine Act will be extended to payments and transfers of value to physician assistants, nurse practitioners, and other mid-level practitioners (with reporting requirements going into effect in ~~connection with any mater within the jurisdiction~~2022 for payments made in 2021). In addition, Section 6004 of the ACA requires annual reporting of information about drug samples that manufacturers and authorized distributors provide to healthcare providers;

	●	federal ~~government, including the delivery of or payment for healthcare benefits, items, or services.~~

	●	~~Analogous~~and state laws requiring pricing transparency or limiting price increases, which are in existence today or are anticipated to be in existence in the near future, may limit the ability to raise prices, require disclosure of price increases or require disclosure of the wholesale acquisition cost of pharmaceutical products to governmental agencies and ~~regulations,~~consumers; and

	●	If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy pharmaceutical products and other products are not adequate, we may not be able to compete effectively in our market.
	●	Our products face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.

	●	~~the presence of new or existing competing products, including generic copies of our hormone therapy drugs and prescription prenatal vitamin products that are not our authorized generic products;~~

	●	~~any supply or distribution problems arising with any of our manufacturing and distribution strategic partners;~~

	●	~~changed or increased regulatory restrictions or regulatory actions by the FDA;~~

	●	~~changes in health care laws and policy, including changes in requirements for rebates, reimbursement, and coverage by federal health care programs;~~

	●	~~the impact or efficacy of any price increases we may implement in the future;~~

	●	~~changes to our labels and labeling, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell our products; and~~

	●	~~acceptance of our products as safe and effective by physicians and patients.~~

●	●	The federal ~~health care~~ Anti-Kickback Statute, or AKS, prohibits, among other things, persons and entities, including pharmaceutical manufacturers, from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of, or arrangement for the referral of, an individual for, or the purchase, lease, order, or recommendation of, any good or service ~~for which payment may be made under~~reimbursable, in whole or in part, by federal ~~health care~~healthcare programs, such as Medicare, Medicaid, ~~TriCare,~~TRICARE, and the State Children’s Health Insurance Program. This statute has been interpreted broadly to apply to, among other things, arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. The term “remuneration” includes kickbacks, bribes or rebates and also has been broadly interpreted to include anything of value, including, for example, gifts, discounts, waivers of payment, ownership interest and providing anything at less than its fair market value. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly, and practices that do not fit squarely within an exception or safe harbor may be subject to scrutiny. The safe harbors are subject to change through legislative and regulatory action, and we may decide to adjust our business practices or be subject to heightened scrutiny as a result. For example, under a final rule issued in 2020 and to take effect January 1, 2022, OIG revised the AKS’s Discount Safe Harbor to explicitly exclude reductions in price offered by drug manufacturers to pharmacy benefit managers and Part D plans from the safe harbor’s definition of a “discount,” meaning AKS immunity would not be available for such arrangements, and as a result potential AKS risks would increase unless arraignments were restructured. The failure to meet the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the AKS. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not meet the criteria for safe harbor protection from AKS liability in all cases. Liability under the AKS may be established without proving actual knowledge of the statute or specific intent to violate it. In addition, federal law provides that the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act, or FCA, described below. Violations of the AKS carry potentially significant civil, criminal, and ~~criminal~~administrative penalties, including imprisonment, fines, ~~administrative~~ civil monetary penalties, and exclusion from participation in government ~~health care~~healthcare programs.

●	The ~~Ethics~~compliance and enforcement landscape, and related risk, is informed by government precedent, Advisory Opinions, and Special Fraud Alerts. For example, on November 16, 2020 the OIG published a Special Fraud Alert addressing manufacturer speaker programs signaling that such programs will be subject to an even higher degree of government scrutiny for potential AKS compliance concerns. Our approach to compliance may evolve over time in ~~Patient Referrals Act~~light of ~~1989, commonly referred~~these types of developments. For example, we are currently evaluating the impact of the November 16, 2020 Special Fraud Alert on our speaker programs; if we are required to ~~as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid~~materially change our speaker programs to comply with the Special Fraud Alert, our speaker programs may be less effective, which may have an adverse effect on our business, financial condition, results of operations, and growth prospects.

	●	The FCA prohibits entities and individuals from intentionally (or with ~~which the physicians~~reckless disregard or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.

●	~~The federal False Claims Act, or FCA, imposes criminal and civil penalties, and authorizes civil whistleblower or qui tam actions, against individuals or entities for knowingly~~deliberate ignorance) presenting or causing to be presented ~~claims for payment involving federally funded programs that are~~ false or fraudulent claims to Medicare, Medicaid, and other federal healthcare programs, or ~~making~~improperly retaining known overpayments;

	●	Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for knowingly and willfully executing or attempting to execute a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including third-party private payers, knowingly and willfully falsifying, concealing, or covering up by trick, scheme, or device, a material fact or making any materially false, ~~statement in connection with the delivery of~~fictitious, or payment for health care benefits, items, or services. Government enforcement agencies and private whistleblowers have asserted liability under the FCA for, among other things, claims for items or services not provided as claimed, with inaccurate coding or for medically unnecessary items or services, kickbacks, promotion of off-label uses, and misreporting of drug prices to federal agencies.

●	Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations, or collectively, HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program, including private payers, or falsifying, concealing, or covering up a material fact, or making any materially falsefraudulent statements in connection with the delivery of or payment for ~~health care~~healthcare benefits, items, or services. ~~HIPAA also imposes obligations, including mandatory contractual terms, with respect~~Similar to ~~safeguarding~~ the ~~privacy, security, and transmission~~AKS, a person or entity does not need to have actual knowledge of ~~individually identifiable health information.~~the statute or specific intent to violate it to have committed a violation. State laws may also govern the privacy and security of health information or other personal information in certain circumstances.

●	~~the scope of rights granted under the agreement and other interpretation-related issues;~~
●	~~our obligations to make milestone, royalty or other payments under those agreements;~~
●	~~whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement;~~
●	~~our right to sublicense patent and other rights to third parties;~~
●	~~the ownership of inventions and know-how arising under the agreement or resulting from the joint creation or use of intellectual property by our licensors and us and our partners;~~
●	~~our right to transfer or assign the license; and~~
●	~~the effects of termination.~~

●	~~we cannot sublicense the rights licensed to us without the consent of the Population Council;~~
●	~~neither we nor the Population Council may develop a competitive product (as defined with respect to each party in the agreement) for six years from the date of the agreement;~~
●	~~currently there are no Orange Book listable patents or patent applications covering this system; and~~
●	~~the Population Council owns any program improvements, as defined in the agreement.~~

	●
	●	issue warning letters or untitled letters asserting that we are in violation of the law;

	●
	●	seek an injunction or impose civil or criminal penalties or monetary fines;

	●
	●	require that we suspend or terminate any ongoing clinical trials;

	●
	●	refuse to approve pending applications or supplements to applications filed by us;

	●
	●	suspend or impose restrictions on operations, including costly new manufacturing requirements;

	●
	●	seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or

	●
	●	exclude us from providing our products to those participating in government ~~health care~~healthcare programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.

	●
	●	~~acceptance by physicians and payers of~~ neither we nor the Population Council may develop a competitive product (as defined with respect to each ~~product as a safe and effective treatment;~~

	●	~~the cost of treatment in relation to alternative treatments, including numerous generic drug products;~~

	●	~~the relative convenience and ease of administration of our products~~party in the ~~treatment~~agreement) for six years from the date of the ~~symptoms for which they are intended;~~

	●	~~the availability~~agreement; and ~~efficacy of competitive drugs;~~

	●	~~the effectiveness of our sales force and marketing efforts;~~

	●	~~the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;~~

	●	the ~~availability of coverage and adequate reimbursement by third parties, such~~Population Council owns any program improvements, as ~~insurance companies and other health care payers, or by government health care programs, including Medicare and Medicaid;~~

	●	~~limitations or warnings contained~~defined in ~~a product’s FDA-approved labeling; and~~

	●	~~prevalence and severity of adverse side effects.~~the agreement.

	●
	●	difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial is completed;

	●
	●	labeling, marketing, or promotional changes and/or restrictions;

	●
	●	decreased demand for our products or products that we may develop in the future;

	●
	●	initiation of investigations by ~~regulators;~~regulators or actions by state attorney generals or the U.S. Department of Justice;